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It is estimated that more than 1/3 of the compounds being developed by the 
pharmaceutical industry are poorly water soluble.  The bioavailability of these drugs is 
limited by their low dissolution rates.  Two nanoparticle engineering processes, 
evaporative precipitation into aqueous solution (EPAS) and antisolvent precipitation were 
developed to enhance the dissolution rate of poorly water soluble drugs.   
EPAS is a process by which a drug solution in a water immiscible organic solvent 
is sprayed through an atomizer into an aqueous solution containing hydrophilic stabilizer 
(s) at high temperature.  The rapid evaporation of the small organic droplets results in fast 
nucleation leading to submicron to micron particles suspensions.  The adsorption of water 
soluble stabilizers on the drug particle surfaces facilitates the dissolution rates of the final 
powder after drying.  The suspensions may be used in parenteral formulations to enhance 
bioavailability or may be dried to produce oral dosage forms with high dissolution rates 
due to small particle size and hydrophilic stabilizer that enhances wetting.  The influence 
 vii
of EPAS process parameters on the physicochemical properties of poorly water soluble 
drugs was determined.  The influence of the dissociation of drug molecules on the 
stability of nanosuspensions at high suspension concentration, as high as 30 mg/ml with a 
drug-to-surfactant ratio of 3:1, was investigated.  High-potency (≥ 90%) drug particles 
with high dissolution rates were produced by removing the non-adsorbed surfactant.   
Antisolvent precipitation is a technique where a drug solution in a water miscible 
organic solvent is mixed with an aqueous solution containing a surfactant(s).  Upon 
mixing, the supersaturated solution leads to nucleation and growth of drug particles, 
which may be stabilized by surfactants.  Temperature was shown to have a large effect on 
the particle size distribution in the suspension.  Crystalline drug particles with particle 
size of 300 nm were successfully recovered from the nanosuspensions by salt flocculation 
followed by filtration and vacuum drying with a drug yield higher than 92%.  Upon 
redispersion, the average particle size was comparable to the value in the original 
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1.1 THE BIOAVAILABILITY OF DRUGS 
It is estimated that more than 1/3 of compounds being developed by the 
pharmaceutical industry are poorly water soluble.1, 2  The oral bioavailability of these 
poorly water soluble compounds is limited by their inadequate dissolution rate.  
Increasing the dissolution rate of poorly water soluble drugs has become a major 
challenge in pharmaceutical formulation development.  
Drug dissolution is a prerequisite to drug absorption and clinical response for 
almost all drugs given orally.  The drug flux (mass· (area·time)-1) through the intestinal 
wall at any position and time can be expressed by Fick’s First Law as3 
),,,(),,,(),,,( tzyxCtzyxPtzyxJ www ⋅=                                   (Eq. 1.1) 
where Pw (x, y, z, t) is the permeability of this membrane and Cw (x, y, z, t) is the drug 
concentration at the membrane (intestinal) surface.  It is assumed that sink condition 
(drug concentration equals zero) exist for the drug inside this membrane and Pw is an 
effective permeability.  The plasma may be assumed to be the physiological sink since 
concentration in the plasma is generally more than several orders of magnitude below 
that in the intestinal lumen in human.4  The drug absorption rate assuming no luminal 
reactions, at any time is: 
dACPdtdmrateAbsoption wA w∫∫== /                         (Eq. 1.2) 
where A is over the entire gastrointestinal surface.  The total mass, M, of drug absorbed 






)(                          (Eq. 1.3) 
The maximal absorption rate occurs when the drug concentration is at its solubility, Cs,  
swwCPJ ,
max =                             (Eq. 1.4) 





where  for permeability limited absorption; ssw CCCC ≥= , sw CCCC ≤= ,  for solubility 
limited absorption.  For high solubility drugs that are dosed in solution or in dosage forms 
that dissolve very rapidly, a good correlation between drug absorption and intestinal 
membrane permeability is often obtained.5-7  A drug with a permeability greater than 2-4 
× 10-4 cm/sec or about 1 cm/hr would be well absorbed with the expected fraction 
absorbed being greater than 95%.8 
Amidon et al.8 divided drugs into four classes on the basis of their aqueous 
solubility and their ability to permeate the mucosa in the gut from the apical to the 
basolateral side.  Class I drugs are defined as those with high permeability which are able 
to dissolve readily in aqueous media over the pH range 1 to 8.  The drug is well absorbed 
(though its systemic availability may be low due to first pass extraction/metabolism) and 
the rate limiting step to drug absorption is drug dissolution or gastric emptying if 
dissolution is very rapid.  Class II drugs are defined as those with high permeability but 
whose solubility in aqueous media is insufficient for the whole dose to be dissolved in the 
gastrointestinal (GI) contents under usual conditions.  For these substances, dissolution is 
the rate limiting step to absorption.  Class III drug are defined as those with high 
solubility but low permeability which is the rate limiting step in drug absorption.  Class 
IV drugs are defined as those with low solubility and low permeability.  Class II-IV drugs 
present significant problems for effective oral delivery.  In this dissertation, two 
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nanoparticles engineering processes, evaporative precipitation in aqueous solution 
(EPAS) and antisolvent precipitation (AP) were applied to increase the dissolution rates 
of class II drugs which have low solubility in water but high permeability into intestinal 
membranes.  







s −=                           (Eq. 1.6) 
The dissolution rate depends upon the diffusion coefficient of drug molecules in 
dissolution media, D; the specific surface area of drug particles, S; the local equilibrium 
concentration of the drug in the diffusion layer surrounding the particle, Cs; the diffusion 
layer thickness, h; and the concentration of the drug in dissolution media at time t, C.  In 
sink conditions, the dissolution rate may be increased by increasing surface area S and 
drug solubility in dissolution media Cs.  The surface area S may be increased by reducing 
the particle size to sub-micro range,9 by increasing the porosity and by enhancing wetting 
of the particles by the dissolution media.  Wetting may be enhanced with hydrophilic 
excipients that are surface active at the API-aqueous interface.10  The solubility of drugs, 
Cs, may be enhanced by trapping the API in metastable crystalline or amorphous states 
with higher free energies than the lowest energy equilibrium crystalline state.      
1.2 MICRONIZATION PROCESSES TO ENHANCE THE DISSOLUTION RATE OF POOLY 
WATER SOLUBLE DRUGS 
The preparation of small drug particles is very challenging in pharmaceutical 
technologies since the formation of nanocrystalline organic particles is highly complex.  
Several techniques have been applied to convert generally coarse crystalline synthesis 
products into ultra fine particles.  In general two strategies are utilized for this purpose:11 
1) the mechanical milling of the raw material by wet or dry milling processes; 2) 
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precipitation of pharmaceuticals from solution.  In the second case the undesirable 
solvent must nearly always be removed.  Milling processes are subject to limitations in 
the production of nanodispersed systems with narrow size distribution.12  With decreasing 
particle size it becomes increasingly more difficult to use the applied mechanical energy 
in the form of shearing and cavitation forces13 for particle milling without simultaneously 
inducing particle agglomeration.  Moreover, milling can be limited by unfavorable yields 
due to solid losses, high polydispersity in particle size, shear-induced particle 
denaturation, long processing time, high energy requirements and the need for separating 
the product and processing agent.12, 14-16  In spite of these disadvantages milling processes 
do find widespread use in the formation of poorly water soluble active compounds since 
alternative technologies still are not as fully developed.9, 17   
Nanometer to micrometer particles of poorly water soluble drugs can be produced 
by precipitation via various mechanisms.  Finely dispersed naproxen can be prepared and 
precipitated by an acid-basic reaction.  Aqueous solutions of naproxen were prepared in 
the presence of polyvinylpyrrolidone (PVP, Mw= 10, 000) and NaOH.  The resulting pH 
was ~12.  Aqueous HCl solutions were then added dropwise into naproxen aqueous 
solutions under agitation.  At pH lower than 6, naproxen precipitates began to form.  
Aggregated particles with diameter of ~10 µm were formed that can be transferred into 
smaller rod-like, but rather uniform, particles which are ~1 µm long and ~0.3-0.4 µm 
wide when heated at a slightly acidic pH.18  The disadvantage is the organic salt, sodium 
naproxen that is included in the product.   
Precipitation in discrete emulsion droplets is a further way to produce small drug 
particles.11  With lipophilic solvents, particle size control occurs through an emulsion step 
as an intermediate stage.  The particle size distribution of an oil in water (o/w) emulsion 
is adjusted mechanically by homogenization19, 20or sonication.21-23  The final droplet size 
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of the emulsion is smaller than 500 nm.20  The conversion of the emulsion into a 
nanodispersion is then carried out by separation of the solvent by evaporation at a 
temperature lower than the boiling point of the organic solvent or at pressure higher than 
the vapor pressure of the organic solvent.19, 21-23  The resulting particle size is determined 
by the size of the droplets in the o/w emulsion, stabilizer type, stabilizer and drug 
concentration, and the viscosity and volume of internal organic phase.  This technique is 
used for the production of carotenoids,24 indomethacin,19 cyclosporine A,21 U-86,22 
poly(MePEGCA-co-HDCA)23 and cholesteryl acetate.20  The solution of β-carotene in a 
lipophilic organic solvent or an oil24 is emulsified in water containing a protective 
colloid.  After removing the solvent by drying or distillation, each droplet forms solid 
nanoparticles.   
Micron-sized particles may also be formed from solution in semi-continuous 
spray processes, for example spray drying.  In these solution-based processes, the 
stabilizer is not likely to coat the surface of the drug particle as it forms during solvent 
evaporation, since the vapor surrounding the particle is highly hydrophobic.25, 26  It is 
difficult to form submicron particles in the spray drying.  Two important techniques have 
been developed to form small particles with compressed liquid and supercritical carbon 
dioxide, rapid expansion from supercritical solution and precipitation with a compressed 
fluid antisolvent (PCA), which is also referred to as the SAS or SEDS process.27-35  The 
low solubility of water in carbon dioxide complicates the use of hydrophilic substances in 
both of these processes.  RESS is often limited by the low solubility of drugs in 
supercritical fluids even when cosolvents are utilized.  Since water is not very soluble in 
CO , ethanol has been used to aid water dissolution in the PCA process by mixing three 
streams in a tri-axial nozzle.   The complicated nature of the resulting phase separation 




Spray-freeze drying (SFD) is used to form nanostructured particles by atomizing 
solutions into droplets which then fall into liquid nitrogen.37-45  Spray freezing into liquid 
(SFL) process is an alternative cryogenic particle engineering process that utilizes the 
atomization of a feed solution37-44 or emulsion45 containing drugs and/or surfactants 
directly into a cryogenic liquid to produce frozen nanostructured particles.  The frozen 
particles are then lyophilized to obtain dry, freely flowing micronized powders.  
Advantages of the SFL process result from intense atomization in conjunction with rapid 
freezing rates.37-45  Because liquid-liquid impingement occurs between the pressurized 
feed solution exiting the nozzle and the cryogenic liquid such as liquid nitrogen, a higher 
degree of atomization is achieved by spraying directly into the cryogenic liquid as 
opposed to spraying into the vapor phase above the cryogenic liquid in spray freeze 
drying.  Ultra-rapid freezing rate prevent the phase separation of solutes within the feed 
solution and induce formation of amorphous structures.  The intense atomization with 
rapid freezing rates have led to nanostructures aggregates composed of amorphous drug 
nanoparticles with high surface area and enhanced dissolution rates.37-45 
1.2.1 Evaporative precipitation into aqueous solution (EPAS) 
Evaporative precipitation into aqueous solution (EPAS) is a newly developed 
process for forming submicron to micron-sized particles of a poorly water-soluble drug 
coated with hydrophilic stabilizers.  As shown in Figure 1.1, a drug dissolved in a water 
immiscible organic solvent is sprayed through an atomizer into an aqueous solution 
containing a hydrophilic stabilizer to produce an aqueous dispersion.  Intense atomization 
leads to rapid evaporation of the small organic droplets in the aqueous solution.  The 
rapid evaporation of the small organic droplets produces large supersaturation and rapid 
nucleation of the drug.  Hydrophilic stabilizers in water surrounding the shrinking 
organic droplets diffuse to the surface of the growing particles to inhibit particle growth 
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and in some cases, crystallization.  The diffusion is facilitated by the intensity of the 
spray.  The temperature may be chosen to optimize the evaporation rates of organic 
solvent and water, solubility of the organic solvent in water, while minimizing thermal 
decomposition of the drug.  The EPAS suspensions may be dried by spray drying, 
lyophilization, and centrifugation followed by vacuum drying etc.  The stabilization of 
the drug particles with water soluble stabilizers in the aqueous suspensions facilitates 
dissolution rates of the final powder after drying.  Since the particle formation stage is 
distinct from the stage in which the aqueous solution is dried, the drying step does not 
slow down the high dissolution rate of fine particles formed in the suspension.   
The mechanism of particle formation and stabilization in EPAS is shown in 
Figure 1.2.  After atomization, the droplet size of the organic solution containing poorly 
water soluble drugs decreases due to the evaporation of the organic solvent at high 
temperature.  At the same time, the drug concentration increases with time.  When the 
supersaturation of drugs in the shrinking droplet is high enough, the drug and in some 
cases, an excipient, nucleate.  There are two mechanisms for the nuclei to form larger 
drug particles: 1) the drug molecules in the organic phase diffuse to the nuclei and 
condense; 2) the nuclei collide and coagulate together to form larger particles.  A 
calculation on the moments of the size distribution in EPAS revealed that the drug 
particles grow predominantly by coagulation.46  Surfactants in both organic and aqueous 
phases diffuse onto the growing particles.  The hydrophobic moiety of the surfactants 
adsorbed onto drug particles and the hydrophilic moiety extend into water and form steric 
or electrostatic stabilization, if the surfactant is ionic.  The adsorbed surfactants stabilize 
drug particles from particle growth and agglomeration.  The particle growth and 
surfactant adsorption compete with each other.  At high supersaturation or low particle 
growth rate, an aqueous suspension of drug particles may form with particle size smaller 
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than 1 µm.  Since the concentration of the organic solvent in water is extremely low,47 the 
particle growth after suspension formation by Oswald ripening may be expected to be 



































Figure 1.2. Mechanism of EPAS particle formation and stabilization 
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1.2.2 Antisolvent precipitation 
Antisolvent precipitation is a widely used process to prepare inorganic and 
organic particles.  A number of recent studies have utilized antisolvent precipitation to 
produce nanoparticles of poorly water soluble drugs.48-52  In this process, a poorly water 
soluble drug with or without surfactant(s) is dissolved in a water miscible organic 
solvent, including methanol, ethanol, tetrahydrofuran (THF) and acetonitrile etc.  The 
organic solution is then mixed with an “antisolvent”, usually an aqueous solution 
containing a surfactant (s) by a confined impinging jets (CIJ) mixer,50, 52 sonication,49 or 
just pouring the antisolvent into organic drug solution.48  Upon mixing, the supersaturated 
solution leads to nucleation and growth of drug particles, which may be stabilized by 
surfactants.  With sufficient supersaturation, and arrested growth by surfactant 
stabilization, it becomes possible to form suspensions of submicron particles in the 
aqueous solution. 
The mechanism of antisolvent precipitation is shown in Figure 1.3.52  A drug and 
a surfactant are dissolved in an organic solvent and mixed rapidly with an antisolvent to 
afford precipitation of the drug into nanoparticles.  When water is the antisolvent, the 
hydrophobic drug and hydrophobic moiety of the surfactant precipitate simultaneously to 
form nanoparticles that are protected from aggregation and stabilized by the surfactant.  
The mixing time, τmix, must be small compare to the process time, τflash, in order to obtain 
a “homogenous kinetics” free of mixing effects and a narrow particle size distribution.  
The precipitation process can be further subdivided into the characteristic induction times 
for surfactant aggregation, τagg and drug nucleation and growth, τng.  The “reactions” 
compete and when times are matched, the surfactant can interact with the growing drug 
particle to alter nucleation and growth and offer colloidal stabilization.    
 
Figure 1.3. Mechanism of antisolvent precipitation  
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1.2.3 Comparison between micronization processes 
Evaporative precipitation into aqueous solution (EPAS) and antisolvent 
precipitation are two efficient processes to produce nanoparticles of poorly water soluble 
drugs based on two different mechanisms.  The dried sample from EPAS or antisolvent 
precipitation yields nanometer to micrometer particle size, high dissolution rates, high 
surface areas and enhanced wettabilities.  High shear, which is optional for antisolvent 
precipitation, is necessary for EPAS to atomize the organic solution to increase heat and 
mass transfer.  Also, high interfacial tension between water immiscible organic 
solvent/vapor can hinder the mixing between drug nuclei and surfactant molecules, 
leading to micron size particles.  Finally, the high temperature in EPAS favors particle 
growth which can lead to larger drug particles than in antisolvent precipitation.   
On the other hand, since poorly water soluble drugs have higher solubility in 
water immiscible organic solvents such as dichloromethane, diethyl ether etc. but low 
solubility in water miscible organic solvents such as methanol, ethanol etc., EPAS is 
preferred process when the drug has a low solubility in water miscible solvents.  Also, 
unlike antisolvent precipitation, the particle formation step in EPAS is separated from 
drying step with little amount of organic solvent left in the suspension.  The suspension is 
more stable and easier to process due to the small amount of organic solvent.   
As will be discussed in detail, nanoparticles of many poorly water soluble drugs 
can be produced with antisolvent precipitation at low temperature.  But the recovery of 
nanoparticles needs more attention than in EPAS.  The remaining of organic solvent in 
the suspension can lead to rapid particle growth by Oswald ripening.  The removal of 
organic solvent from the suspension needs to be carefully controlled to prevent 
unnecessary particle growth, especially at high temperature.   
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1.3 Objectives 
Two particle engineering technologies, evaporative precipitation into aqueous 
solution (EPAS) and antisolvent precipitation, were developed to micronize poorly water 
soluble drugs for the purpose of enhancing wetting and dissolution rates.  The high 
surface area, enhanced wettability and even amorphous structure for some drugs of 
micronized particles enhanced dissolution.  In this dissertation, Chapters 2-4 utilize the 
EPAS process and Chapter 5 utilizes antisolvent precipitation.  Chapter 2 deals with the 
formation and stabilization of cyclosporine A nanoparticles.  In Chapter 3, the effect of 
dissociation of ketoprofen in pure water, which adds ionic stabilization to steric 
stabilization is shown to lead nanosuspensions at extremely high suspension 
concentration and drug-to-surfactant ratio, as high as 30 mg/ml and 3:1; The interaction 
between ketoprofen and Pluronic F127 also leads to gels at low Pluronic F127 
concentration with extremely small ketoprofen nanoparticles.  In Chapter 4, high potency 
danazol formulations with high dissolution rates are formed by centrifugation to remove 
free surfactant.  The dissolution rate of high potency drug formulations is correlated with 
surface area, crystallinity and particle size.  Chapter 5 discusses nanoparticles formation 
by antisolvent precipitation.  The nanoparticles are flocculated with salt and recovered by 
filtration to simplify solvent removal and to raise the drug potency.  
In Chapter 2, amorphous nanoparticle suspensions of a poorly-water soluble drug, 
cyclosporine A, are produced by a new process, evaporative precipitation into aqueous 
solution (EPAS).  The rapid evaporation of a heated organic solution of the drug, which 
is atomized into an aqueous solution, results in fast nucleation leading to nanoparticles 
suspensions.  Hydrophilic stabilizers, introduced in the organic or aqueous phases, limit 
particle growth and inhibit crystallization for drug concentrations as high as 35 mg/ml, 
and drug-to-surfactant ratios up to 1.0.  The suspensions may be used in parenteral 
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formulations to enhance bioavailability or may be dried to produce oral dosage forms 
with the potential for high dissolution rates due to the low crystallinity, small particle size 
and hydrophilic stabilizer that enhances wetting. 
In Chapter 3, aqueous nanoparticle gels of a poorly-water soluble drug, 
ketoprofen, were produced by evaporative precipitation into aqueous solution (EPAS).  
Liquid droplets of coated ketoprofen were dispersed in water from 60 to 90oC, rather than 
solid particles, due to the freezing point depression from residual organic solvent.  The 
dissociation of ketoprofen in pure water enhanced particle stabilization due to 
electrostatic repulsion to complement steric stabilization.  Stable ketoprofen particles 
with a mean particle size of 135 nm, measured by dynamic light scattering, were formed 
with only 0.1% w/v Pluronic F127 and an exceptionally high drug-to-surfactant ratio of 
10:1.  With 5% w/v Pluronic F127, interactions between the polymer and ketoprofen 
produced a bluish, transparent gel of ~50 nm particles.  The presence of the ketoprofen 
particles lowered the gellation concentration for the Pluronic F127 from 18 wt% all the 
way to 5.8 wt%.  In 2 min, 98% ketoprofen in the gel nanoparticles dissolved, whereas 
the dissolution was slower if the gels were dried.   
In Chapter 4, high-potency danazol particles with high dissolution rates were 
produced by evaporative precipitation into aqueous solution (EPAS).  Aqueous 
suspensions formed by EPAS were centrifuged to remove the non-adsorbed surfactant.  
The resulting surfactant-coated drug particles had extremely high drug-to-surfactant 
ratios greater than 5, corresponding to potencies (wt drug/wt drug + wt surfactant) as high 
as 93%.  The mechanism of the high dissolution rates was characterized as a function of 
surfactant adsorption, particle size and surface area, drug crystallinity, and the contact 
angle for water on the drug surface.  For danazol stabilized by polyvinylpyrrolidone 
(PVP) alone or with sodium lauryl sulfate (SLS), small particle diameter and high surface 
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area led to high dissolution rates with ~90% drug dissolved in 2 min.  The crystallinity of 
the danazol was typically 80%.  The properties of the particles and the dissolution rates 
were mostly unchanged under a two-week thermal cycling stress test.  
In Chapter 5, crystalline naproxen nanoparticle aqueous suspensions, formed by 
antisolvent precipitation, were flocculated with sodium sulfate, filtered and dried to form 
redispersible powders for oral delivery.  The particles were stabilized with 
polyvinylpyrrolidone (PVP K-15) and poly(ethylene oxide-b-propylene oxide-b-ethylene 
oxide) (Pluronic F127) or both.  The yield of the drug in the powder was typically 92 to 
99%, and the drug potency varied by only 1 to 2%.  The filtration process increased the 
drug potency by up to 61% relative to the initial value.  Upon redispersion, the average 
particle size measured by light scattering, as low as 300 nm, was comparable to the value 
in the original aqueous suspension and consistent with primary particle sizes observed by 
SEM.  The dissolution rate was correlated with the particle size after redispersion.  
Extremely rapid dissolution, up to 95% of the powder in two min, was achieved for 300 
nm particles.  The redispersibility of dried powders is examined as a function of the salt 
concentration used for flocculation and the surfactant composition and concentration.  
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Preparation of Cyclosporine A Nanoparticles by Evaporation 
Precipitation into Aqueous Solution 
2.1 INTRODUCTION 
The dissolution rate of many poorly water-soluble drugs limits their 
bioavailability via absorption into the gastrointestinal tract.  Dissolution rates may be 
increased by reducing the particle size to increase the interfacial surface area and by 
inhibiting crystallization to form amorphous particles.  Coating drug particles with 
polymeric and low molar mass hydrophilic stabilizers to enhance wetting and solvation 
by intestinal fluids may increase the rates further.  The simultaneous application of all of 
these strategies would be desirable in attempting to achieve high dissolution rates; 
however, few existing micronization or particle formation techniques are capable of 
achieving such a goal. 
Widely used mechanical techniques based on high shear or impaction, including 
microfluidization and milling can be limited by unfavorable yields due to solid losses, 
high polydispersity in particle size, shear-induced particle denaturation, long processing 
time, high energy requirements and the need for separating the product and processing 
agent.1-4  To overcome many of these limitations, particles may be formed from solution 
in semi-continuous spray processes, for example spray drying.  In these solution-based 
processes, it is often not possible to formulate a solvent that can dissolve both the poorly 
water-soluble drug and hydrophilic stabilizer.  Even if such a solution may be formed, the 
stabilizer may not coat the surface of the drug particle as it forms during solvent 
evaporation, since the vapor surrounding the particle is highly hydrophobic.5, 6  In 
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addition, it is difficult to form submicron particles in the above mechanical processes and 
spray drying.   
Two important techniques have been developed to form small particles with 
compressed liquid and supercritical carbon dioxide, rapid expansion from supercritical 
solution and precipitation with a compressed fluid antisolvent (PCA), which is also 
referred to as the SAS or SEDS process.7-15  The low solubility of water in carbon dioxide 
complicates the use of hydrophilic substances in both of these processes.  RESS is often 
limited by the low solubility of drugs in supercritical fluids even when cosolvents are 
utilized.  Since water is not very soluble in CO2, ethanol has been used to aid water 
dissolution in the PCA process by mixing three streams in a tri-axial nozzle.16  The 
complicated nature of the resulting phase separation and particle formation can make it 
challenging to control the particle morphology.  
The objective of this study is to develop a new process, evaporative precipitation 
into aqueous solution (EPAS), for forming submicron particles of a poorly water-soluble 
drug coated with hydrophilic stabilizers.  As shown in Figure 2.1, a drug dissolved in an 
organic solvent is sprayed through an atomizer into an aqueous solution containing a 
hydrophilic stabilizer to produce an aqueous dispersion.  Intense atomization leads to 
rapid evaporation of the small organic droplets in the aqueous solution.  The rapid 
evaporation produces large supersaturation of the drug.  The resulting rapid nucleation of 
the drug has the potential to produce amorphous instead of crystalline particles.  
Hydrophilic stabilizers in water diffuse to the surface of the growing particles to inhibit 
particle growth and crystallization.  The diffusion is facilitated by the intensity of the 
spray.  The temperature may be chosen to optimize the evaporation rates of organic 
solvent and water, solubility of the organic solvent in water, while minimizing thermal 
decomposition of the drug.  The EPAS suspensions may be dried by spray drying, 
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lyophilization etc.  The stabilization of the drug particles with water soluble stabilizers in 
the aqueous suspensions facilitates dissolution rates of the final powder after drying.   
Since the particle formation stage is distinct from the stage in which the aqueous solution 
is dried, EPAS has the potential to provide greater control over particle size and 
morphology than the above techniques.  In this study, cyclosporine A, a water insoluble 
immunosuppresant for organ transplantation, was used as a model drug.  The solvent, 
nature of the stabilizer, feed concentration of the drug, concentration of the stabilizer, 




Cyclosporine was obtained from North China Pharmaceutical Corporation and 
used without any further purification.  L-α-phosphatidylcholine (Sigma), Myrj 52 (ICI 
Americas), Pluronic F127 (BASF), Polyvinylpyrrolidone (Sigma), Polyethylene glycol 
(Sigma), Brij 97 (Sigma) and Tween 80 (Aldrich) were used without further purification.  
The chemical structures of cyclosporine A and these surfactants are shown in Table 2.1.  
HPLC grade methanol was obtained from EM Science.  Extra dry nitrogen was purchased 
from Matheson.  Water was purified to Type I reagent grade by passing it through a 
Barnstead (NANOpure II) filtration system. 
2.2.2 High performance liquid chromatography (HPLC) and gas chromatography 
(GC) 
HPLC was used to measure the drug concentration in the aqueous suspension with 
a 250 mm long C-18 column (SGE ODS, 5 µm).  The mobile phase was methanol and the 
detection wavelength was 210 nm.  GC was used to measure the residual concentration of 
the organic solvent in the aqueous suspension.  It was equipped with a fused silica 
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precolumn (i.d. = 0.53 mm, 0.5 m, methylated, Supelco) followed by a SPB-5 column 
(i.d. = 0.53 mm, 30 m, Supelco).  To prepare the GC samples, 1 ml dimethylformamide 
was mixed with 1 ml EPAS suspension to dissolve the drug and then 1 µl of the internal 
standard 1-butanol was added into the solution.  The temperature program was: 35oC 
initial temperature for 1 min with a temperature ramp of 15oC/min and final temperature 
200oC for 10 min.  The injection volume was 1 µl, and FID detection was used.  The 
retentions times were: 1-butanol, 0.68 min; dichloromethane, 1.36 min; DMF, 3.33 min. 
2.2.3 Calculation of vapor-liquid-liquid equilibrium for the organic solvent-water 
system. 
For vapor-liquid-liquid equilibrium of an organic solvent and water binary 
system, there is only one degree of freedom.  The equilibrium was calculated with the 
isothermal flash model at 1 atm (ASPEN, Cambridge, MA), utilizing UNIQUAC to 
calculate the activity coefficients, in order to determine the solubility of the organic in the 
aqueous phase. 
2.2.4 Particle size and particle size distribution 
Particle size and particle size distribution were measured in aqueous suspensions 
by dynamic light scanning with a Brookhaven Zetaplus (Brookhaven Instruments 
Corporation, New York).  To measure the particle size distribution, 0.5 ml suspension 
was diluted with distilled water to 8 ml before the measurement, and the results were 
based on the volume fraction distribution.  
2.2.5 Particle crystallinity  
The suspensions were flash frozen with liquid nitrogen and lyophilized to produce 
dry powder.  The crystallinity of the dry powders was examined with a PW1720 x-ray 
generator (PHILIPS). 
 25
2.2.6 Preparation of phosphatidylcholine vesicles  
Phosphatidylcholine was added into water to make a 10% w/v solution.  The 
solution was stirred and sonicated to break up any large clumps.  Then it was passed 30 
times through a high-pressure homogenizer (Avestin Emulsiflex C-5) at a shear pressure 
drop of 15, 000 psi to produce small unilamellar vesicles.  The outlet of the homogenizer 
was submerged in an ice bath to keep the solution under 10°C.  At the end of the run, 0.1 
M NaOH solution was added to adjust the pH between 7.5 and 8.0.  Prior to the 
experiments, the phosphatidylcholine solution was filtered through a 0.2 µm filter.  
2.2.7 Evaporative precipitation into aqueous solution (EPAS) 
The EPAS apparatus is shown in Figure 2.1.  Either the drug solution or pure 
solvent could be fed to the HPLC pump.  The organic cyclosporine A solution was fed 
through a 3 m long 1/16 in. o.d. × 0.030 in. i.d. stainless steel coiled tube contained 
within a 1-1/2″ OD × 24″ long plastic water jacket (Alltech).  Water was circulated 
through the jacket with a Julabo MP temperature controller.  The organic solution was 
atomized through a crimped nozzle into hot water.  The nozzle was made from a 10 in. 
long, 1/16 in. o.d. × 0.030 in. i.d. stainless steel tube.  The tube was cut with a wire cutter 
to produce a crimped thin slit orifice.  The tapered section of the tube was only 0.5 mm 
long.  The tip was filed until the desired pressure drop was achieved for a given flow 
rate.13, 15  The flow rate of the solution was checked by spraying drug solution in pure 
methanol, which would dissolve the drug completely, and the sample was analyzed by 
HPLC.  
The aqueous stabilizing solution was contained in a 125 ml separatory funnel that 
was submerged in a temperature-controlled water bath.  The nozzle was submerged 
approximately 2 cm under the surface of the aqueous solution.  As shown in Figure 2.2, 
the turbulence of the spray mixed the precipitated drug and the surfactant solution 
 26
vigorously.  To suppress and drain the foam produced by the organic vapor, nitrogen was 
blown downwards on top of the foam at 20 psi into the funnel through three 1/16 in. o.d. 
× 0.030 in. i.d. stainless steel tubes.  A thermocouple was submerged next to the nozzle in 
the stabilizing aqueous solution to measure the actual temperature of the aqueous 
solution.  About a 6°C temperature drop resulted from the evaporation of organic solution 
at the thermocouple tip.  Unless indicated otherwise, the stabilizer was added in the 
aqueous phase and was not present in the organic feed solution.  After spraying for a 
required time to produce the desired drug/surfactant ratio, the suspension was recovered 
and analyzed within 1 h to determine the particle size by DLS.  The suspensions were 
flash frozen in liquid nitrogen and lyophilized into dry powders for characterization by 
X-ray diffraction.  
After the spray, the stabilizing solution was replaced by pure water and feed was 
switched to pure solvent to flush the remaining drug out of the tube.  Without this pure 
solvent flush, the drug would precipitate and plug up the nozzle. 
Table 2.1. The chemical structures of drug and surfactants 













































































































Figure 2.1. Apparatus for EPAS 
   
 
Figure 2.2.  Spray of pure dichloromethane into aqueous solution at 80°C in the EPAS 
process for a flow rate of 1 ml/min. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Particle sizes with phosphatidylcholine in the aqueous solution 
The organic solutions were sprayed into small unilamellar vesicles composed of 
phosphatidylcholine.  All EPAS experiments in this section were performed with a 
surfactant concentration of 10% w/v, a temperature of 75°C for the aqueous solution and 
the preheater and a flow rate of 1 ml/min.  The final concentration of drug in suspension 
was measured by HPLC and used to determine the drug/surfactant ratio.  The yield was 
determined by comparing the measured drug concentration and the amount sprayed into 
the aqueous solution.  The experiments with dichloromethane were unsuccessful as this 
solvent modified the vesicles such that the phosphatidylcholine phase separated from the 
water during the spray.    
Table 2.2. EPAS results for 10% w/v phosphatidylcholine in the aqueous solution. 
Csoln. Davg Particle size distribution Caq. Yield Drug/surf. 
 ratio 
(% w/v) (nm) (nm) (mg/ml)  (%) (w/w) 
0 131 53-66 (65%); 225-323 (35%) 0 / 0 
1 253 134-160 (48%); 324-386 (52%) 14.4 96 0.14 
2 526 120-212 (13%); 375-663 (87%) 30.8 87 0.30 
5 477 217-253 (20%); 507-615 (80%) 37.1 100 0.37 
5 408 96-166 (19%); 287-496 (79%) 34.6 98 0.35 
5 446 53-73 (44%); 188-414 (39%); 
1252-2357 (17%) 
31.8 90 0.32 
36.0a 460 123-642 (97%) 35.2 83 0.35 
36.0a 466 267-327 (61%); 653-801 (39%) 34.9 79 0.35 
a: phosphatidylcholine in organic solution 
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The initial size of the SUVs produced during the homogenization process was 
only 48.7 nm.  As shown in Table 2.2, when pure diethyl ether was sprayed into the 
surfactant solution without drug, the vesicle size increased modestly to 130 nm, with 65% 
by volume of the vesicles still smaller than 65 nm.  This result indicates that the vesicles 
are still intact after exposure to the diethyl ether and would be available to stabilize a 
drug.  Upon spraying drug solution into the vesicles, stable turbid suspensions were 
formed.  The mean size of the drug particles increased with the concentration of drug in 
the aqueous suspension Caq, which was a function of the drug concentration in the 
organic feed Csoln, and the spray time.  As Caq increased from 14 mg/ml to values over 30, 
a significant increase in particle size was observed.  At a drug concentration of ~14 
mg/ml, the dispersed particles had a mean size of 253 nm with a size range of 134-386 
nm.  At a concentration of ~35 mg/ml, the mean size increased to 526 nm with a very 
broad size distribution, including some particles larger than 1 µm.  The particle size did 
not change significantly with a change in Csoln from 2 to 5% w/v, as long as Caq was 
constant.  The three experiments with a drug concentration of 5% w/v in diethyl ether 
showed that the experimental reproducibility in particle size was 7.5% and in yield was 
4.2%.  Several factors may contribute to this particle growth with an increase in Caq.  The 
collision frequency increases, which may increase aggregation.  As the drug/surfactant 
ratio increases during the spray, surfactant is transferred from the empty vesicles to the 
surface of the drug particles.  Fewer empty vesicles are available to stabilize the drug 
particles and prevent growth.  Also, the coverage of the drug by surfactant is lower when 
the drug/surfactant ratio increases, leading to less effective stabilization against 
aggregation.  Finally, the longer the spray, the longer the time for aggregation.  Shear 
induced collisions during the spray and an increase in exposure time to organic solvent 
residues could lead to particle growth.  However, this effect of shear was not observed as 
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Csoln was increased from 2 to 5% w/v, as this lowered the spray time from 18 to 7 min for 
a constant Caq of 35 mg/ml. 
To further explore the mechanism of surfactant stabilization, phosphatidylcholine 
was dissolved in diethyl ether with cyclosporine and sprayed into pure water, as shown in 
the last two entries in Table 2.2.  Despite the lack of vesicles in the aqueous solution at 
the start of the process, the mean size and size distribution of the drug particles were 
similar to the case above where vesicles were already present in the water at the start of 
the spray.  This comparison may be made in Table 2.2 at a nearly constant drug to 
surfactant ratio of 0.35.  It is possible that the high shear in the spray produced vesicles.  
The particle sizes at the low end of the distribution were not as small as in the case where 
the vesicles were made in water prior to the EPAS spray.  Thus, the vesicles formed 
during the EPAS spray appeared to be larger than those formed by homogenization.  
Regardless of the size of the vesicles, the surfactant was available to coat and stabilize the 
growing drug particles. 
Heavy foam was formed in the aqueous solution when the organic drug-surfactant 
solution was sprayed into water.  The shear from the evaporating organic jet created 
vapor bubbles that were stabilized by the phosphatidylcholine.  In the earlier experiments 
where the phosphatidylcholine was present only in the aqueous solution, much less foam 
was produced.  In this case the surfactant did not diffuse as quickly to the organic vapor-
water interface to stabilize the foam.  Despite the large degree of foam generation, the 
foam did not leave the top of the vessel containing the aqueous solution due to the 
downward flow of nitrogen.  
2.3.2 Effect of solvents on particle size.   
Two solvents were compared in EPAS experiments, diethyl ether and 
dichloromethane.  They have similar boiling points, vapor pressures and heats of 
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vaporization.17  At a temperature of 75oC, the liquid phase concentration of 
dichloromethane in water is 0.004 g/ml for the equilibrium flash calculation described 
above.  The corresponding value for diethyl ether is 0.012 g/ml due to a lower value of 
the activity coefficient resulting from polar interactions and hydrogen bonding with 
water.  In each spray, the solvent evaporated, and a layer of organic solvent was not 
observed in the precipitation vessel.  As shown in Table 2.3, the size of drug particles 
was much smaller when the organic solvent was dichloromethane versus diethyl ether for 
Pluronic F127 (HO(CH2CH2O)~98(CH2C(CH3)HO)~67(CH2CH2O)~98H, HLB =18-23) as a 
stabilizer.  Additional experiments were performed by spraying pure diethyl ether at 75°C 
into a stable suspension formed by EPAS with dichloromethane, which had an average 
particle size of 423 nm.  After spraying diethyl ether for 10 min at 1 ml/min, large 
particles several microns in diameter formed and settled.  This experiment indicates that 
the large particles formed with diethyl ether are influenced by the stability of the aqueous 
suspensions, and not just the particle formation stage.  Given that the two solvents have 
similar volatilities and heats of vaporization, it is likely that the difference in size is 
related to the much different solubility of the solvents in water and the influence of the 
solvent on Oswald ripening and/or steric interactions between surfactant coated drug 
particles. 
Table 2.3. Solvent effect on the particle size for 1% w/v Pluronic F127 in the aqueous 
phase for a drug/surfactant ratio: 0.93-1.07  
Solvent Davg Size distribution Yield 
 (nm) (nm) (%) 
Diethyl ether 1218 316-1000 (91%) 86 
Dichloromethane 423 358-424 (96%); 909-990 (4%)  96 
Dichloromethane 499 263-303 (38%); 576-689 (62%) 93 
2.3.3 Effect of surfactant type and feeding drug concentration on particle size.   
In addition to phosphatidylcholine, a variety of other surfactants and polymers 
were used in the aqueous solution to stabilize the drug particles, as shown in Table 2.4.  
All of the experiments were done with preheater and aqueous solution temperatures of 
75°C, a flow rate of 1 ml/min, dichloromethane as the solvent, a drug concentration of 
1% w/v, and a surfactant concentration of 1% w/v.  In these experiments, concentrations 
of cyclosporine were significantly higher than typical solubility levels in micelles 
composed of these surfactants.13, 15  Unlike the case for the other surfactants, 
dichloromethane/water emulsions were formed with Brij 97 (C18H35(OCH2CH2)nOH, n 
=1-10, HLB = 12.4) due to its low HLB value.  Much of the drug was lost to the 
emulsion droplets which settled, leaving an aqueous suspension with unusually low 
turbidity.  For a feed concentration of 5% w/v, the results were similar for the Tween 80 
(HLB = 15.0) and Myrj 52 (CH3(CH2)16(OCH2CH2)40OH, HLB = 16.9) nonionic 
ethoxylated surfactants, which had similar HLB values.  However, the particle sizes were 
much larger for the homopolymer stabilizers, which had much higher molecular weights.  
These particles may have had more time to grow due to slower diffusion of stabilizer to 
the particle surface.  However, the steric stabilization provided by the high molecular 
weight of the adsorbed PVP molecules led to suspensions that were stable overnight.  The 
suspensions for the other surfactants were only stable for 1-2 h.    
As shown in Table 2.4, increasing the feed drug concentration to 5% w/v 
decreased the particle size even though the suspension concentration Caq and 
drug/surfactant ratios were approximately the same for Myrj 52, Tween 80, and PVP. 
With an increase in the feed drug concentration, Csoln, the supersaturation increases 
during evaporation, leading to smaller particles, if the steric stabilization is sufficient.  
Furthermore, the shorter spray time for the higher Csoln may produce less shear induced 
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aggregation.  For a given homopolymer, steric stabilization increased with molecular 
weight, as is evident in comparing particle sizes for PVP and PEG.  











1% Brij 97a 1 1177 664-1038 (90%); 3962-5663 (10%) 87 
1% Myrj 52 1 625 512-738 (100%) 86 
1% Myrj 52 5 339 324-349 (100%) 93 
1% Tween 80 1 532 151-191 (19%); 529-713 (81%) 91 
1% Tween 80 5 338 78-571 (100 %) 96 
1% PEG 8, 000 5 1365 1343-1387 (100%) 88 
1% PEG 18, 500 5 1018 77-437 (45%); 876-2091 (55%) 95 
1% PVP 40, 000 1 1076 909-1374 (100%) 95 
1% PVP 40, 000 5 595 577-741 (100%) 89 
1% PVP K-15 5 1115 932-1222 (100%) 98 
a: suspension concentration: 10 mg/ml water and drug/surfactant ratio =1.0. 
2.3.4 Effect of surfactant concentration in the aqueous solution  
All of the experiments in Table 2.5 were conducted under the same conditions in 
Table 2.4 unless otherwise denoted.  The drug to surfactant ratio was chosen to be 
approximately 0.35 at the end of each spray.  As the surfactant concentration was 
doubled, the particle size decreased, even though the drug concentration in the suspension 
increased.  Early in the sprays, the drug to surfactant ratio was lower in the case where 
the surfactant concentration was higher.  This difference may be expected to lead to 
smaller particles, if the particles are well stabilized.  It would not be expected to occur if 
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the particles were not well stabilized, due to enhanced particle collisions with higher 
suspension concentrations.  Thus surfactant concentration may have a large effect on the 
particle formation mechanism. 




Davg Size distribution Suspension 
concentration 
Yield 
 (nm) (nm) (mg/ml) (%) 
1% PVP 40, 000 1076 909-1374 (100%) 3.3 95 
2% PVP 40, 000 861 719-1136 (100%) 6.8 94 
1% Tween 80 559 492-644 (100%) 3.7 101 
2% Tween 80 361 226-435(100%) 6.6 103 
5% Tween 80 122 33-47 (23%); 124-177 (77%) 20.0 97 
 2.3.5 Effect of temperature on particle size. 
The temperature affects the equilibrium concentration of the organic solvent in 
water markedly.  For example, the solubility of dichloromethane in water without 
surfactant in vapor-liquid-liquid equilibrium is 0.0081 g/ml at a temperature of 55°C but 
only 0.0023 g/ml at 85.0°C.  As shown in Table 2.6, the particle size increased with 
temperature for Tween 80 as a stabilizer, but decreased with temperature for PVP 40, 
000.  The other experimental conditions were the same as in Table 2.4.  As temperature 
increases, more rapid evaporation of the organic solvent enhances nucleation favoring 
smaller particles.  Higher temperature also increases the rate of diffusion of the PVP.  
These two factors may explain the decrease in particle size for the PVP data.  For Tween 
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80 other factors were dominant.  The hydrogen bonding between the EO group of Tween 
80 and water is well known to become much weaker over this temperature range.  In fact, 
this reduction of hydrogen bonding often leads to precipitation of EO based surfactants in 
water.18  The steric stabilization from the EO tails in Tween 80 becomes weaker with this 
loss in hydration, and this may lead to particle growth, as observed experimentally.      
Table 2.6. Temperature effect on the particle size for a drug/surfactant ratio: 0.3-0.4  
Surfactant 1% w/v Tween 80 1% w/v PVP 40, 000 
T Davg Size Distribution Davg Size Distribution 
(°C) (nm) (nm) (nm) (nm) 
55 308 37-68 (68%); 168-308 (6%) 
765-1632 (26%) 
1354 577-741 (38%);  
1570-2017 (62%) 
65 438 204-233 (3%); 400-473 (97%) 1144 503-563 (11%);  
1149-1335 (89%) 
75 559 492-644 (100%) 1076 909-1374 (100%) 
85 774 622-925 (100%) 803 594-938 (100%) 
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2.3.6 Effect of drug loading on particle size.   
The drug loading, as reflected in the drug/surfactant ratio, increased linearly with 
the spray time.  As shown in Table 2.7, with an increase in drug loading, and 
consequently, the concentration of the suspension, the mean particle size and 
polydispersity increased.  When the drug to surfactant was above 0.7, very large particles 
were formed, some as large as 3.6 µm.  As the drug/surfactant ratio and the drug 
concentration in the suspension increased, less surfactant was available to stabilize the 
growing drug particles.  Also, the coverage of surfactant on the drug particles decreased 
providing less stability to flocculation and agglomeration.  Both of these reasons may 
contribute to the larger particle size at high drug loading.   
Table 2.7. Effect of drug/surfactant ratio (drug loading) on particle size for 1% Tween 80 





Davg Size distribution 
(% w/v)  (mg/ml) (nm) (nm) 
1a 0.37 3.7 559 492-644 (100%) 
1a 1.16 11.6 518 211-409 (76%); 695-1180 (24%) 
5 a 0.33 3.3 338 78-571 (100%) 
5 a 0.72 7.2 523 168-301 (89%); 2687-3598 (11%) 
5 b 2.50 25.0 921 563-691 (80%); 1740-2249 (20%) 
a: Q=1 ml/min; b: Q=2.5 ml/min 
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2.3.7 Residual solvent concentration 
The residual solvent concentration was measured by gas chromatography (HP 
5890A).  As shown in Table 2.8, the residual concentration of dichloromethane did not 
change significantly with spray time, but did change slightly with surfactant type.  In 
Pluronic F127 aqueous solution, some dichloromethane will be dissolved in the micelles. 
This factor may contribute to higher residual concentration than for PVP, which does not 
form micelles.  The residual concentrations of dichloromethane in the suspension at 75oC 
are slightly smaller than the equilibrium value for the binary system, which is 0.0039 
g/ml.  When the temperature increased from 75 to 85oC, the residual solvent decreased 
from 0.0041 to 0.0021 g/ml, consistent with the decrease in solubility (binary system) 
from 0.0039 to 0.0023 g/ml.  In a single experiment a new nozzle was formed that 
required a higher pressure drop of 4000 psi for the same flow rate to produce more 
intense atomization.  However, the residual solvent was not changed.  Dichloromethane 
is a class 2 solvent with a permitted daily exposure of 6 mg/day.19 
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Table 2.8. Concentration of residual dichloromethane in the aqueous suspension for a 







1% PVP 40, 000 10 0.0031 
1% PVP 40, 000 20 0.0029 
1% PVP 40, 000 30 0.0035 
1% Pluronic F127 10 0.0041 
1% Pluronic F127a 10 0.0044 
1% Pluronic F127b 10 0.0021 
a: Pressure drop = 4000 psi; b: Temperature = 85oC 
2.3.8 X-ray study.   
The drug particle suspensions were flash frozen with liquid nitrogen and 
lyophilized to dry powder.  The x-ray diffraction patterns of several samples are shown in 
Figure 2.3 (a) and (b).  Originally, cyclosporine A was crystalline with sharp peaks in the 
diffraction pattern.  After the EPAS process, these sharp peaks disappeared indicating a 
large loss in crystallinity.  The crystalline peaks of the samples with Myrj 52 come from 
the bulk Myrj 52 and not the drug.  The large loss in crystallinity may be expected to 

























Figure 2.3 (a). The X-ray diffraction pattern of cyclosporine A+PVP 40, 000 powder 





















Figure 2.3 (b). The X-ray diffraction pattern of cyclosporine A + Myrj 52 powder 




The rapid evaporation of the heated organic solution in EPAS results in fast 
nucleation leading to amorphous nanoparticle suspensions.  A variety of hydrophilic 
stabilizers were found to diffuse to the surface of the growing particles rapidly enough to 
prevent growth of the nanoparticles.  Nanoparticle suspensions with low drug 
crystallinity were formed for cyclosporine A with L-α-phosphatidylcholine vesicles, low 
molecular weight ethyoxylated nonionic surfactants, and high molecular weight 
homopolymers.  The drug concentrations were as high as 35 mg/ml, and drug/surfactant 
ratios reached unity.  Both of these values are far in excess of the values obtained for 
solvation of this drug in micelles or vesicle bilayers.13, 15  For the two solvents studied, 
diethyl ether and dichloromethane, the difference in particle size is related to Oswald 
ripening and/or steric interactions between surfactant coated drug particles, and in the 
case of L-α-phosphatidylcholine, to the effect of solvent on the vesicle stability.  The 
particle sizes were larger for the high molecular weight homopolymer stabilizers versus 
the low molecular weight ethoxylated surfactants.  It is likely that the slower diffusion for 
the former allowed more time for particle growth.  For a given drug/surfactant ratio, 
particle size decreased with increasing surfactant concentration, despite the increase in 
the concentration of the suspension.  An increase in temperature speeds up evaporation 
and nucleation leading to smaller particles, except in the cases where it is detrimental to 
steric stabilization, as was found for ethoxylated surfactants.   
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Ketoprofen Nanoparticle Gels Formed by Evaporative Precipitation 
into Aqueous Solution (EPAS) 
3.1 INTRODUCTION 
The bioavailability of many class II poorly water-soluble drugs is dissolution-rate 
limited as their high lipophilicity leads to rapid permeation of biomembranes.1  
According to Noyes-Whitney equation,2 dissolution rates may be increased by reducing 
the particle size to increase the interfacial surface area.  Coating drug particles with 
polymeric and low molar mass hydrophilic stabilizers enhances wetting of this interfacial 
surface area by intestinal fluids to increase the rates further.  Recently a new process, 
evaporative precipitation into aqueous solution (EPAS), was introduced to form rapidly 
dissolving poorly water-soluble drug coated with hydrophilic stabilizers.3-6  A drug 
dissolved in an organic solvent is sprayed through an atomizer into an aqueous solution to 
produce an aqueous dispersion.  Amphiphilic stabilizers diffuse to the surface of the 
growing particles to inhibit particle growth and in some cases, crystallization.  Although 
nanoparticles have been produced for cyclosporine A,3 particle aggregates several 
microns in diameter composed of smaller primary particles have been reported for other 
drugs such as danazol and itraconazole.4,5  However the relatively high surface areas on 
the order of 5 m2/g led to rapid dissolution, which is desirable for oral delivery 
formulations.  However, for parenteral, pulmonary and transdermal applications, it would 
be desirable to produce aqueous dispersions in which the particle size is well below 1 
micron.7-9 
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The primary objective of this study was to develop an understanding of how to 
produce nanoparticles by EPAS rather than the typically reported micron-sized 
particles.4-6  Ketoprofen, a nonsteroidal anti-inflammatory drug, was chosen as a model 
drug due to its tendency to ionize in neutral water.  The particle size was studied as a 
function of the drug concentration in the organic feed solution, to influence the 
supersaturation, the surfactant structure, the suspension concentration, typically 10 to 30 
mg/ml, and the surfactant concentration in the aqueous suspension.  A polyethylene 
oxide-b-polypropylene oxide-b-polyethylene oxide triblock copolymer, Pluronic F127, 
was used to form viscous hydrogels in the aqueous phase with ketoprofen upon cooling to 
prevent particle growth.  Ketoprofen is shown to interact with the polymer to lower the 
polymer concentration needed for gellation markedly.  Amorphous ketoprofen particles 
were formed, whereas EPAS produces crystalline drugs in most cases,4, 10 with some 
exceptions.3  Electrostatic repulsion is shown to stabilize the aqueous suspensions, as the 
particles coalesced upon lowering the pH to protonate the ketoprofen or with the addition 
of salt.  The dissolution rate of the ketoprofen in the original hydrogels and in dried 
hydrogels and suspensions is reported and the stability of the particle size in the gel after 
one month is investigated.    
3.2. EXPERIMENTAL  
3.2.1 Materials 
Ketoprofen, Pluronic F127, Pluronic F68, polyvinylpyrrolidone (PVP K-15, Mw 
=10, 000) and hydrolyzed polyvinly alcohol (PVA, Mw= 22, 000) were purchased from 
Spectrum Chemicals& Laboratory Products Corporation (Gardena, CA).  Myrj 52 
(Sigma) was used as received.  Spectral grade dichloromethane was from Fisher 
Scientific Co. (NJ, USA).   
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3.2.2 Determination of ketoprofen solubility in Pluronic F127 micelles 
Excess ketoprofen was added into 50 ml 1%, 2% and 5% w/v Pluronic F127 
aqueous solutions, respectively, and stirred with a magnetic stir bar for 24 h to achieve 
equilibrium.  10 ml suspensions were filtered with 0.45 µm syringe filters and then 2 ml 
of the filtrates were mixed with 0.2 ml of methanol/water mixture (v:v= 57:40).  All 
samples were then filtered through 0.45 µm filters and ketoprofen concentrations were 
measured by HPLC (Shimadzu, LC-10AT VP, Japan) with a 250 mm long C-18 column 
(SGE ODS, 5 µm). 
3.2.3 Evaporative precipitation into aqueous solution (EPAS) 
The EPAS apparatus is described in elsewhere.3-6  The organic ketoprofen with or 
without surfactant solution in dichloromethane was atomized through an elliptical conical 
nozzle into hot water at flow rate of 1 ml/min and pressure drop of 3500-5000 psi.  100 
ml aqueous stabilizing solution was added to a graduated cylinder that was submerged in 
a temperature-controlled water bath.  The nozzle was submerged approximately 4 cm 
under the surface of the aqueous solution.  Unless indicated otherwise, the stabilizer was 
added in the aqueous phase and was not present in the organic feed solution.  After 
spraying for a required time, typically less than 20 min, to produce the desired 
drug/surfactant ratio, the suspension was recovered and analyzed within 2 h to determine 
the particle size by dynamic light scattering (DLS).  
3.2.4 Particle size and particle size distribution 
The particle size distribution was measured in the aqueous suspensions by 
dynamic light scanning (Brookhaven Zetaplus, Brookhaven Instruments Corporation, 
New York).  The EPAS suspension was diluted with distilled water until the count rate of 
the suspension in DLS ranged in 5-250 kcps.  For example, for a suspension 
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concentration of 30 mg/ml, 0.2 ml of the EPAS suspension was added to 10 ml of water.  
The particle size distributions were based on intensity.  The EPAS suspensions were 
measured in 2 h while the gels were analyzed overnight.  The particle size did not change 
overnight for the ketoprofen suspension.  The particle size of the ketoprofen gel increased 
only slightly over one month, as discussed below.   
3.2.5 Crystallinity and surface area measurement 
The crystallinity of the dry powders was examined by x-ray diffraction with a 
Philips PW 1720 X-ray generator (Philips Analytical Inc., Natick, MA).  The reflected 
intensity of EPAS sample was measured between 5o to 45o with a step size of 0.05o and a 
dwell time of 1 s.  The surface area of the dry powders was measured with a high-speed 
surface area BET analyzer (NOVA 2000, Quantachrome Instruments, Boynton Beach, 
FL) with nitrogen as adsorbate. 
3.2.6 Dissolution test   
After freeze drying or vacuum drying, dry powder containing ~5 mg ketoprofen 
was placed into a USP basket assembly and stirred at 50 rpm in pure water.  5 ml aliquots 
of the dissolution medium were sampled at 2, 5, 10, 20, 30, 60 min.  The aliquots were 
filtered through 0.45 µm syringe filters and 2 ml of each sample were diluted with 0.1 ml 
methanol before analysis.  Ketoprofen concentrations were measured using HPLC 
(Shimadzu, LC-10AT VP, Japan).  
3.3 RESULTS AND DISCUSSION 
3.3.1 Ketoprofen solubility in Pluronic F127 aqueous solutions 
The solubility of ketoprofen in water containing various concentrations of 
Pluronic F127, the primary surfactant in this study, was measured by HPLC.  The 
solubility measurements were repeated three times for each surfactant concentration.  The 
 49
solubilities of ketoprofen in 1, 2, 5% w/v Pluronic F127 solutions were 0.34 ±0.01, 0.81± 
0.03, and 2.67± 0.02 mg/ml, respectively, much higher than its solubility in pure water, 
0.05 mg/ml.  The solubility of ketoprofen in the micelles increased linearly with the 
concentration of Pluronic F127.  In each case, the Pluronic F127 concentration was well 
above the cmc, 4×10-3% w/v.11  In EPAS experiments, the drug concentration in 
suspension was much higher than its micellar solubility in Pluronic F127 aqueous 
solutions, indicating the drug particle were stabilized by surfactant and not merely 
dissolved in the cores of micelles. 
3.3.2 Appearance of ketoprofen dispersions in the aqueous suspensions formed by 
EPAS 
Ketoprofen, with a carboxylic acid group, has a pKa of 4.45.  Relative to other 
commonly studied water insoluble drugs such as danazol and itraconazole etc., 
ketoprofen has a rather high water solubility, 51 mg/L.  In water at the pH of 7 in this 
study, ketoprofen dissociates and has the potential to function as an anionic surfactant 
itself in water, as it contains a hydrophobic moiety.  Another key property of ketoprofen 
is its low melting point, 94oC.12  The temperature of EPAS experiments in this paper 
ranged from 60 to 90oC.  With residual dichloromethane (Tm= -96.7oC)13 and the 
surfactants in the suspension, ketoprofen was likely dispersed in water as a liquid droplet 
instead of as a solid particles, as discussed below. 
To investigate the ketoprofen dispersion produced in EPAS, 20% w/v ketoprofen 
in dichloromethane was sprayed into pH 1.5, pH 2.0 KCl/HCl buffer solutions and into 
pure pH neutral water without any surfactant at temperature of 60, 70, 80, and 90oC for 
10 min.  The ketoprofen concentration in the final dispersion was 20 mg/ml.  The 
dispersions were cooled down after spray while stirring at room temperature and 
photographed to characterize the state of ketoprofen.  For example, pictures of ketoprofen 
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dispersions formed in pH 1.5 buffer solution and pure water at 80oC are shown in Figure 
3.1 (a) and (b).  The white object at the bottom of the container was a magnetic stir bar.  
At pH 1.5, individual liquid droplets were visible with the naked eye.  It is easy to tell 
that these were liquid droplets and not solid particles as they were transparent.  When the 
dispersions were cooled down, ketoprofen changed from liquid (72.4, 55.7oC), to 
semisolid (46.2oC) and to its solid state (43.9oC) as the particles became progressively 
more opaque.  The same behavior was observed with pH 2.0 buffer solutions (not 
shown).  When ketoprofen was sprayed into pure water at neutral pH, the liquid emulsion 
was much milkier and the droplet size appeared to be significantly smaller than in pH 1.5 
buffer solution.  Single droplets of ketoprofen in this fine emulsion were not present to 
the naked eye, as shown Figure 3.1 (b).  
For a poorly water soluble drug, drug solubility in water increases significantly as 
the pH crosses the pKa.14  In pH 1.5 or 2.0 buffer solution below the pKa of 4.45, 
ketoprofen does not dissociate.  In neutral water (pH= 7), it is dissociated and the 
solubility becomes significant, 51 mg/L.  Here ketoprofen contains an anionic moiety and 
a hydrophobic residue.  This amphiphilic character will lower the interfacial tension 
between ketoprofen droplets and water.  For a given shear produced by the nozzle, much 
smaller droplets were produced in neutral water where ketoprofen ionized, in the form of 
a milky white emulsion, than in the low pH buffer solutions.  The same change in 
emulsion morphology was observed at other temperatures, 60, 70, and 90oC.  Since the 
melting point of ketoprofen is 94oC, the formation of ketoprofen liquid droplets rather 
than solid, indicated the presence of residual dichloromethane, which has a low melting 
point of -96.7oC.  At lower temperatures the amount of residual dichloromethane may 
increase due to the decrease in its volatility.  In the results presented below, the 
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dispersion formed in EPAS was cooled down to room temperature and the particle size of 
the solid ketoprofen was then measured by DLS. 
 
        T=72.4oC            T=55.7oC               T=46.2oC         T=43.9oC 
(a): In pH 1.5 KCl/HCl buffer solution 
 
 T=75.9oC     T=72.7oC             T=54.0oC          T=42.9oC 
(b): In pure water 
Figure 3.1. Liquid ketoprofen dispersed in aqueous solution.  20% w/v ketoprofen in 
dichloromethane was sprayed into a pH 1.5 KCl/HCl buffer solution and pure 
water without any surfactant at 80oC for 10 min.  Ketoprofen concentration in 




3.3.3 Effect of surfactant type and temperature on particle size of ketoprofen  
5% w/v ketoprofen in dichloromethane solution was sprayed into 1% w/v aqueous 
solutions containing various surfactants at 90oC for 20 min.  The suspension 
concentration of ketoprofen was 10 mg/ml.  The particle sizes of ketoprofen with various 
stabilizers are shown in Table 3.1.  Some experiments were repeated to check 
experimental reproducibility and shown as (a), (b) and (c).  Stable nanosuspensions of 
ketoprofen with mean particle size smaller than 400 nm were formed with all three 
surfactants, Pluronic F127 (HO(CH2CH2O)~101-b-(CH2CH(CH3)O)~56-b-
(CH2CH2O)~101H), Pluronic F68 (HO(CH2CH2O)~80-b-(CH2CH(CH3)O)~27-b-
(CH2CH2O)~80H) and Myrj 52 (CH3(CH2)~16(OCH2CH2)~40OH).  For Pluronic F127, 
Pluronic F68 and Myrj 52, ketoprofen nanoparticles with mean particle size of 230, 383, 
and 381 nm, respectively, were formed in EPAS.  Among these three copolymers, the 
hydrophilic EO moieties of Pluronic F127 were the longest.  Greater steric stabilization 
with longer hydrophilic blocks would yield smaller particles if the other factors were 
equal, for example the level of surfactant adsorption.  Even though the lowest molecular 
weight surfactant Myrj 52 may be expected to diffuse the fastest, it produced larger 
particles than Pluronic F127.  Perhaps the shorter stabilizing PEO chain provided weaker 
steric stabilization.  Another possibility is that a single PEO chain provides less 
stabilization than dual PEO end segments.  The adsorption of Pluronic F127 on the 
particles may be expected to be higher than for Pluronic F68 since it has higher weight 
fraction of hydrophobic moieties.  Differences in solubilities of ketoprofen in the three 
different types of micelles could also influence the particle size.  Both surfactant micelles 
and free surfactant diffuse to the growing particle surface.  The micelle diffusion and the 
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deposition of surfactant from the micellar surface will depend upon the micelle size and 
surfactant mobility in the micelles.   
With the homopolymer PVA in aqueous solution, the particle size was much 
larger than with the various copolymesr in the aqueous phase.  A dispersion was not 
formed with PVP K-15 in the aqueous phase.  An oily ketoprofen liquid layer floated on 
the top of aqueous phase.  It is well known that a homopolymer is often a less effective 
stabilizer than a properly designed copolymer, since the copolymer has both hydrophilic 
and hydrophobic moieties.  The hydrophobic moieties attach to the particle/droplet 
surface and hydrophilic moieties extend to water, stabilizing the particles/droplet from 
agglomeration, flocculation and coalescence.   
To determine the effect of temperature on ketoprofen particle size, experiments 
were conducted at various temperatures from 60 to 90oC with 1% w/v Pluronic F127 in 
aqueous solution.  As the temperature was decreased from 80 to 70oC, the particle size 
distribution shifted significantly to smaller particles.  This decrease can be influenced by 
several factors.  Decreasing temperature may increase the steric repulsion between the 
EO blocks due to better solvation by water.15  At lower temperature, particle growth by 
diffusion of ketoprofen molecules in the organic phase is slower.  The lower evaporation 
rate will slow down nucleation of the ketoprofen droplets.  This slower production of 
nuclei may give the surfactant more time to diffuse from the water phase and coat the 
particles to lower growth.  However, the evaporation was fast enough to prevent the 
buildup of large organic droplets in the water phase.  As the temperature was lowered 
further, the average particle size increased slightly and some much larger particles were 
formed.  The large particles may reflect too much time for growth in large slowly 
evaporating organic droplets. 
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Table 3.1. Effect of surfactant type and temperature on ketoprofen particle size.  Organic 
phase: 5% w/v ketoprofen in dichloromethane; aqueous phase: 1% w/v 









Particle size distribution  
(nm) 
Pluronic F127  90 81.4 230 16-25 (3%); 48-139 (50%);  
214-626 (47%) 
Pluronic F68 90 81.4 381 212-251 (51%); 485-597 (49%) 
Myrj 52 90 81.4 383 224-264 (57%); 509-625 (43%) 
PVA 90 81.4 2551 13-32 (14%); 56-237 (54%);  
>5 µm (32%) 
PVP K-15   Did not form suspension 
Pluronic F127  80 75.3 184 17-22 (4%); 79-159 (67%);  
278-487 (29%) 
Pluronic F127  70 64.4 114 27-39 (25%); 123-164 (75%) 
Pluronic F127 (a) 60 55.1 133 12-25 (5%); 53-135 (91%);  
729-879 (1%); 1279-1860 (3%) 
Pluronic F127 (b) 60 54.9 126 17-24 (2%); 49-121 (95%);  
1056-1266 (1%); 1816-2607 (2%) 
(a), (b): experiment reproducibility 
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3.3.4 Effect of drug feed concentration and concentration of the ketoprofen aqueous 
suspension on the particle size 
To investigate the effect of feed concentration, ketoprofen solutions were sprayed 
into 1% w/v Pluronic F127 at a temperature of 80oC.  As summarized in Table 3.2, 
increasing in the ketoprofen concentration in the aqueous suspension increases the 
particle size.  At a given drug feed concentration, 20% w/v, the particle size of ketoprofen 
increased from 136 nm to 401 nm when the suspension concentration increased from 10 
to 30 mg/ml.  The higher particle concentration in the suspension increases the collision 
rate and increases the drug-to-surfactant ratio.  The higher ratio may lead to reduced 
surfactant adsorption and thus weaker steric stabilization.  Both of these factors would be 
consistent with the observed larger particles.   
At a given ketoprofen suspension concentration, the ketoprofen particle size 
decreased with increasing drug feed concentration.  For a 10 mg/ml aqueous suspension, 
when the drug feed concentration increased, the mean particle size of ketoprofen 
decreased slightly from 183 nm to 152 nm and the percentage of the largest particles also 
decreased.  At 1% w/v drug in the feed, 2% of the particles were larger than 2 µm, but at 
20% w/v drug in the feed, all the particles were smaller than 300 nm.  At a suspension 
concentration of 30 mg/ml, when the feed concentration increased from 20% w/v to 70% 
w/v, the mean particle size of ketoprofen decreased by a factor of more than three with all 
particles smaller than 200 nm.  With an increase in the drug feed concentration, the 
supersaturation increases during evaporation, leading to faster nucleation resulting in 
smaller particles.  Furthermore, the shorter spray time for the higher feed drug 
concentration provided less time for particle growth.  The formation of stable 
nanosuspensions of ketoprofen, despite the very high drug-to-surfactant ratio of 3, is 
unique relative to other drugs such as cyclosporine A, danazol and itraconazole etc.3-6  
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Table 3.2. Effect of feed drug concentration and suspension concentration on ketoprofen 













Particle size distribution  
(nm) 
1 10 100 1 183 25-51 (15%);104-253 (83%);  
2129-3037 (2%) 
5 10 20 1 184 17-22 (4%); 79-159 (67%);  
278-487 (29%) 
20 (a) 10 5 1 136 10-13 (2%); 47-94 (56%);  
163-327 (42%) 
20 (b) 10 5 1 147 35-46 (21%); 144-206 (79%) 
20 (c) 10 5 1 152 13-18 (3%); 46-73 (29%);  
144-255 (68%) 
20  20 10 2 169 27-51 (12%); 95-210 (80%);  
395-635 (8%) 
20 30 15 3 401 27-41 (6%); 95-222 (88%);  
3474-5303 (6%) 
70 (a) 30 4.3 3 122 29-37 (16%); 118-163 (84%) 
70 (b) 30 4.3 3 122 30-40 (19%); 122-174 (81%) 




3.3.5 Effect of surfactant concentration, pH and ionic strength on ketoprofen 
particle size 
The negative charge due to dissociation of the carboxylic acid groups may 
enhance the stability of the ketoprofen suspension in the aqueous phase by adding 
electrostatic stabilization to complement the steric stabilization from the nonionic 
surfactant.  To study the influence of ketoprofen dissociation on the stabilization, 20% 
w/v ketoprofen solution in dichloromethane was sprayed into various concentrations of 
Pluronic F127 at two different values of pH for 5 or 10 min.  The concentration of 
Pluronic F127 in the aqueous phase ranged from 0 to 1% w/v.  The temperature was 
80oC.  As shown in Table 3.4, with no surfactant in the aqueous phase, ketoprofen did not 
float to the top of the suspension, unlike the case for other drugs tested in EPAS 
including danazol, itraconazole and carbamazepine.3-6  A milky suspension with a mean 
particle size of 4.0 µm formed.  At 0.1% w/v Pluronic F127, the mean particle size of 
ketoprofen was 135 nm and only 5% of the particles were larger than 500 nm.  When the 
Pluronic F127 concentration was increased to 1% w/v, the mean particle size changed 
only slightly, but all particles were smaller than 210 nm.    
To examine the effect of pH, the same ketoprofen organic solution was sprayed 
into 1% w/v Pluronic F127 dissolved in pH 2.0 KCl/HCl buffer solution.  At a suspension 
concentration of 10 mg/ml, stable ketoprofen suspensions were still formed with a mean 
particle size of 151 nm.  But after 5 min where the suspension concentration reached 10 
mg/ml, further spray would cause phase separation of liquid ketoprofen and water.  The 
milky dispersion would suddenly become much clearer due to coalescence of ketoprofen 
droplets.  In contrast, stable nanosuspensions of ketoprofen were formed in pH neutral 
pure water at suspension concentrations of even 30 mg/ml, as shown in Table 3.3.  It is 
apparent that electrostatic stabilization due to the negative charge on the ketoprofen 
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droplets retarded emulsion flocculation and coalescence.  Steric stabilization requires 
time for the surfactant to be adsorbed, whereas electrostatic stabilization is extremely 
rapid once the particles are surrounded by a sufficient amount of water.  At low pH below 
the pKa, 1% Pluronic F127 was not sufficient to stabilize concentrated ketoprofen 
particles/droplets without the electrostatic stabilization, as the droplets coalesced and 
phase separated.  The effect of drug-to-surfactant ratio has been characterized for the 
steric stabilization of drug particles during Young et al.16 in a related process, rapid 
expansion from supercritical to aqueous solution (RESAS).   
The effect of ionic strength on the ketoprofen suspension was also investigated.  
A 20% w/v ketoprofen solution in dichloromethane was sprayed into 1% w/v Pluronic 
F127 dissolved in 1% w/v NaCl aqueous solution, which had an ionic strength of 0.17 M.  
At a suspension concentration of 10 mg/ml, a milky but unstable ketoprofen suspension 
was formed which coalesced after 1.3 min stirring at 80oC after the spray.  This 
experiment further confirmed that electrostatic stabilization due to the negative charge on 
the ketoprofen droplets retarded emulsion flocculation and coalescence.  The high ionic 
strength screened the electrostatic stabilization, and the emulsion coalesced whereas it 
was very stable at zero ionic strength.  
Table 3.3. Effect of aqueous surfactant concentration and pH on ketoprofen particle size 
at 80oC.  Organic phase: 20% w/v ketoprofen solution in dichloromethane; t= 5 











Particle size distribution  
(nm) 
0 7 10 ∞ 3986 192-332 (38%); 861-1296 (20%);  
>5 µm (42%) 
0.01 7 10 100:1 1378 42-178 (50%); 422-1778 (38%); 
>5 µm (12%) 
0.1 7 10 10:1 135 89-136 (95%); 578-746 (5%) 
1 (a) 7 10 1:1 147 35-46 (21%); 144-206 (79%) 
1 (b) 7 10 1:1 163 20-30 (8%); 78-133 (50%); 
203-345 (42%) 
1 2 10 1:1 151 19-27 (3%); 57-85 (27%);  
154-252 (70%) 
1 2 14 1.4:1 Phase separation  





3.3.6 Ketoprofen-Pluronic F127 Gel formation at high Pluronic concentration in 
aqueous phase. 
For certain PPO-PEO-PPO block polymers (Pluronics) in water, a gel region 
appears at high concentration (typically>20 wt%) and intermediate temperatures.17-20  
Due to the possibility of solubilization of both water-soluble and water-insoluble solutes 
in these gels, they are of great interest in drug delivery.20-22  For the Pluronic F127-water 
system,17 the gel region occurs at polymer concentration above approximately 18 wt%, 
but only at intermediate temperatures, e.g. between 20 and 85oC for a concentration of 25 
wt%.  The viscosity becomes small, even in concentrated solutions at temperatures above 
or below the gellation temperature.  According to Wanka et al.11 and Mortensen et al.,23 
gels of Pluronics consist of a close-packed array of block copolymer micelles.   
Gel formation was investigated in EPAS experiments.  Either 20 or 70% w/v 
ketoprofen with or without 5% Pluronic F127 in the organic phase was sprayed into 
Pluronic F127 aqueous solution.  The temperatures ranged from 60 to 90oC.  Figure 3.2 
shows a photograph of ketoprofen-Pluronic F127 gel formed at room temperature after 
cooling from the spray temperature of 90oC.  When the gel was heated in hot water 
(80°C) for 3 min, the gel was converted to a turbid suspension.  Upon recooling to room 
temperature, the translucent gel reformed.  Thus the gellation was thermally reversible.  
The particle size of ketoprofen did not change during the heating and recooling.  It was 
found that if the stirring was too strong and a lot of air was trapped in the gel, ketoprofen 
would crystallize along the air cavities.  In the air cavities, the unprotected ketoprofen 
that was not complexed with the gel began to crystallize and form large particles.   
The conditions where the gel formed and the resulting particle sizes at various 
conditions are shown in Table 3.4.  Either with or without Pluronic 127 in the organic 
feed, when the Pluronic F127 concentration in the aqueous phase was 5% w/v,  the 
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sprayed suspension was as milky as in the above experiments with less Pluronic F127, 
except more viscous.  When the suspension was cooled down at room temperature with 
gentle magnetic stirring, a bluish, transparent ketoprofen-Pluronic gel formed.  The 
ketoprofen particles in the gel were much smaller than those formed in suspensions with 
lower Pluronic F127 concentrations, where a gel did not form upon cooling.  At least 
90% particles were smaller than 50 nm, while the samples with lower Pluronic F127 
concentrations contained particles larger than 150 nm.  For surfactant concentrations 
lower than 5% w/v, no gel was formed.  Compared to the Pluronic F127-water binary 
system, a gel was formed at a much lower Pluronic concentration (5.75-6.61 wt% 
including the water evaporation during EPAS spray) with ketoprofen than without 
ketoprofen (>18 wt%).  In the presence of 1 M NaCl, the gel concentration of Pluronic 
F127 only shifted from 18 wt% at 50oC to 17 wt% at 30oC.17  Since the solubility of 
ketoprofen is only 0.05 mg/ml or 1.97×10-4 M at room temperature, it would not be 
expected to shift the Pluronic F127 gel concentration due to a general effect based on 
ionic strength.  Ketoprofen particles may be distributed both inside the PPO core of 
Pluronic F127 micelles and in the PEO corona.  The polar and ionic carboxylate groups 
will interact favorably with the EO moieties of Pluronic F127 to provide order and 
enhance gel formation.  Also, since the size of the coated drug particles (50 nm) is larger 
than that of the Pluronic micelles (15-20 nm),24 the Hamaker interaction between 
ketoprofen particles may also be expected to aid.  At high temperature, the lattice of the 
Pluronic F127 gel was disrupted by contraction of the micelles as the average 
polyethylene oxide hydrodynamic radius (RH) decreased with temperature.17  
The viscosity of the ketoprofen-Pluronic F127 gel was measured with a 
Brookfield digital viscometer (model DV-I+, Brookfield Engineering Laboratories, Inc. 
Middleboro, MA) at room temperature.  A spindle (LV 2 with a LV guardleg) was 
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rotated at various speeds in a 500 ml gel sample contained in a 600 ml beaker.  The 
viscosity was measured at 6 min after rotation of the spindle.  The gel yielded a non-
Newtonian rheology; the viscosity decreased from 1185 cp at 2 rpm shear rate to 294 cp 
at 10 rpm and leveled off to 85 cp at 100 rpm.  Gels in this viscosity range are appropriate 
for parenteral injection.25  Because of high viscosity of the gel, the ketoprofen diffused 
slowly in the gel and particle aggregation and Ostwald ripening were very slow.  A gel 
formed at 80oC was stable for 1 month with a slight increase in mean particle size from 









Figure 3.2. Thermo reversible gel of ketoprofen-Pluron
temperature 
 64Gel formed again with
cool it down 
Dmean = 80 nm 
23-39 nm (84%);  
475-595 nm (16%)  Gel heated in 80oC
water bath for 3 
min.Gel formed at 90oC 
Dmean= 71 nm 
21-39 nm (90%);  
353-576 nm (10%) ic F127 formed at room 
Table 3.4. Gel formation with 5% w/v Pluronic F127 in aqueous phase.  Organic phase: 20% or 70% w/v ketoprofen solution 
in dichloromethane; suspension concentration: 30 mg/ml. 
CF127 in 
organic 

















Particle size distribution  
(nm) 
0 1 70 4.3 80 N 122 29-37 (16%); 118-163 (84%) 
0 2 70 4.3 80 N 136 18-27 (14%); 45-76 (29%); 157-264 (57%) 
0 (a) 5 70 4.3 80 Y 95 18-32 (28%); 59-96 (58%); 251-408 (14%) 
0 (b) 5 70 4.3 80 Y 81 26-37 (50%); 104-165 (50%) 
5 1 20 15 90 N 139 37-49 (21%); 140-198 (79%) 
5 2 20 15 90 N 120 18-39 (23%); 85-185 (73%) 
5 5 20 15 90 Y 71 21-39 (90%); 353-576 (10%) 
5 5 20 15 80 Y 76 18-45 (98%); 2570 (2%) 
5 5 20 15 70 Y 108 29-47 (41%); 123-222 (59%) 
5 5 20 15 60 Y 50 24-32 (78%); 104-151 (22%) 
(a), (b): experiment reproducibility; Y: gel formed; N: no gel formed. 
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3.3.7 The crystallinity, surface area and dissolution rate of dried ketoprofen-
Pluronic F127 gel and suspension 
A ketoprofen gel was formed by spraying 20% w/v ketoprofen + 5% w/v Pluronic 
F127 in dichloromethane into 5% w/v Pluronic 127 for 15 min at 80oC and cooling the 
suspension to room temperature with magnetic stirring.  The ketoprofen concentration in 
the suspension was 30 mg/ml.  A ketoprofen suspension was also formed by spraying 
20% w/v ketoprofen in dichloromethane into 1% w/v Pluronic F127 for 5 min at 80oC.  
The ketoprofen concentration in the suspension was 10 mg/ml and the drug-to-surfactant 
ratio was 1:1.  The gel was dried with two different methods.  One gel sample was 
vacuum dried at room temperature and -30 in. Hg.  100 ml of the gel was poured into 
three 500 ml beakers to form a thin gel layer.  It took more than three days to dry the gel 
at room temperature due to slow diffusion of water from the gel.  The other sample was 
dried by slowly injecting the gel into liquid nitrogen with a syringe and then lyophilizing 
the frozen mixture for 3 days.  The suspension was also dried by flash freezing in liquid 
nitrogen and was lyophilized for 3 days.   
The BET method was used to measure the surface area of the dried ketoprofen 
gels.  The surface area of the ketoprofen gel dried by lyophilization was 9.7 m2/g, while 
that of the gel dried with vacuum was 8.3 m2/g.  The surface area for the 50 nm particles 
in the gel that was not dried would be much larger.  The x-ray diffraction patterns for the 
dried gel and suspension are shown in Figure 3.3.  Whereas ketoprofen in the suspension 
remained amorphous after lyophilization, the ketoprofen in the gel crystallized during the 
drying step.  The highest ketoprofen peaks coincided with those of bulk Pluronic F127.  
The ketoprofen peaks were much smaller and broader in EPAS samples as well as in the 
physical mixture.  However, the ketoprofen peaks at 2θ= 18.4o were evident for the gels 
dried by vacuum or lyophilization.  Thus, ketoprofen crystallized during drying by either 
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technique, lyophilization or vacuum drying.  As observed in the above experiments with 
the trapped air, it is likely that any vapor bubbles formed during drying may have caused 
crystallization.  Another possibility is that the ketoprofen at the surface of the thin film of 
the gel crystallized.  Finally as the gel dried out, the residual water may have added 
mobility to the ketoprofen and caused crystallization.  The dried gel was redispersed into 
water by magnetic stirring and the particle size was measured.  The mean particle size of 
ketoprofen gel after drying by vacuum and lyophilization was 12.7 and 12.2 µm 
respectively, as measured with a Mastersizer-S (Malvern Instruments Ltd., U. K.) since 
the particle size was too large for DLS.  The particles from Mastersizer were somewhat 
aggregated based on the BET surface areas.   
The dissolution rates of the wet ketoprofen gel, the gels dried by vacuum and by 
lyophilization, the suspension dried by lyophilization (formed with dilute Pluronic F127), 
and a physical mixture of ketoprofen and Pluronic F127, with the same composition as 
the gel, are shown in Figure 3.4.  The ketoprofen release from the wet gel or lyophilized 
suspension, 98% and 94%, respectively, in 2 minutes was extremely rapid.  However, 
when the gel was dried by vacuum or lyophilization, the dissolution rate of ketoprofen 
was much slower than for the wet gel.  There are two reasons for the slower dissolution 
rates.  One is due to the large particle size and smaller surface area after drying.  The 
other is due to slow hydration and swelling of ketoprofen-Pluronic F127 complex which 
was observed during dissolution test.  The slow hydration rate of this complex slowed 
down the dissolution.  In all cases, the release rate of ketoprofen gel was much higher 
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Figure 3.3. X-ray diffraction profiles of dried ketoprofen gels and suspensions by 
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Figure 3.4. Dissolution profiles of dried ketoprofen gels and suspensions by 
lyophilization or vacuum drying 
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3.4 CONCLUSIONS  
Aqueous ~50 nm gels of a poorly-water soluble drug, ketoprofen, were produced 
by evaporative precipitation into aqueous solution (EPAS) followed by cooling.  In only 
two minutes, 98% of this wet gel dissolved.  In addition, 94% of the ketoprofen dissolved 
from suspensions with lower surfactant concentration, which were dried by 
lyophilization.  The size of the particles in the gel changed only a small amount over one 
month reaching only 115 nm.  The addition of electrostatic repulsion, due to ketoprofen 
ionization, to complement steric stabilization led to much smaller particles than normally 
produced by EPAS.  Furthermore, the particles were amorphous, whereas crystalline 
particles are normally formed.  The favorable interactions between ketoprofen and 
Pluronic F127 led to amorphous particles for low Pluronic F127 concentrations.  Stable 
ketoprofen particles with a mean particle size of 135 nm, measured by dynamic light 
scattering, were formed with only 0.1% w/v Pluronic F127 and with an exceptionally 
high drug-to-surfactant ratio of 10:1.  Here the concentration was well below the gellation 
concentration.  For higher Pluronic concentrations, these interactions induced gellation 
and produced unusually smaller particles, as small as 50 nm.  When the drug 
concentration in the organic phase increased from 20% to 70% w/v, the particle size of 
ketoprofen decreased from 401 to 122 nm at suspension concentration of 30 mg/ml due to 
higher supersaturation.  The rapidly dissolving wet gels, with relatively low viscosities, 
are of interest in transdermal and parenteral delivery; furthermore, the gels may be dried 
for oral delivery.  
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Rapid Dissolution of High Potency Danazol Particles Produced by 
Evaporative Precipitation into Aqueous Solution 
4.1 INTRODUCTION 
From a therapeutic and biological point of view, a drug delivery system with a 
high drug-to-surfactant ratio or payload has many advantages.  This will allow an 
effective dose to be administered and consequently produce high blood levels with less 
potential interactions from the excipients.  A major challenge for water insoluble drugs is 
to achieve rapid release with a high drug-to-surfactant ratio or payload.  Typically, the 
ratio of drug-to-surfactant ranges from 1:10 to 1:1.1-3  For these compounds, permeability 
of biological membranes is often not an obstacle to absorption since the lipophilicity of a 
drug, which facilitates permeation, generally increases as the solubility decreases.4 
Oral bioavailability of water insoluble drugs is often dependent upon the rate of 
dissolution of the drug in the gastrointestinal tract.5  The dissolution rate of an active 
pharmaceutical ingredient (API) into an aqueous solution depends upon the diffusion 
coefficient, D, the surface area, S, the local equilibrium concentration of API in the 
diffusion layer surrounding the particle, Cs, and the diffusion layer thickness, h, as 
follows: 





s −=                                                              (Eq. 4.1) 
where C is the concentration of the API in bulk solution.  The surface area S may be 
increased by reducing the particle size,6 by increasing the porosity and by enhancing 
wetting of the particles by the dissolution media.  Wetting may be enhanced with 
hydrophilic excipients that are surface active at the API-aqueous interface.7  The value of 
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Cs may also be enhanced by trapping the API in metastable crystalline or amorphous 
states with higher free energies than the lowest energy equilibrium crystalline state.      
Although APIs may be dissolved in micelles, vesicles or microemulsions, the 
drug-to-surfactant ratios are typically well below 1:1.8-10  An alternative approach is to 
stabilize drug particles formed by mechanical milling.11,12  Widely used batch mechanical 
techniques based on high shear or impaction, including microfluidization and milling can 
be limited by unfavorable yields due to solid losses, high polydispersity in particle size, 
shear-induced particle denaturation, long processing time, high energy requirements and 
the need for separating the product and processing agent.13, 14  To attempt to overcome 
many of these limitations, particles may be formed from solution in spray processes.  
However, drug-to-surfactant ratios are still typically below 1:1.  It has been highly 
challenging to raise the potency further due to incomplete coating of particles by 
surfactant that leads to poor wetting, particle aggregation, and low surface area.  
Amorphous cyclosporine particles coated with various surfactants have been produced by 
rapid expansion from supercritical to aqueous solution (RESAS) utilizing CO2 as the 
supercritical fluid.15  The average particle size increased from below 1 micron to well 
over 1 micron at a threshold drug/surfactant ratio of about 0.6-0.7. 
Another approach is to use solid dispersions to increase effective surface area.  
However, the dissolution rate of triamterene from melted and spray-dried solid 
dispersions containing D-mannitol decreased significantly as the drug loading increased 
from 5% to 40%.16  Similar behavior was observed with ketoprofen-PEG 6000 
dispersions.17  Rowley et al.18 and Brown et al.19 showed that adsorption of a surfactant at 
a solid drug particle surface, by equilibrating drug particles with surfactant aqueous 
solution, improved wetting, as indicated by the contact angle, and dissolution rates. 
Reduction in contact angle from 91o for untreated danazol to 62o was achieved at a high 
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drug/surfactant ratio of 99:1, with a corresponding increase in drug dissolution from 35 to 
65% in 10 minutes. 
Evaporative precipitation into aqueous solution (EPAS) is a new process to 
produce submicron to micron-sized hydrophobic drug particle dispersions stabilized by 
surfactants.20, 21  As shown in Figure 4.1, a drug dissolved in an organic solvent is sprayed 
through an atomizer into an aqueous solution containing a hydrophilic stabilizer to 
produce an aqueous dispersion.  Rapid evaporation of the small organic droplets produces 
large supersaturation and rapid nucleation of the API.  Hydrophilic stabilizers in water 
surrounding the shrinking organic droplets diffuse to the surface of the growing particles 
to inhibit particle growth and in some cases, crystallization.  In previous studies, EPAS 
suspensions were dried by spray drying or lyophilization.  All of the surfactant stabilizer 
remained with the product after drying leading to a moderate drug-to-surfactant ratio 
ranging from 1:4 to 1:1.  Here we show that only a fraction of the surfactant utilized to 
stabilize the aqueous suspension formed during the EPAS process is needed in the final 























Figure 4.1. The apparatus of EPAS 
The primary objective of this study is to produce danazol particles by EPAS with 
high dissolution rates and extremely high drug-to-surfactant ratios greater than 5, 
corresponding to a potency (wt drug/wt drug + wt surfactant) above 80%.  An aqueous 
suspension is produced by EPAS as done earlier20, 21 to produce surfactant coated 
particles.  The suspension is then centrifuged and the supernatant is decanted to remove 
the free surfactant in order to raise the potency in the precipitate.  Also, this 
centrifugation process is utilized to determine the adsorption of the surfactant on the drug 
surface.  We hypothesize that the free surfactant is not needed for high dissolution rates 
 76
 77
once the particles are coated with adsorbed surfactant.  It will be shown that the adsorbed 
surfactant is sufficient to prevent aggregation and enhance wetting to maintain a high S.  
The dissolution rate is analyzed as a function of the surfactant adsorption, particle size, 
surface area, contact angle, particle morphology and crystallinity to provide an 
understanding of the mechanism of enhanced dissolution rates.  From a processing point 
of view, removal of water by centrifugation followed by vacuum drying is faster and 
more economical than lyophilization.  Also, the yields can be improved relative to spray 
drying due to ease of particle recovery.  Danazol was chosen as the model drug given its 
low water solubility of 0.6 µg/ml. 
4.2 EXPERIMENTAL  
4.2.1 Materials 
Danazol was purchased from Spectrum Chemicals& Laboratory Products 
Corporation (Gardena, CA).  Pluronic F127 (BASF, Mount Olive, NJ), polyvinyl 
pyrrolidone (PVP K-15, Mw =10, 000 and PVP 40T, Mw = 40, 000) (Sigma, St. Louis, 
MO), sodium lauryl sulfate (Sigma) and sodium deoxycholic acid (Sigma) were used as 
received.  HPLC grade acetonitrile was from EM Science (NJ) and spectro grade 
dichloromethane was from Fisher Scientific Co. (NJ). 
4.2.2 Evaporative precipitation into aqueous solution (EPAS) 
The EPAS apparatus is shown in Figure 4.1.  The danazol solution in 
dichloromethane was fed by an HPLC pump through a 3 m long 1/16 in. o.d. × 0.030 in. 
i.d. stainless steel coiled tube contained within a 1-1/2 in. o.d. × 24 in. long plastic water 
jacket (Alltech).  Water was circulated through the jacket with a Julabo MP temperature 
controller.  The organic solution was atomized through an unheated insulated adjustable 
restrictor (5 mm dia. × 136 mm long, ISCO, USA) into hot water.  The angle of the stem 
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was 30o, and the diameter was tapered from 0.038 in. down to 0.022 in.  The angle of the 
seat was 60o.  Atomization was achieved by adjusting the nozzle valve manually to 
maintain a pressure drop to about 3500 psi.  The aqueous stabilizing solution was 
contained in a 250 ml plastic cylinder submerged in a temperature-controlled water bath.  
The nozzle was submerged approximately 4 cm under the surface of the aqueous 
solution.  To suppress and drain the foam produced by the organic vapor, nitrogen was 
blown downwards on top of the foam at 20 psi into the cylinder through three 1/16 in. 
o.d. × 0.030 in. i.d. stainless steel tubes.  Unless indicated otherwise, the stabilizer was 
added in the aqueous phase and was not present in the organic feed solution.  After 
spraying for a required time to produce the desired drug/surfactant ratio, the suspension 
was recovered and analyzed within 30 min to determine the particle size by light 
scattering with a Malvern Mastersizer-S (Malvern Instruments Ltd., U. K.). 
4.2.3 Surfactant adsorption measurement 
To quantify surfactant stabilization of the danazol particles in the EPAS 
suspension, surfactant adsorption was measured based on a mass balance between the 
supernatant and precipitate.  In these measurements, Wsup,wet was the weight of the 
supernatant before drying, which included danazol, which may dissolve in micelles or 
surfactant complexes if formed.  Wsup,dry was the weight of the supernatant after drying to 
remove water.  Wppt,wet was the weight of the precipitate before drying, which includes 
danazol, adsorbed surfactant and a small amount of supernatant with the same 
composition as the bulk supernatant.  Wppt,dry was the weight of the precipitate after 
drying.  Wdrug,ppt was the amount of danazol in the precipitate measured by HPLC.  
Wsurf,ads was the amount of adsorbed surfactant on danazol.  Since the composition of the 
small amount of supernatant left on the precipitate was assumed to be the same as that in 
the bulk supernatant 

















                 (Eq. 4.2)                              
where it has been assumed that the amount of danazol in the precipitate was at least 50 
times more than danazol dissolved in micelles.  From this equation, the amount of 











×−−−=                 (Eq. 4.3)                               
To measure the amount of surfactant adsorbed on the particles, 1% w/v danazol 
solution in dichloromethane was sprayed into 15 ml aqueous solution containing 1% w/v 
surfactant at a flow rate of 1 ml/min for 7.5 min to produce a suspension with a drug-to-
surfactant ratio of 0.5:1.  The pressure drop was 3000-4000 psi and the temperature was 
75oC.  4 ml of the suspension was centrifuged.  After centrifugation, the supernatant and 
the precipitate were weighed before and after vacuum drying at 40oC and –30 in. Hg to 
determine surfactant adsorption. 
4.2.4 High potency danazol powder by centrifugation 
2% w/v danazol solution in dichloromethane was sprayed at a flow rate of 1 
ml/min into 100 ml aqueous solution containing 1% w/v surfactant or a surfactant 
mixture at 1:1 w/w ratio, if two surfactants were used, to stabilize the drug particles.  The 
temperatures of both heating jacket and water bath were 80oC and the pressure drop was 
3500-4000 psi.  After 25 min of spray, a suspension with a drug-to-surfactant ratio of 0.5 
was recovered and the particle size of the danazol particles was measured with Malvern.  
The suspensions were centrifuged (Beckman, Model TJ-6, USA) at 3000 rpm for 30 min.  
The supernatants were decanted and the precipitates were placed into a vacuum oven and 
dried at 40oC, and -30 in. Hg overnight.  The potency was determined by dissolving a 
known amount, about 10 mg, dry powder into 50 ml danazol mobile phase 
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(acetonitrile/water mixture, v:v = 70:30) and measuring danazol concentration by HPLC 
(Shimadzu, LC-600, Japan).  The crystallinity of the dry powders was examined by x-ray 
diffraction (PW1720, Philips).  The surface area of the dry powders was measured with a 
high-speed surface area BET analyzer (NOVA 2000, Quantachrome Instruments, USA). 
4.2.5 Dissolution test 
The dissolution media of danazol in USP 25 is 0.75% SLS aqueous solution.  In 
this article, pH = 9.0 SLS/tris buffer, which contained 0.75% w/v sodium lauryl sulfate 
and 1.21% w/v tris (hydroxymethyl) aminomethame PD 2960 in aqueous solution was 
used.  According to experimental measurements, pH of 0.75% SLS aqueous solution is 
8.5.  Also, results showed that the solubility of danazol (0.44 mg/ml vs. 0.40 mg/ml in 
0.75% SLS and pH 9 SLS/tris buffer, respectively) and the dissolution rate of bulk 
danazol in both dissolution media were very close, almost identical.  With the same 
concentration of SLS, very close pH values, almost identical danazol solubility and 
release rate, pH 9 SLS/tris buffer is a better dissolution media than 0.75% SLS aqueous 
solution, minimizing a possible pH change of the dissolution media by the surfactants 
from EPAS process. 
After centrifugation and vacuum drying, ~ 20 mg dry powder was placed into a 
USP basket assembly and stirred at 50 rpm for 30 min in SLS/tris buffer.  Aliquots of the 
dissolution medium (5 ml) were sampled at 2, 5, 10, 20, 30 minutes.  The aliquots were 
filtered through 0.45 µm syringe filters and 2 ml of each sample was diluted with 0.1 ml 
acetonitrile before analysis.  Danazol concentrations were measured using HPLC 
(Shimadzu, LC-600, Japan).  Dissolutions were repeated for three times and the statistics 
was shown in the dissolution figures. 
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4.2.6 Particle size 
Particle size distributions, based on volume fraction, of the original EPAS 
suspension and redispersed dry powder were measured by static light scattering with a 
Malvern Mastersizer-S.  To measure the particle size distribution, 5 ml suspension with 5 
mg drug/ml water concentration, was diluted with 500 ml distilled water, to produce a 
light obscuration in the range of 10-30% for accurate measurement.  To study the 
redispersibility of the dry powders after centrifugation and vacuum drying, about 25 mg 
dry powder were suspended into 500 ml distilled water to produce an obscuration in the 
range 10-30%.  After 1 min, the particle size distribution was measured.  In a control 
experiment, bulk danazol was dispersed in 500 ml 0.02% w/v non micelle-forming PVP 
40T aqueous solution, since it is very hydrophobic and difficult to disperse in pure water.  
Ultrasound was used in the measurement to break up the agglomerated particles. 
4.2.7 Contact angle 
Dry powder (100 mg) was loaded into a 0.7 cm diameter flat faced die and 
compressed with a Carver Laboratory Press (Model M, Fred S. Carver Inc, WIS, USA) at 
1500 kgf into a tablet.  A 5 µl drop of distilled water was placed on the surface of the 
tablet and contact angle was measured from the tangential angle of the water drop with 
help of a camera (Panasonic WV-1410, Philippines). 
4.2.8 Thermal cycling stress test 
Dry powders were placed in 60 ml Qorpak® glass bottles, sealed with sodium 
calcium aluminosilicate hydrate desiccant containing cobaltous chloride indicator (VWR 
International, West Chester, PA) in a temperature controlled oven.  The temperature 
cycle was: increase temperature from –5oC to 40oC over 30 minutes, hold at 40oC for 2.5 
hours and then decrease temperature from 40oC to – 5oC over 30 minutes.  The cycle was 
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repeated 6 times per day.  The duration of the stability study was 2 weeks.  The 
characteristics of the dry powders were studied over two weeks. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Surfactant adsorption study 
The adsorption of various surfactants onto drug particle surfaces formed during 
the EPAS process is listed in Table 4.1 and 4.2.  For this short spray time of 7.5 min, the 
adsorption of PVP K-15 was 30% larger than that of PVP 40T.  At equilibrium, the 
adsorption of the higher molecular weight PVP 40T may be expected to be larger due to 
its higher molecular weight than PVP K-15.  The equilibrium adsorption of a polymer 
often increases with molecular weight, since the adsorbed chains form a thicker layer, as 
predicted by the Scheutjens-Fleer model.22  Since thermodynamics would favor higher 
adsorption for the higher molecular weight PVP 40T for a given surface area, it is likely 
that mass transfer and kinetic factors may also contribute to the difference observed in the 
adsorption.  Part of this higher adsorption for PVP K-15 may result from generally larger 
surface area for the PVP K-15 samples relative to the PVP 40T samples, as shown in 
Table 4.3.   
The rate of adsorption depends upon the diffusion rate to the surface and the 
kinetics of adsorption at the surface.  The kinetics of polyethylene oxide (PEO) 
adsorption on a flat silica surface has been studied in a stagnation-point flow cell with a 
fixed angle reflectometer.23, 24  The rate of adsorption decreased with increasing polymer 
molecular weight because of a lowering of the diffusion constant, indicating that the 
adsorption rate is mass transfer rate limited up to at least 70% of the plateau.  From the 
scaling theory of polymer solutions,25 in a good solvent, the diffusion coefficient D of a 
polymer is correlated with its molecular weight M as D ~ M-γ with γ= 0.5 for low M and 
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0.588 for high M.  The diffusion coefficient of PVP 40T is expected to be about 40% 
lower than PVP K-15 due to its higher molecular weight.  Both slower diffusion and 
slower adsorption kinetics at the surface would lower the amount of adsorbed PVP 40T 
relative to the lower molecular weight homopolymer PVP K-15. 
For the copolymer Pluronic F127 in the aqueous solution, only 3.87% w/w 
surfactant to drug was adsorbed during the EPAS spray in contrast with much larger 
values for both PVP polymers.  After storage at ambient temperature without stirring for 
3 days, the molecules of the adsorbed surfactant may rearrange on the drug particle 
surface providing space for much more surfactant to adsorb as shown in Table 4.1 and 
4.2.  The adsorption of Pluronic F127 increased from 3.87 to 11.21% w/w drug.  These 
dynamics are consistent with fundamental studies of block copolymer adsorption by 
FTIR spectroscopy.26  In the adsorption dynamics of PS-b-PEO on hydrophilic silica, 
three distinct zones were observed.  In the first 5 minutes, the polymer adsorbs on many 
vacant sites with little rearrangement as a function of the differential sticking enthalpies 
and geometric sizes of the blocks.  In the next two time zones, PEO interactions with the 
silica displace PS interactions to produce a polymer brush.  The kinetics of rearrangement 
of PS-b-PEO on the surface to accommodate more polymer on progressively fewer 
surface sites takes several hours, as was observed in the present study for Pluronic F 127.





Chemical structure of surfactants Mw of surfactants Wsurf,ads /Wdrug,ppt  
(w/w, %) 
PVP K-15 homopolymer 10, 000 13.0 ± 2.43 




40, 000 10.0 ± 1.01 
Pluronic F127 triblock copolymer 12,500 3.87 ± 1.43 
Pluronic F127a  
HO(CH2CH2O)98(CH2CHO)67(CH2CH2O)98H
CH3   11.2 ± 0.72
a




















414 5.79 ± 1.61 
SLS  anionic surfactant CH3(CH2)10CH2O-SO2-ONa  288 5.44 ± 0.46 
a: Adsorption measurement after 3 days 
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Table 4.2. Pluronic F127 adsorption on danazol particles after 3 days storage.  The two 
entries indicate the reproducibility of the experiment for 4 ml samples of the 














 (w/w, %) 
1.8987 0.0414 0.1276 0.0200 15.820 1.888 11.9 
1.5594 0.0373 0.0901 0.0213 17.753 1.862 10.5 
The difference in adsorption dynamics for PVP homopolymer and Pluronic F127 
copolymer may be examined in terms of the different conformations on the drug particle 
surface.  For the Pluronic F127, the PEO blocks favor water.  It is likely that significant 
rearrangement on the surface is needed for the central hydrophobic PPO blocks to 
displace the more prevalent PEO blocks in order to adsorb on the drug surface.  For PVP 
homopolymers, these rearrangements between two types of blocks are not needed leading 
to faster adsorption.  Attachment of only a fraction of the homopolymer segments on the 
surface of drug particles can lead to adsorption, with loops and dangling ends of 
homopolymer protruding into water and providing steric stabilization. 
As shown in Table 4.1, the adsorption (Wsurf,ads/Wdrug,ppt) of the anionic surfactants 
SLS and DCA was significantly smaller than that of PVP.  For a given area per surfactant 
on the surface, the lower molecular weight of these surfactants will lead to a thinner 
adsorbed layer and thus a smaller number of grams of adsorbed surfactant at equilibrium.  
The kinetics of adsorption is rapid as the number of rearrangements of the low molecular 
weight tails are much smaller than for polymeric surfactants. 
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4.3.2 The recovery of danazol in the precipitate and its potency 
In the aqueous suspensions produced by EPAS, certain surfactant stabilizers form 
micelles that dissolve a small fraction of the API.  This small amount of soluble API will 
be lost to the supernatant after centrifugation.  As shown in Table 4.3, the concentration 
of danazol in the supernatant is strongly dependent on the surfactant type.  For PVP 40T 
and PVP K-15, which do not form micelles in water, the concentration of danazol in the 
supernatant solution was expected to be its solubility in water, 0.6 µg/ml, which was too 
low to be measured reproducibly with HPLC used in the experiments (Shimadzu, LC-
600). The danazol recovery is defined as the fraction not found in the supernatant after 
centrifugation.  It is not the overall yield from the EPAS process as some of the drug may 
be lost to other places such as the side of the collection vessel.  The fraction of danazol in 
the aqueous suspension recovered in the precipitate after centrifugation was above 99%.  
For the micelle-forming surfactants, Pluronic F127, SLS and DCA, the recoveries 
decreased, but were still greater than 96.2% for each surfactant except for SLS.  The 
recovery was high in all cases except SLS since the concentration of drug in the 
suspension was far above the micellar solubility of the drug.  After centrifugation and 
vacuum drying, the potency of danazol in the dry powders was higher than 83.2%, as 
shown in Table 4.3.  Drug-to-surfactant ratios varied from 5:1 to 13:1.  These values are 
much higher than typical values of 1:4 to 1:1 observed for milling and spray processes 
including earlier EPAS studies.21, 27  The high potencies result from the removal of a large 
amount of the surfactant with the supernatant. 
 87

















height at  
2θ = 15.9o 







Bulk danazol / / / 3182 0.52 61.3 
PVP K-15 Xa 100 88.5 2358 5.55 41.1 
PVP 40T Xa 100 92.3 1942 4.89 47.9 
Pluronic F127 0.035 99.3 89.3 2843 3.13 34.0 
DCA 0.084 98.3 85.1 2413 3.72 18.9 
SLS 0.804 82.1 83.2 2867 3.07 7.0 
PVP40T 
+Pluronic F127 
0.009 99.8 91.5 2546 3.28 39.8 
PVP 
40T+DCA 
0.020 99.6 86.4 2371 3.22 35.1 
PVP 40T+SLS 0.191 96.2 92.9 2465 4.98 13.9 







4.3.3 Dissolution rate 
As shown in Figures 4.2 (a) and (b), the dissolution rate was strongly dependent 
on the type of surfactant.  It was much higher for PVP K-15, PVP 40T or PVP 40T + SLS 
than the other stabilizers.  In 2 min, 78, 88 and 90% danazol dissolved with PVP 40T, 
PVP K-15 or PVP 40T+ SLS as the surfactants, respectively.  For the other systems, the 
dissolution rates were much lower, closer to that of bulk danazol.  We will show below 
that these systems with low dissolution rates had larger particle sizes and lower surface 
areas. 
Pure PVP 40T powder was added to a sample of high potency powder already 
stabilized by PVP 40T in EPAS.  The high potency powder was produced by 
centrifugation.  The objective was to determine if the addition of free surfactant would 
raise the dissolution rate even further, relative to the high potency EPAS powder without 
free surfactant.  The free surfactant lowered the overall drug-to-surfactant ratio from 12:1 
to 1:2.  As shown in Figure 4.2 (a), the dissolution rate did not change.  Apparently, the 
changes in S from the EPAS spray and adsorbed surfactant were sufficient to produce 
high dissolution rates, without any need for mixing in additional stabilizer. 
Notice the dissolution rate is higher for PVP 40T+ SLS than for PVP 40T even 
though the surface areas were similar.  Perhaps the SLS was able to coat danazol particle 
surface not covered by the high molecular weight polymer to enhance wetting. 
As a control experiment, 0.5 g bulk danazol was dispersed into 100 ml 1% w/v 
PVP K-15 under magnetic stirring for 25 min (same composition and adsorption time as 
EPAS).  The dispersion was then centrifuged and the precipitate was vacuum dried at 
40°C and -30 in. Hg.  The potency of danazol in this dried powder was 93.0%; ~20 mg 
dried powder was put in the dissolution media, and the drug release rate of danazol was 
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measured by HPLC.  The release rate of danazol was higher than bulk danazol but much 
slower than EPAS high potency danazol dry particles stabilized by PVP K-15, PVP 40T, 
or PVP 40T and SLS binary mixture, as shown in Figure 4.2 (a).  The enhancement of 
dissolution rate of EPAS samples came from a much smaller particle size and higher 
surface area, as discussed later in the article. 
4.3.4 Particle size distribution and redispersibility of the dry powders 
The mean particle sizes of the EPAS suspensions, EPAS suspensions after 
sonication, and suspensions of dry powders after centrifugation, vacuum drying and 
redispersion are shown in Table 4.4.  The particle sizes for the EPAS suspensions 
dropped by a factor of 2 or more in most cases upon sonication for 30 s, as the shear 
broke particle aggregates.  The particle sizes were larger than those produced in the 
previous EPAS studies.20  The atomization for the ISCO variable nozzle with a stem angle 
of 30o tapered from 0.038 to 0.022 in. and a seat angle of 60o, was observed to be less 
intense than for the crimped nozzles with a 675 × 12 µm slit.  However, the atomization 
generated by the ISCO variable nozzle was sufficient to produce high dissolution rates in 
this study. 
For particles with high dissolution rates in Table 4.4 and Figure 4.2 (a), the mean 
particle size was less than 15 µm in the EPAS suspension after sonication.  Conversely, 
low dissolution rates were observed for particle sizes larger than 20 µm.  The particle 
sizes of danazol coated with the better excipients for high dissolution rates, PVP K-15, 
PVP 40T or PVP 40T +SLS, were much smaller than those stabilized with the less 
effective excipients.  After sonication, the reduction in particle size was greater for the 
less effective excipients than for the more effective excipients.  This result suggests that 
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Figure 4.2 (b). Danazol systems with low dissolution rate (conditions were the same as in Table 4.3). 
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Table 4.4. Particle size of danazol produced in an EPAS suspension at a concentration of 5 mg/ml with a surfactant 




















Aqueous surfactants D (v, 0.5)  
(µm) 
 Suspension Suspension 











Bulk danazol     29.6 21.1 
PVP K-15      
       
       
      
      
29.5 15.3 12.5 14.2 7.60
PVP 40T  49.3 17.6 13.8 14.1 
 
10.5 
PVP 40T+SLS (1:1)  16.8  13.8 18.0  12.1 
Pluronic F127 80.4 32.3 25.1 39.7 22.2
DCA 100.1 24.6 56.9 23.9
SLS 70.6 31.7 27.5 61.1
 
29.3 
PVP 40T +Pluronic F127 (1:1) 126  28.8 71.7 26.2 






The particle sizes, both with and without sonication, are correlated with the 
adsorption during the EPAS spray given in Table 4.1 and 4.2.  The adsorption for the 
PVP K-15 and PVP 40T systems above, that produced the smaller particles, was far 
greater than for the other surfactants that led to the larger particles.  The high level of 
surfactant adsorption was needed to prevent agglomeration of growing crystals.  The 
smaller particle size for the EPAS suspensions stabilized with PVP K-15 versus PVP 40T 
is also consistent with the higher adsorption for PVP K-15.  However, the particle sizes 
became the same after sonication suggesting breakup of the large agglomerates.  The 
agglomerates may have been produced by polymer bridging flocculation, which is more 
prevalent for the higher molecular weight PVP 40T.28  The smallest particles were 
produced when SLS was combined with PVP 40T in the aqueous solution.  Small linear 
SLS molecules bind onto PVP macromolecules29 and add electrostatic stabilization to the 
steric stabilization.  The presence of both stabilization mechanisms led to the smallest 
particles. 
For Pluronic F127, the surfactant adsorption was low, as shown in Table 4.1.  The 
thickness and surface coverage of the surfactant layer was not sufficient to provide 
enough steric repulsion to overcome the attractive van der Waals forces between growing 
particles.  Agglomeration led to large particles.  The combination of Pluronic F127 and 
PVP 40T at a ratio of 1:1 led to very large particles, 126 µm without sonication.  Perhaps 
interactions between the polymers and Pluronic F127 micelles impeded diffusion to the 
surface and the adsorption kinetics.  Yet another possibility is that Pluronic micelles in 
the solution about the particles produced depletion flocculation.  
The particle sizes produced with the low molecular weight ionic surfactants were 
large.  Several factors may contribute to this unsuccessful stabilization.  First, the 
adsorption for these surfactants was only about half that for the PVP stabilizers.  Also, 
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the ionic surfactant molecules are not long enough to provide significant steric 
stabilization to prevent the van der Waals attraction between particles.  As the solvent in 
the organic droplets evaporates, the drug particles nucleate and grow.  The surfactant 
must diffuse across the dichloromethane-water interface to begin to adsorb on the 
particles.  The driving force is small for SLS because it is insoluble in dichloromethane.  
Drug particles size distribution can be used to characterize the particle growth 
mechanism.  Particle growth can generally occur through two mechanisms: condensation 
of free molecules onto nucleated cores and coagulation of cores into larger crystals.  The 
moments of the size distribution indicate that the drug particles grow through coagulation 
and not condensation. 
It was very easy to redisperse each of the dry powders in water after the particles 
were dried after centrifugation.  Without sonication, the particle sizes of redispersed dry 
powder were comparable or even smaller than those of the original EPAS suspension, as 
shown in Table 4.4.  After 30 s sonication, the particle sizes of redispersed dry powder 
were in most cases smaller than those of the original EPAS suspensions after the same 
amount of sonication.  For the PVP systems, the particle size for the redispersed 
suspensions without sonication were about the same as those in the original EPAS 
suspension after 30 s sonication.  Thus the redispersion appeared to reduce the amount of 
aggregation.  In the redispersed samples, the free polymer had been removed after 
centrifugation leaving only the adsorbed polymer.  Bridging flocculation would be 
expected to decrease with the removal of this large amount of excess surfactant.  With 
less bridging flocculation in the redispersed suspensions, ultrasound did not appear to be 
needed to produce the small particle sizes.  All of these effects will be beneficial in 
enhancing dissolution rates.   
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4.3.5 X-ray diffraction 
X-ray diffraction was used to analyze the crystallinity of the dry powders.  As 
shown in Figure 4.3, the crystallinity of danazol was lower for the vacuum dried 
precipitates from EPAS relative to bulk danazol.  The α-peak heights of danazol in 
different surfactant systems at 2θ = 15.9o are listed in Table 4.3.  It was assumed that the 
crystallinity was linear in danazol peak height, corrected for the potency.  The reduction 
in crystallinity was less than 20%, and was similar for each of the excipients except for 
PVP 40T.  Thus enhanced dissolution rates are possible even with only a small reduction 
in crystallinity. 
4.3.6 Surface area 
As shown in Table 4.3, systems with small particle size and high dissolution rates, 
that is, danazol with PVP K-15, PVP 40T or PVP 40T +SLS, had higher surface areas, on 
the order of 5 m2/g.  Surface areas were higher for drug particles stabilized with PVP K-
15 than with PVP 40T, consistent with the smaller particle sizes.  Systems with larger 
particles and lower dissolution rates had significantly lower surface areas, about 3 m2/g as 
expected.  Thus surface area is a primary factor for predicting dissolution rate. 
The surface areas for danazol with PVP K-15, PVP 40T or PVP 40T +SLS were 
an order of magnitude higher than that of the bulk danazol.  However, the particle 
diameters in the EPAS suspension after 30 s sonication were only modestly smaller than 
that of the bulk particles.  The calculated surface area for monodisperse sphere with a 
similar particle diameter would be 1.36 m2/g.  The much larger surface area for the 
powders in Table 4.3 suggests that the particles were not uniform spheres, but were 
aggregates composed with smaller primary particles, which was confirmed with an 
ESEM micrograph of dried high potency danazol precipitate stabilized with PVP K-15.  
As shown in Figure 4.4, the primary particle size of danazol was smaller than 1 µm.  
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These small primary particles contributed to the high surface area and high dissolution 
rate for EPAS samples stabilized with PVP or PVP and SLS binary system.  The light 
scattering measurements indicated the size of the aggregates composed of these 
nanoparticles.  In the dissolution rate experiments, not only is the surface area, S, much 
higher for these nanostructured particle aggregates, but this much larger surface area is 
accessible to water given the hydrophilic surfactant coating on the particle surface.   
4.3.7 Contact angle 
The contact angle results are shown in Table 4.3.  Although each surfactant 
reduced the contact angle indicating improved wettability, there was no apparent 
correlation between dissolution rate and contact angle.  For systems with high dissolution 
rates, contact angles were close to the value of pure PVP, which is 43o, indicating high 
surface coverage by PVP.  For the anionic surfactant systems, the contact angles were 
very low due to high wetting of a surface covered with the anionic charges.  However, the 
surface areas and particle sizes for these systems were unfavorable for high dissolution 
rates.  The overall contact angle may be written as 
                    cos θ = f1 cos θ1 + f2 cos θ2                                                                                  (Eq. 4.4)
where f1 and f2 are the fractions of the surface occupied by surface types having contact 
angles θ1 and θ2.  This equation has been shown to be accurate for the contact angle of a 
mixed monolayer of OH and CH3 terminated alkyl thiols as a function of alkylthiol 
ratio.30  The contact angles in Table 4.3 are below the values expected from this equation, 
based on the pure component values θ1 and θ2, indicating that the surface is enriched by 
the hydrophilic excipient.  This enrichment may be expected to be generated during the 
EPAS spray, as the surfactant hydrophobic moieties prefer the surface of the drug 
particles and hydrophilic moieties orient outward to interact with water.  This orientation 
of the surfactant to the drug-water interface produces a hydrophilic surface that enhances 
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dissolution rates.  This driving force for orientation of the surfactant at the surface is not 
present in nonaqueous particle formation processes, such as spray drying and 






































Figure 4.4. ESEM picture of danazol precipitate stabilized with PVP K-15 after 
centrifugation and drying under 40oC and –30 in. Hg 
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4.3.8 Thermal cycling stress test on high potency danazol EPAS particles 
Two-week thermal cycling stress tests were undertaken under harsh storage 
conditions for the three systems with the highest dissolution rates.  This short time 
thermal cycling stress test was used to determine the stability of EPAS danazol particles 
with small amounts of stabilizer, as an indicator for long term and accelerated stability 
studies.  Samples were analyzed each week to determine if the particle size, crystallinity, 
surface area and dissolution rate had changed with time.  The potencies of danazol in the 
three systems were: 88.9% with SD (standard deviation) of 2.9% in PVP K-15 +Danazol, 
93.6% with SD of 1.4% in PVP 40T +Danazol and 89.6% with SD of 5.0% in PVP 40T 
+SLS +Danazol. 
The particle size, crystallinity, surface area, and dissolution rate of these three 
EPAS samples changed slightly in 2-week thermal cycling stress test.  After 2 weeks, the 
redispersed particle size of danazol measured by Malvern with 15 s of sonication changed 
from original value of 8.20 to 8.09 µm for the PVP K-15 system, 8.89 to 9.30 µm for 
PVP 40T, and 6.38 to 6.37 µm for the PVP 40T + SLS system.  The α-peak height of 
danazol at 2θ =15.9o change from 2275 to 2210, 2297 to 2612, and 1899 to 2209 counts 
for the PVP K-15, PVP 40T, and PVP 40T +SLS systems, respectively.  The surface area 
of these samples changed from 7.43 to 6.27, 5.88 to 5.87, and 5.91 to 5.72 m2/g for the 
PVP K-15, PVP 40T, and PVP 40T +SLS systems, respectively.  The dissolution rate did 
not change in the thermal cycling stress test because the key properties of these drug 
powders, especially the particle size and surface area, did not change with time.  As an 
example, the dissolution profile of danazol stabilized with the PVP 40T + SLS binary 
system is shown in Figure 4.5.  Under 2-week thermal cycling stress test, high potency 
danazol dry powders with PVP K-15, PVP 40T or PVP 40T + SLS as stabilizing 















PVP 40T+SLS+danazol (1 week)
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Figure 4.5. Dissolution profile of system danazol +PVP 40T+SLS during 2-week thermal 




High dissolution rates were obtained for danazol produced by EPAS with PVP 
40T, PVP K-15 or PVP 40T together with SLS as stabilizers.  The high dissolution rates, 
e.g. 90% in 2 min with a drug-to-surfactant ratio of 9:1, are remarkable given the high 
potencies, that is the very low amounts of excipients.  Since only about 5% of the 
surfactant required for forming the EPAS suspensions is adsorbed onto the particles, the 
rest may be removed after centrifugation.  After removal of the free surfactant and 
drying, the particles may be redispersed in pure water without any growth in particle size 
or loss in surface area.  The dissolution rates were high only for surfactants with an 
adsorption of 10% w/w or more during the EPAS spray.  The dissolution rates were high 
for surfactants that produced particles smaller than 15 µm with surface areas greater than 
5 m2/g and much lower for the other systems with larger particles and smaller surface 
areas.  The high surfactant adsorption levels were required to prevent particle 
agglomeration and growth.  These results indicate that the small particle size and large 
surface area of the surfactant-coated particles, with reduction in crystallinity less than 
20%, was enough to produce high dissolution rates.  Not only is the surface area, S, much 
higher for the EPAS particles, but this much larger surface area is accessible to water 
given the hydrophilic surfactant coating on the particle surface.  The high surface area 
was evident in the nanostrutured aggregates shown in the ESEN micrographs.  In a 2-
week thermal cycling stress test with desiccant, the powders were very stable as the 
dissolution rate, crystallinity, particle size and surface area changed only a minimal 
amount with time.  The ability to engineer stable particles with high potencies and high 
dissolution rates with EPAS presents new opportunities in the development of 
commercial formulations for water insoluble drugs. 
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Flocculation of Suspensions Formed by Antisolvent Precipitation to 
Produce Redispersible Naproxen Nanocrystals 
5.1 INTRODUCTION 
It is estimated that more than 1/3 of the compounds being developed by the 
pharmaceutical industry are poorly water soluble.1, 2  The bioavailability of class II poorly 
water soluble drugs is often dependent upon the dissolution rate of the drug in the 
gastrointestinal tract.3  Dissolution rates may be increased by reducing the particle size to 
increase the surface area, and by coating drug particles with hydrophilic surfactants to 
enhance wetting and solvation.  Ultra fine particles can be readily dissolved and are 
easily absorbed due to their small size and, consequently, high specific surface area.4-6  
The model drug of choice in this study, Naproxen, d-2-(6-methoxy-2-naphthyl)propionic 
acid, CH3OC10H6CH(CH3)CO2H, is an anti-inflammatory compound with a low water 
solubility of 15 mg/L.7 
Antisolvent precipitation is a widely used process to prepare inorganic and 
organic particles.  A number of recent studies have utilized antisolvent precipitation to 
produce nanoparticles of poorly water soluble drugs.8-11  In this process, a poorly water 
soluble drug with or without surfactant(s) are dissolved in a water miscible organic 
solvent, including methanol, ethanol, tetrahydrofuran (THF) and acetonitrile etc.  The 
organic solution is then mixed with an “antisolvent”, usually an aqueous solution 
containing a surfactant (s) by a confined impinging jets (CIJ) mixer,10 sonication,9 or just 
pouring the antisolvent into organic drug solution.8  Supercritical fluid antisolvents can 
be used to achieve a great deal of control over particle morphology.12-15  Upon mixing, 
the supersaturated solution leads to nucleation and growth of drug particles, which may 
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be stabilized by surfactants.  With sufficient supersaturation, and arrested growth by 
surfactant stabilization, it becomes possible to form suspensions of submicron particles in 
the aqueous solution.    
Several drying techniques have been used to recover the drug nanoparticles from 
aqueous suspensions produced by antisolvent precipitation.  Ketoconazole, itraconazole 
and ibuprofen micronized particles were spray dried.8  Budesonide particles with a size 
range from 1 to 10 µm were filtered with 0.8 µm-pore-size polycarbonate membranes.9  
A wiped film evaporator was used to strip the organic solvent, and then spray drying was 
used for drying the suspension.11  
The objective of this study was to recover nanoparticles of poorly water soluble 
drugs produced by antisolvent precipitation at low temperatures from 0 to 22oC by 
flocculation and filtration and to examine their properties.  Temperature is shown to have 
a large effect on the particle size distribution in the suspension.  The particles were 
separated from the solvent by flocculation with concentrated salt solution, to collapse the 
steric stabilizers, followed by filtration and vacuum drying.  The surfactant composition 
and structure, and the type and concentration of salt in the drug suspension were 
optimized to produce large, loose flocs which could be redispersed into pure water 
readily after filtration and drying.  The increase in drug potency upon filtration and the 
reproducibility in the composition and yield of the powder are examined.  Another goal 
was to achieve particles sizes after redispersion similar to those in the original 
suspensions prior to flocculation.  The dissolution rate of naproxen powder produced by 
flocculation was compared with that of suspensions dried by lyophilization and that of 
bulk naproxen.  X-ray diffraction was used to investigate the crystallinity of naproxen.  
Optical microscopy and SEM were used to characterize the morphologies of the naproxen 
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flocs in the suspension and after drying.  The concentration of residual salt in the dried 
samples was measured by conductivity and shown to be far below the toxic limit.    
Compared to other solvent removal techniques, the use of flocculation and 
filtration offers several advantages.  The flocs may be filtered much more rapidly and 
efficiently than the original nanoparticle suspension.  Rapid filtration reduces the time for 
the growth of the primary particles in the concentrated precipitate.  Particle growth is a 
potential problem in this step as the stabilizers are no longer solvated.  The filtration can 
be operated at low temperatures much more easily than in the case of spray drying and 
other solvent evaporation techniques.  Otherwise drying at high temperatures may lead to 
undesirable particle growth.11  Separation by filtration avoids challenges in evaporation, 
for example for solvents such as ethanol that form azeotropes with water.  Whereas it 
may take days for lyophilization, the time for flocculation and filtration was on the order 
of minutes.  Finally, the potency of the drug can be increased in the filtration step since 
the dispersed particle phase contains a higher fraction of drug than the continuous phase.   
5.2 EXPERIMENTAL  
5.2.1 Materials 
Naproxen, polyvinylpyrrolidone (PVP K-15, Mw = 10, 000) and poly(ethylene 
oxide-b-propylene oxide-b-ethylene oxide) (Pluronic F127) with a nominal molecular 
weight of 12, 500 and a PEO/PPO ratio of 2:1 by weight were purchased from Spectrum 
Chemical Mfg. Corp. (Gardena, CA).  Sodium sulfate (anhydrous) and sodium carbonate 
(anhydrous) were obtained from Fisher Scientific Company (Fair lawn, NJ).  Sodium 
phosphate tribasic dodecahydrate was from EM Science (Gibbstown, NJ).  HPLC grade 
acetonitrile and methanol was obtained from EM Industrial Inc (Gibbstown, NJ).  
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5.2.2 Antisolvent precipitation  
The antisolvent apparatus is shown in Figure 5.1.  The naproxen solution in 
methanol or ethanol was fed by a HPLC pump through a 1 m long 1/16 in. o.d. × 0.030 
in. i.d. stainless steel tube.  The organic solution was sprayed in the shape of a cylindrical 
column without atomization through the stainless steel tubing into precooled aqueous 
surfactant solution.  The aqueous surfactant solution was contained in a 250 ml glass 
cylinder submerged in a temperature controlled water/ethylene glycol bath controlled to 
3oC.  The stainless steel tube was submerged approximately 4 cm under the surface of the 
aqueous solution.  To enhance the mixing between organic phase and aqueous phase, a 
magnetic stir bar was placed inside the glass cylinder and stirred at a fixed rate to form a 
vortex.  Unless specified elsewhere, 7% w/v naproxen with or without surfactant was 
dissolved into methanol.  The organic solution was then sprayed into 50 ml aqueous 
solution at 5 ml/min for 1.4 min to yield a suspension concentration of 10 mg/ml.  After 
spraying for a required time to produce the desired suspension concentration, the 
suspension was analyzed within 5 min to determine the particle size by static light 
scattering with Malvern Mastersizer-S (Malvern Instruments Ltd., U. K.).  The 
suspension was sonicated in the Mastersizer to break up the aggregates until stable 
particle size distribution was obtained.  The particle size of the same suspension was also 
measured after 5 min sonication with a powerful sonicator (Beckman, Model TJ-6, USA) 








5.2.3 Recovery of naproxen nanoparticles by salt flocculation followed by filtration 
and vacuum drying 
After particle size measurement, another suspension produced at exactly the same 
experimental conditions was sonicated in an ice/water bath at an output control of 7 and 
30% duty cycle for 5 min.  Then, a given volume of 20% w/v sodium sulfate was added 
into the suspension and mixed thoroughly with a spatula.  The suspension was left at 
room temperature for 3 min to form large flocs.  The flocs were filtered with P2 filter 
paper (Fisher Scientific, Fair lawn, NJ) under vacuum (-27 in. Hg).  Gentle stirring was 
necessary in the first 3 min of filtration to prevent forming dense precipitate cake which 
would increase resistance to filtration and result in a long filtration time.  The filtration 
was continued for 10 s after no more water droplets were formed at the tip of the ceramic 
funnel.  The precipitate was placed into a vacuum oven and dried overnight at room 
temperature at a vacuum of -30 in. Hg.  To check the reproducibility of this process, for 
each formulation, triplicate samples were prepared. 
The precipitate weight was determined after vacuum drying.  A known amount of 
this dry powder, about 5 mg, was dissolved into 50 ml acetonitrile/water mixture, 50:50 
(v:v).  The potency of naproxen was determined by measuring the naproxen 
concentration by HPLC (Shimadzu, LC-10AT VP, Japan).  The salt concentration was 
determined from the electrical conductivity as described below.  The surfactant 
composition in the final powder was calculated by difference given the total precipitate 
weight, the drug potency and the salt concentration.  The drug recovery was calculated 
from the HPLC measurement and the total amount of drug fed to the suspension in the 
antisolvent process.  The surfactant recovery was calculated with the same method, given 
the surfactant composition in the dry powder.  Wide angle X-ray scattering was employed 
to detect the crystallinity of naproxen.  CuK α1 radiation with a wavelength of 1.54054 Å 
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at 40 kV and 20 mA from a Philips PW 1720 X-ray generator (Philips Analytical Inc., 
Natick, MA) was used.  The samples were well-mixed to minimize the effects of 
preferred orientation.  A Philips goniometer was used to measure the reflected intensity at 
a 2θ angle between 5 and 45° with a step size of 0.05° and a dwell time of 1 s.   
5.2.4 Particle size 
Particle size distributions based on volume fraction were measured for the 
original antisolvent suspension prior to flocculation and for the dried powders after 
redispersion and sonication with laser light scattering (Mastersizer-S, Malvern 
Instruments Ltd., U. K.).  Approximately 5 ml of the suspension with a concentration of 
10 mg drug/ml water was diluted with 500 ml distilled water, to produce a light 
obscuration in the desired range of 10-30%.  The amount of drug in the water was several 
folds above the solubility limit.  In control experiments, samples were stirred in the 
Mastersizer for up to 10 min, and there was very little change in the particle size 
distribution.  To study the redispersibility of the dry powders, about 100 mg dry powder 
was suspended into 500 ml distilled water to produce an obscuration in the range 10-
30%.  After 1 min, the particle size distribution was measured.  Ultrasound was used in 
the measurement to break up the aggregated particles.  The uncertainty in mean particle 
size for different sprays at the same experimental conditions was about 10 to 15%.  
5.2.5 Measurement of residual salt concentration in flocculated samples by 
conductivity 
The residual concentration of sodium sulfate was measured by conductivity.  The 
conductivities of a series of standard concentration of sodium sulfate solutions in 
acetonitrile/water mixture (v:v= 50:50)  were measured with a conductivity probe with 
cell constant of 1/cm (Model 3252, YSI Inc., Oh.).  For salt concentrations ranging from 
0.003 to 0.05 mg/ml, a linear standard line was obtained with a correlation coefficient of 
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0.9999.  A small amount, about 5 mg, of dried naproxen powder was dissolved in the 
same acetonitrile/water mixture to yield a salt concentration in the linear range of the 
standard curve to determine the conductivity.   
5.2.6 Morphology of the flocs in the suspension and after drying 
Optical microscopy and scanning electron microscopy (SEM) were used to 
characterize the morphology of the naproxen flocs in the suspension and in the dried 
powder.  A drop of antisolvent suspension flocculated with sodium sulfate solution was 
placed onto a microscope slide (25×75 mm, Erie Scientific Co. Portsmouth, N.H) and 
carefully covered with a microspore cover glass (22×22 mm, Fisher Scientific, Pittsburg, 
PA).  The morphology of naproxen flocs in the suspension was examined with an optical 
microscope (Axioskop 2 plus, Cal Zeiss Vision GmbH, Germany).  Another suspension 
produced with the same experimental conditions was filtered with a P2 filter paper under 
vacuum for 11 min.  The dried powders were mounted on an aluminum cylinder using 
double adhesive carbon conductive tabs (Ted Pella, Inc.) and coated with Au for 25 s 
using a Pelco Model 3 sputter-coaler under an Ar atmosphere.  A Hitachi S-4500 
scanning electron microscope (SEM) (Hitachi Instruments Inc., Irvine, CA) at an 
accelerating voltage of 10 kV with a secondary electron detector was used to obtain 
digital images of the samples. 
5.2.7 Dissolution test 
The dissolution of naproxen powder was tested in pure water using a USP 
Apparatus II (Vankel 7000, Vankel Technology Grul, Cary, NC) at 50 rpm.  All 
dissolution tests were conducted at sink conditions, in this case at 15% of its solubility in 
water.  Antisolvent powders containing approximately 2 mg naproxen were added to 900 
ml pure water at 37oC.  Aliquots of the dissolution medium (5 ml) were sampled at 2, 5, 
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10, 20 and 30 min.  The aliquots were filtered through 0.45 µm syringe filters and 2 ml of 
each sample was diluted with 0.1 ml acetonitrile before analysis.  Naproxen 
concentrations were measured using HPLC (Shimadzu, LC-10AT VP, Japan).  
Dissolutions were repeated two to three times for the powder and the average deviations 
are reported in the dissolution figures. 
5.3 RESULTS AND DISCUSSION 
5.3.1 Effect of temperature on drug particle size in antisolvent precipitation 
The effect of temperature on the particle size distribution in the aqueous 
suspension produced by antisolvent precipitation was determined.  5% w/v naproxen and 
2% w/v Pluronic F127 in ethanol solution was sprayed into 50 ml 3% w/v PVP K-15 at 
flow rate of 1 ml/min for 5 min.  The final suspension concentration was 5 mg/ml.  The 
organic solution was at room temperature.  As shown in Figure 5.2, the mean particle size 
doubled from 270 nm at 0oC to 540 nm at 30oC.  At temperatures higher than 30oC, the 
mean particle size increased markedly and reached 9.3 µm at 60oC.  This temperature 
behavior was also observed for ketoconazole.  When 4% w/v ketoconazole and 2% w/v 
Pluronic F127 in methanol solution was sprayed into 50 ml 3% w/v PVP K-15 at flow 
rate of 1 ml/min for 20 min, to form a suspension concentration of 16 mg/ml, the mean 
particle size of ketoconazole increased from 350 nm at 4.6oC to 9.1 µm at 23.8oC.  
Several factors may lead to larger particles at high temperature including degree of 
supersaturation, crystal growth rate and Ostwald ripening.  The solubility of both drugs in 
the organic-water mixture increases with temperature.  Thus, for a given drug 
concentration in the feed, the supersaturation decreases with temperature.  The lower 
supersaturation lowers the nucleation rate.  The smaller number of nuclei may be 
expected to produce larger particles for a given drug concentration in the final 
suspension.  Also, the diffusion rate of drug molecules to the surface of the growing 
particles and the kinetics of addition of drug molecules to the surface increase with 
temperature.  Furthermore, Ostwald ripening or diffusion of molecules from smaller 
crystals to larger crystals is also favored by higher solubility at higher temperature.  
Based on these experiments, all other experiments in this paper were performed at room 
































Figure 5.2. Temperature effect on particle size of naproxen suspensions produced by 
antisolvent precipitation.  Organic phase: 5% w/v naproxen+ 2% w/v Pluronic 
F127 in ethanol; aqueous phase: 50 ml 3% w/v PVP K-15; flow rate Q= 1 
ml/min; t= 5 min; suspension concentration= 5 mg/ml. 
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5.3.2 Compositions of the Formulations 
As shown in Table 5.1, four systems were studied.  In system A, only 10% w/v 
PVP K-15 was used in organic phase and there was no surfactant in the aqueous phase.  
This system was designed for long-term stability since PVP K-15 has a high glass 
transition temperature which is helpful for drug stability by decreasing the mobility of 
drug molecules.  In system B, 10% w/v Pluronic F127 
(HO(CH2CH2O)~98(CH2C(CH3)CHO)~67(CH2CH2O)~98H) was used in the organic phase, 
as it has been shown to be an effective stabilizer16, 17 and 3% w/v PVP K-15 was included 
in the  aqueous phase to raise the Tg of the final powder.  To attempt to raise the potency 
of the drug, in system C the Pluronic F127 concentration was reduced to 5% w/v and in 
system D, the PVP K-15 concentration was reduced to 1% w/v.  The overall 
drug/Pluronic F127/PVP K-15 ratios in the final suspension based on the amounts fed are 
also given.  The total solid weight was 1.22 g for system A, 2.72 g for system B, 2.36 g 
for system C and 1.36 g for system D.  The total drug potencies (weight of drug/total 
weight) if all fed materials ended up in the solid were 41.2% for system A, 18.5% for 
system B, 21.3% for system C and 37.0% for system D. 
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Table 5.1. System investigated 
 
Sys.  Organic phase Aqueous phase Drug/Pluronic/









A 10% PVP K-15  Pure water 1/0/1.4 1.22  41.2 
B 10% Pluronic F127 3% PVP K-15 1/1.4/3 2.72  18.5 
C 5% Pluronic F127  3% PVP K-15 1/0.7/3 2.36  21.3 
D 5% Pluronic F127 1% PVP K-15 1/0.7/1 1.36  37.0 
 
5.3.3 Particle size of naproxen in aqueous suspensions 
As shown in Table 5.2 and 5.3, aggregated naproxen nanoparticles were produced 
during antisolvent precipitation at both 22 and 3oC.  With only PVP K-15 in the organic 
phase and pure water in the aqueous phase (System A, overall drug/Pluronic F127/PVP 
K-15 ratio= 1/0/1.4), the particle sizes were large in the original suspensions after 
spraying at either 22oC or 3oC.  Even after sonication in the Mastersizer, the mean 
particle size was still undesirably large, as shown in Table 5.2.  After the original 
suspensions were stirred with a magnetic stir bar for 20 h at room temperature and then 
sonicated, the mean particle sizes became extremely small, well below 0.4 µm at both 
temperatures.  More surfactants may adsorb to the particles during stirring and aid 
breakup of the aggregates.   
In order to attempt to reduce the aggregation of the particles at 3oC, 5% w/v 
Pluronic F127 was added to the aqueous phase.  The mean particle size of the original 
suspension was 15.9 µm.  After 6 min sonication in the Mastersizer, the mean particle 
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size decreased to 0.29 µm.  In this case the aggregates broke up without the need to stir 
the solution for 20 h.  Since the copolymer Pluronic F127 has hydrophobic moieties 
which adsorb onto hydrophobic drug particle surfaces, the adsorption of Pluronic F127 
with PVP K-15 provided greater steric repulsion and looser aggregates.  The looser 
aggregates may be broken up more easily by sonication.  
The particle sizes for the other formulations were determined as shown in Table 
5.3.  The results for suspensions prior to flocculation are shown in the second and third 
columns.  In order to avoid the need for stirring for long periods of time to break up 
aggregates, the organic phase stabilizer was changed to Pluronic F127 for all of the 
systems in Table 5.1 except the first one.  In addition, PVP K-15 was utilized in the 
aqueous phase to achieve a sufficiently high Tg for the final powder.  For system B and 
C, the mean particle sizes were extremely small, below 0.5 µm, in the original suspension 
even without sonication.  After sonication, the particle size decreased only a small 
amount given that the particles were already very small.  However, when the PVP K-15 
concentration in the aqueous phase was lowered to 1% w/v in system D, the mean 
particle size of the original suspension increased to 9.8 µm.  These aggregates were 
broken up readily upon sonication.  After sonication the mean particle size was 0.29 µm 
for systems B-D, although the D (v, 0.9) was 7.0 µm for system D.  Without sonication, a 
higher concentration of 3% w/v PVP K-15 in the aqueous phase was helpful in forming 
the nanosuspension.  In system B and C, the overall concentration of PVP K-15 was 
much higher than that of Pluronic F127, unlike the case for system D.  The higher overall 
stabilizer concentration may have been required to provide enough steric stabilization to 
prevent aggregation of naproxen nanoparticles. 
Table 5.2. Particle size of naproxen suspensions produced by antisolvent precipitation vs. time for system A without any added 
salt.  Organic phase: 7% w/v naproxen+ 10% w/v PVP K-15 in methanol. 
 
Temperature  T=22oC T=3oC 
suspension   





















Aqueous phase: pure water 
Original 
suspension 
7.5/15.9/28.4  2.4/5.3/7.2 7 6.2/12.6/153.1 2.3/4.5/6.3 15 
After 20 hours 
stirring at room 
temperature  
4.5/6.4/11.0 0.15/0.36/2.1 3 6.1/12.1/19.7 0.11/0.29/0.88 5
Aqueous phase: 5% w/v Pluronic F127 




Table 5.3. Particle size of naproxen in the original suspension before and after sonication, and after flocculation, filtration, 








after 5 min 
sonication  
(µm) 

















in 2 min 
(%) 
A         4.5/6.4/11.0 0.15/0.36/2.1 175 1.10 16.5/91.6/243.0 0.12/0.32/3.24 3 27.3
A         
        
         
        
         
         





100 0.94 0.10/0.30/6.8 0.10/0.27/3.07 1 95.4
B 125 1.01 0.11/0.31/1.87 0.11/0.28 /1.13 1 96.4
B  150 1.06 0.23/0.48/19.3 0.11/0.32/7.72 1 74.8
C 0.11/0.30/3.8 0.12/0.29/0.68 125 1.01 0.11/0.31/2.57 0.10/0.25/0.79 1 94.9





5.3.4 Polymer-salt cloud point concentrations and flocculation of naproxen 
nanoparticles with various salts 
Sterically stabilized dispersions may be flocculated by reducing the solvency of 
the dispersion medium for the stabilizing moieties to induce the onset of instability.  
Pelton18 reported that the critical flocculation temperature (CFT) corresponds to the cloud 
point temperature of the stabilizing polymer.  A few reports have described the influence 
of inorganic salts on the cloud point behavior of Pluronics19-21 and PVP.22-24  As shown in 
Figure 5.3, the cloud point temperatures of PVP 44, 000 and Pluronic F127 decreased 
linearly with increasing concentrations of sodium sulfate.  At a given temperature, the 
polymer precipitates as the salt concentration increases.  In Figure 5.3, the concentration 
of PVP was 0.74% w/v on the basis of a partial specific volume of 0.952 cm3/g for 
PVP.25  The concentration of Pluronic F127 was 5 mg/ml or 0.5% w/v.  PVP contains N-
C=O units on the lactam rings that hydrogen bond with water as observed with 
viscometric measurements26 and spectrophotometric studies.27  The decrease of the 
Huggins constant with the addition of inorganic salt into PVP aqueous solution indicates 
a loss in water-PVP H-bonding and thus in PVP hydration leading to precipitation.22  For 
the same reasons, salt also precipitates PEO homopolymers28-31 and of PEO-containing 
nonionic surfactants such as Pluronics.19-21   
The reciprocal of cloud point temperatures, 1/Tcp of two fractionated and two 
unfractionated PVP samples have been shown to be linear in  1/
2/1
wM .24  With a lower 
molecular weight of 10, 000, more sodium sulfate is required to precipitate the PVP K-15 
used in this study than the PVP 44, 000 shown in Figure 5.3.23 
The stabilizing moieties collapse at the onset of the cloud point where the solvent 
is worse than a θ-solvent, as a result of the large number of interacting segments.32   
Steric repulsion becomes weak and the stabilizing chains interact with each other leading 
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to flocculation as the Brownian collisions between particles become sticky.  Some free 
surfactant might also precipitate out from the solution and interact with flocculating 
particles.  Since the particle size of coated naproxen was typically larger than 200 nm and 
the molecular weight of stabilizing polymers was not more than 12, 500, the van der 
Waals attraction between the particles is also important in addition to attraction between 
polymer segments.32  If the flocs are sufficiently large, the drug particles may easily be 
recovered from the solution by filtration.   
To more fully understand the salinity of flocculation, the critical flocculation 
salinity was measured for a 1.26% w/v concentration of either PVP K-15 or Pluronic 
F127.  The solvent was a mixture of methanol (12.6%, v/v) and water (87.4%, v/v) with 
the same composition as the system A suspension.  A concentration of 1.06 M salt was 
needed to precipitate PVP from solution at room temperature in the methanol/water 
mixture while only 0.98 M was needed without any methanol.  For pure Pluronic F127, 
0.71 M salt concentration was needed for solution with methanol while 0.58 M was need 
without methanol.  Apparently, at same concentration and temperature, Pluronic F127 
was precipitated much more easily with sodium sulfate than PVP K-15 which is 
consistent with Figure 5.3.  Less salt is needed to flocculate Pluronic F127 than PVP (Mw 
= 44, 000) at 25oC from pure water without methanol.  This difference is expected to be 
even larger for PVP K-15 since a greater salt concentration is required to precipitate the 
lower molecular weight.23  The critical flocculation salinities, despite the presence of 
methanol are in the same order expected from the cloud points.  Methanol is also raises 
the cloud point temperature for poloxamine 908, a copolymer containing polyethylene 
oxide moieties.33  
A much lower salt concentration is required for a divalent sulfate to precipitate 
these polymers relative to a monovalent anion.19, 22  Three multivalent inorganic salts 
which are known to produce a large reduction in the cloud point temperature of PVP22 
and Pluronic F127,19 sodium carbonate, sodium sulfate and sodium phosphate, were used 
to attempt to flocculate the nanoparticles.  Large flocs were formed with sodium sulfate 
which were readily filtered.  20% w/v sodium carbonate and 10% w/v sodium phosphate 
were also tested for flocculation.  In each case, when a small volume of the salt solution 
was added to the suspension to produce a molarity less than 0.04 M, a clear solution was 
formed as the naproxen particles dissolved.  When 0.4 ml sodium carbonate or 1 ml 
sodium phosphate solution was added into 25 ml of the suspension, the pH of the solution 
increased to 11.3 for CO32- and 11.9 for PO43- due to the acid-base hydrolysis.  The 
solubility of naproxen increases from 0.0159 mg/ml in pure water to 196.7 mg/ml at a pH 
higher than 8,34 which is well above the pKa of naproxen.  This solubility is much higher 
than the naproxen concentration in the suspension, consistent with our observation of 
dissolution.  Based on these results all of the flocculation experiments utilized sodium 
sulfate.  
5.3.5 Dissolution rate 
The dissolution rates of the dried naproxen powders are shown in Figure 5.4 (a) 
for system B and for a series of formulations in Figure 5.4 (b).  The dissolution rates were 
highly reproducible as shown by the error bars which represent the average deviation, 
defined by ∑ − xxn
1 .  The dissolution rates were very high for systems B and C, and 
significantly slower for systems A and D.  As shown in Figure 5.4 (a), approximately 
100% naproxen was released in 2 min for the suspension dried by lyophilization.  For 
samples flocculated with 100 ml or 125 ml salt solution, the dissolution rates of naproxen 
were only slightly slower than for the lyophilized ones.  The flocculated sample of 
system B was stored with desiccant under vacuum at room temperature.  After 1 month, 
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the dissolution rate of this sample did not change, as shown in Figure 5.4 (b).  The 
differences in these dissolution rates will now be analyzed in terms of the particle size 
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Figure 5.3. Cloud point temperature of PVP22 and Pluronic F12719 at various sodium 
sulfate concentrations in water.  The data were obtained and extrapolated from 
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Figure 5.4 (a). Effect of salt concentration on dissolution rate of flocculated, filtered and vacuum dried naproxen nanoparticles 
produced by antisolvent precipitation (system B). Conditions were the same as Table 5.3 and 5.4.  As marked, 
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Figure 5.4 (b). Effect of stabilizers on dissolution rate of flocculated, filtered and vacuum dried naproxen nanoparticles 
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Figure 5.4 (c). Correlation between initial dissolution rate and specific surface area of flocculated, filtered and vacuum dried 
naproxen particles (R2= 0.97).   
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5.3.6 Particle redispersibility into water after flocculation followed by filtration and 
vacuum drying  
The dry powder was redispersed into pure water, and the particle sizes are shown 
in the sixth and seventh columns of Table 5.3.  For system A flocculated with a salt 
concentration of 1.10 or 1.13 M, the dried naproxen particles formed a very coarse 
suspension upon stirring without sonication.  The mean particle size of the dried particles 
was 91.6 µm without sonication at 1.10 M salt concentration, but decreased to 0.32 µm 
after 3 min sonication.  With a higher salt concentration of 1.13 M, the mean particle size 
of naproxen decreased from 155 µm without sonication to 2.02 µm after 6 min 
sonication.  Because the mean particle size was only 0.29 µm after flocculation and 
filtration but before drying, the particle growth must have take place during the drying 
step.  The slow dissolution rates in system A are consistent with the large particle sizes 
upon redispersion without sonication.   
In order to study the reversibility of flocculation, a suspension flocculated at 1.13 
M salt concentration was filtered with a 0.45 µm Whatman® nylon membrane filter 
paper (Whatman International Ltd. Maidstone, England) for 43 min.  The particle size of 
redispersed naproxen after drying was 17.1 µm after sonication.  Apparently, if the 
particles are allowed to remain flocculated for tens of minutes or more, redispersion is no 
longer complete.  Perhaps slow diffusion of the stabilizer away from the stress zones that 
are created by the close approach of the particles leads to irreversible aggregation.32 
For system B, with either 0.94 or 1.01 M salt, the dried particles could be 
redispersed into water readily with particle sizes similar to the original suspensions.  
Consequently the dissolution rates were extremely rapid with 96% release in two min.  
As the concentration was increased to 1.06 M, the mean size of redispersed particles 
increased modestly to 0.48 µm with a high D (v, 0.9) of 19.3 µm.  Likewise, the 
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dissolution rate decreased to 75% in two min.  Here, 1 min sonication was needed to 
reduce the particle size to the value prior to flocculation.  Higher salt concentrations 
appeared to produce tighter flocs after drying, requiring sonication to fully break them 
up, whereas sonication was not needed for the lower salt concentrations.   
For system C, particles flocculated at 1.01 M salt concentration could be 
redispersed easily after drying to achieve a similar particle size as in the original 
dispersion.  Consequently, the dissolution rate was extremely fast as in the case for the 
two lowest salinities in system B.  However, for system D, with a low PVP K-15 
concentration in the aqueous phase, the mean particle size of the redispersed dried 
powders without sonication was extremely large, 2.7 µm.  The size decreased most of the 
way to the value prior to flocculation after 2 min sonication.  The dissolution rate was 
much slower than in systems B and C.  Therefore, the dissolution rate is more closely 
related to the aggregate size than the size of the particles after sonication.   
For all of the examples in Table 5.3, the dissolution rate was correlated closely 
with the particle size of the redispersed powder without sonication.  Assuming spherical 
particles, the specific surface area of naproxen particles was calculated by, S = 6/D, 
where D is the average diameter of the particles from the Mastersizer, shown in the sixth 
column of Table 5.3.  As shown in Figure 5.4 (c), a straight line with a correlation 
coefficient of 0.97 was obtained between initial dissolution rate (% released in 2 min) and 
specific surface area of naproxen particles after redispersion.  This correlation is 
consistent with Noyes-Whitney equation, where the dissolution rate is proportional to the 
specific surface area of drug particles. 
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5.3.7 Reproducibility of salt flocculation process on precipitate weight, drug 
potency, salt concentration, surfactant concentration, drug and surfactant yield 
The filtration time and properties of the precipitate including naproxen potency 
(drug/total solids, w/w), drug yield (fraction in precipitate versus total amount fed), 
surfactant yield (fraction in precipitate) and filtration selectivity ((g precipitate drug/g 
filtrate drug) / (g precipitate surfactant/g filtrate surfactant)) for four systems flocculated 
with various concentrations of sodium sulfate are shown in Table 5.4.  Compared to the 
overall naproxen potencies in Table 5.1 for the suspensions, the naproxen potencies in the 
precipitate were higher, since some free or nonadsorbed surfactant ended up in the 
filtrate.  For system A, even at salt concentration of 1.10 M, the resulting flocs were not 
stable.  Stirring or pouring broke up the fragile flocs.  Thus, the precipitate weight was 
not reproducible, relative to the other systems.  The poor flocculation was due to a 
salinity too close to the critical flocculation salinity, 1.06 M with 12.6% v/v methanol in 
the suspension.  When salt concentration was increased to 1.13 M, larger flocs formed 
and consequently the drug and surfactant yields increased.  The naproxen potencies were 
similar for both salinities and were well above the overall potency in the suspension.     
For system B, a control was performed in which the suspension was filtered 
without adding any salt.  Without flocculation by salt, only 0.050 g precipitate was 
recovered as the particles were too small for the filter.  At salt concentration of 0.47 M, 
only a small amount of flocculation occurred, and the drug particles plugged up the filter 
paper in 5 min.  As the salt concentration increased from 0.94 to 1.01 to 1.06 M, the drug 
and surfactant yields increased significantly.  A drug yield higher than 92% was obtained 
at a salt concentration higher than 1.4 times of the critical flocculation salinity of Pluronic 
F127.  The naproxen potency decreased a small amount with salinity and was about 
double the overall potency.  The relative deviation (average deviation/mean value) of the 
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precipitate weight decreased from 5.5% with 0.94 M salt to 0.9% with 1.01 or 1.06 M 
salt.  The increase of reproducibility of precipitate weight and drug yield with salt 
concentration likely indicates more stable, stronger and larger aggregates that could be 
filtered more effectively.  An increase in aggregate size with an increase in the distance 
above the cloud point temperature has also been observed for clay particles stabilized 
with PEO formed at higher temperature above the cloud point.30  The increase in the 
flocculation efficiency was attributed to an increase in the tendency for the PEO to phase 
separate and adsorb onto the clay particles.30   
As the Pluronic 127 concentration was lowered 2 fold in system C relative to 
system B for a given salinity, the potency increased from 36.7 to 54.1%, yet the 
dissolution rate remained extremely high.  The potency was over 2.5 times that of the 
overall potency in the suspension.  The drug yield increased to 97.6% while the surfactant 
yield decreased significantly.  Furthermore, the particle size changed very little.  Given 
these beneficial results, the PVP K-15 concentration was reduced by a factor 3 in system 
D relative to system C and the drug yield increased to nearly 100%.  The concentrations 
of drug and surfactant were similar, while the salt concentration decreased to 6.4%.   
The selectivity for drug particles over surfactants (g precipitate drug/g filtrate 
drug) / (g precipitate surfactant/g filtrate surfactant) in the filtration process was very 
high and usually quite reproducible as shown is the last column of Table 5.4.  The high 
deviation for system C was due to high drug yield, and thus the very small amount of 
drug in the filtrate.  The excellent reproducibility in nearly all of the properties in Table 
5.4 for most systems makes the flocculation/filtration concept of practical interest. 
Based on dissolution rate and drug recovery, systems B and C flocculated at 1.01 
M salt concentration may be expected to produce the highest drug bioavailability.  The 
recommended daily dose of naproxen in adults for rheumatoid arthritis, osteoarthritis, and 
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ankylosing spondylitis is 500-1000 mg.35  According to the ratio of sodium sulfate to 
naproxen in systems B or system C, the daily dose of sodium sulfate from these powders 
would be 81-286 mg.  This amount is much less than the commercial daily dose from 
OCL®, a saline laxative (Abbott), in which 1.29 g sodium sulfate was used.36  Thus 
flocculation of naproxen nanoparticles with sodium sulfate is applicable in the 
pharmaceutical industry based on toxicity.
Table 5.4. Properties of the precipitate after vacuum drying including selectivity for drug vs. surfactant 
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A   
   
   
   
   
   
1.13 7.7 0.6552± 66.3±0.7 





















































C 1.01 12 0.9021± 54.1±0.5 

























5.3.8 Morphology of flocculated naproxen nanoparticles by optical microscope and 
SEM 
The morphology of naproxen nanoparticle flocs of system B flocculated at 1.01 M 
salt concentration in the suspension and after drying is shown in Figure 5.5 (a) and (b).  
As shown in Figure 5.5 (a), naproxen flocs with sizes ranging from 5 µm to 150 µm were 
formed in the suspension.  These flocs were larger than the 2 µm limit for P2 filter paper 
and thus more than 90% of the naproxen was recovered.  As shown in Figure 5.5 (b) (left 
panel), a floc with size larger than 30 µm was formed during flocculation and drying.  
This particle, however, was composed of primary nanoparticles of approximately 300 
nm, shown on the right, consistent with the size measured by light scattering.   
5.3.9 X-ray diffraction 
X-ray diffraction was used to analyze the crystallinity of the dry powders.  As 
shown in Figure 5.6, the highest naproxen peaks coincided with those of bulk Pluronic 
F127.  The naproxen peaks were much smaller and broader in the physical mixtures of 
the various formulations as well in the dried powders produced by antisolvent 
precipitation.  However, the naproxen peaks at 2θ = 22.6o and 2θ = 23.9o, especially in 
the high potency samples produced by flocculation, were evident.  Thus, crystalline 
naproxen was formed whether the suspension was dried by lyophilization or flocculation 
followed by filtration and vacuum drying.  The presence of sodium sulfate in the final 
powder is also apparent in the diffraction pattern.  
m
 
                     
Figure 5.5 (a). Microscopic pictures of naproxen flocs of system B in
















Figure 5.5 (b). SEM pictures of naproxen flocs after filtration and vac
sample as Figure 5.5 (a).50 µ
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Figure 5.6. X-ray diffraction of flocculated, filtered and vacuum dried naproxen particles produced by antisolvent 
precipitation.  One of the suspensions without flocculation was dried by lyophilization as marked.  




Crystalline naproxen powders composed of submicron primary particles produced 
by antisolvent precipitation were successfully recovered from aqueous suspensions by 
flocculation with sodium sulfate followed by filtration and vacuum drying.  The 
flocculation was reversible as the particle size upon redispersion in water under various 
conditions was comparable to the original particle size in the aqueous suspension prior to 
flocculation.  Less salt was need for flocculation when the stabilizer was Pluronic F127, 
where the hydrophilic group was ethylene oxide, than for PVP K-15, where it was N-
C=O units on lactam rings, consistent with the trend for cloud point phase equilibria 
curves.  The dissolution rate of dried, flocculated naproxen particles coated with 
stabilizers was very high when the size of the nanoparticles upon redispersion was on the 
order of only 300 nm.  The size measured by light scattering was consistent with the 
primary particle size in the powders measured by SEM.  The redispersibility of the dried 
powders was successful for a minimum salt concentration and the proper composition 
and concentration of the stabilizer.  The dissolution rate was linearly correlated with the 
specific surface area calculated from the average particle diameter after redispersion.  
Extremely rapid dissolution, up to 95% of the powder in two min, was achieved for 300 
nm particles.  The salt concentration could be optimized to control the flocculation to 
balance the drug yield versus potency with excellent reproducibilites in each of 1-2%.  
The drug potencies of flocculated samples were enhanced by up to 61% relative to the 
initial value by the filtration step.  The yield of the drug in the powder was typically 92 to 
99% and the drug potency varied by only 1 to 2%.  The residual sodium sulfate 
concentration in the dried powders, typically 10% or less was far below toxic limits based 
on the recommended dose of naproxen.  The flocculation/filtration process simplifies 
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drying to obtain powder relative to lyophilization.  It also produces smaller particles upon 
redispersion of the powder than would be expected in spray drying, where the particle 
sizes are usually above one micron.  
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CHAPTER 6  
Conclusions and Recommendations for Further Study 
6.1. CONCLUSIONS 
6.1.1 Preparation of Cyclosporine A Nanoparticles by Evaporation Precipitation 
into Aqueous Solution (EPAS) 
The rapid evaporation of the heated organic solution in EPAS results in fast 
nucleation leading to amorphous nanoparticle suspensions.  A variety of hydrophilic 
stabilizers were found to diffuse to the surface of the growing particles rapidly enough to 
prevent growth of the nanoparticles.  Nanoparticle suspensions with low drug 
crystallinity were formed for cyclosporine A with L-α-phosphatidylcholine vesicles, low 
molecular weight ethyoxylated nonionic surfactants, and high molecular weight 
homopolymers.  The drug concentrations were as high as 35 mg/ml, and drug/surfactant 
ratios reached unity.  Both of these values are far in excess of the values obtained for 
solvation of this drug in micelles or vesicle bilayers.1, 2  For the two solvents studied, 
diethyl ether and dichloromethane, the difference in particle size is related to Ostwald 
ripening and/or steric interactions between surfactant coated drug particles, and in the 
case of L-α-phosphatidylcholine, to the effect of solvent on the vesicle stability.  The 
particle sizes were larger for the high molecular weight homopolymer stabilizers versus 
the low molecular weight ethoxylated surfactants.  It is likely that the slower diffusion for 
the former allowed more time for particle growth.  For a given drug/surfactant ratio, 
particle size decreased with increasing surfactant concentration, despite the increase in 
the concentration of the suspension.  An increase in temperature speeds up evaporation 
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and nucleation leading to smaller particles, except in the cases where it is detrimental to 
steric stabilization, as was found for ethoxylated surfactants.   
6.1.2 Ketoprofen Nanoparticle Gels Formed by Evaporative Precipitation into 
Aqueous Solution (EPAS) 
Aqueous ~50 nm gels of a poorly-water soluble drug, ketoprofen, were produced 
by evaporative precipitation into aqueous solution (EPAS) followed by cooling.  In only 
two minutes, 98% of this wet gel dissolved.  In addition, 94% of the ketoprofen dissolved 
from suspensions with lower surfactant concentration, which were dried by 
lyophilization.  The size of the particles in the gel changed only a small amount over one 
month reaching only 115 nm.  The addition of electrostatic repulsion, due to ketoprofen 
ionization, to complement steric stabilization led to much smaller particles than normally 
produced by EPAS.  Furthermore, the particles were amorphous, whereas crystalline 
particles are normally formed.  The favorable interactions between ketoprofen and 
Pluronic F127 led to amorphous particles for low Pluronic F127 concentrations.  Stable 
ketoprofen particles with a mean particle size of 135 nm, measured by dynamic light 
scattering, were formed with only 0.1% w/v Pluronic F127 and with an exceptionally 
high drug-to-surfactant ratio of 10:1.  Here the concentration was well below the gellation 
concentration.  For higher Pluronic concentrations, these interactions induced gellation 
and produced unusually smaller particles, as small as 50 nm.  When the drug 
concentration in the organic phase increased from 20% to 70% w/v, the particle size of 
ketoprofen decreased from 401 to 122 nm at suspension concentration of 30 mg/ml due to 
higher supersaturation.  The rapidly dissolving wet gels, with relatively low viscosities, 
are of interest in transdermal and parenteral delivery; furthermore, the gels may be dried 
for oral delivery.  
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6.1.3 Rapid Dissolution of High Potency Danazol Particles Produced by Evaporative 
Precipitation into Aqueous Solution 
High dissolution rates were obtained for danazol produced by EPAS with PVP 
40T, PVP K-15 or PVP 40T together with SLS as stabilizers.  The high dissolution rates, 
e.g. 90% in 2 min with a drug-to-surfactant ratio of 9:1, are remarkable given the high 
potencies, that is the very low amounts of excipients.  Since only about 5% of the 
surfactant required for forming the EPAS suspensions is adsorbed onto the particles, the 
rest may be removed after centrifugation.  After removal of the free surfactant and 
drying, the particles may be redispersed in pure water without any growth in particle size 
or loss in surface area.  The dissolution rates were high only for surfactants with an 
adsorption of 10% w/w or more during the EPAS spray.  The dissolution rates were high 
for surfactants that produced particles smaller than 15 µm with surface areas greater than 
5 m2/g and much lower for the other systems with larger particles and smaller surface 
areas.  The high surfactant adsorption levels were required to prevent particle 
agglomeration and growth.  These results indicate that the small particle size and large 
surface area of the surfactant-coated particles, with reduction in crystallinity less than 
20%, was enough to produce high dissolution rates.  Not only is the surface area, S, much 
higher for the EPAS particles, but this much larger surface area is accessible to water 
given the hydrophilic surfactant coating on the particle surface.  The high surface area 
was evident in the nanostrutured aggregates shown in the ESEN micrographs.  In a 2-
week thermal cycling stress test with desiccant, the powders were very stable as the 
dissolution rate, crystallinity, particle size and surface area changed only a minimal 
amount with time.  The ability to engineer stable particles with high potencies and high 
dissolution rates with EPAS presents new opportunities in the development of 
commercial formulations for water insoluble drugs. 
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6.1.4 Flocculation of Suspensions Formed by Antisolvent Precipitation to Produce 
Redispersible Naproxen Nanocrystals 
Crystalline naproxen powders composed of submicron primary particles produced 
by antisolvent precipitation were successfully recovered from aqueous suspensions by 
flocculation with sodium sulfate followed by filtration and vacuum drying.  The 
flocculation was reversible as the particle size upon redispersion in water under various 
conditions was comparable to the original particle size in the aqueous suspension prior to 
flocculation.  Less salt was need for flocculation when the stabilizer was Pluronic F127, 
where the hydrophilic group was ethylene oxide, than for PVP K-15, where it was N-
C=O units on lactam rings, consistent with the trend for cloud point phase equilibria 
curves.  The dissolution rate of dried, flocculated naproxen particles coated with 
stabilizers was very high when the size of the nanoparticles upon redispersion was on the 
order of only 300 nm.  The size measured by light scattering was consistent with the 
primary particle size in the powders measured by SEM.  The redispersibility of the dried 
powders was successful for a minimum salt concentration and the proper composition 
and concentration of the stabilizer.  The dissolution rate was linearly correlated with the 
specific surface area calculated from the average particle diameter after redispersion.  
Extremely rapid dissolution, up to 95% of the powder in two min, was achieved for 300 
nm particles.  The salt concentration could be optimized to control the flocculation to 
balance the drug yield versus potency with excellent reproducibilites in each of 1-2%.  
The drug potencies of flocculated samples were enhanced by up to 61% relative to the 
initial value by the filtration step.  The yield of the drug in the powder was typically 92 to 
99% and the drug potency varied by only 1 to 2%.  The residual sodium sulfate 
concentration in the dried powders, typically 10% or less was far below toxic limits based 
on the recommended dose of naproxen.  The flocculation/filtration process simplifies 
 144
drying to obtain powder relative to lyophilization.  It also produces smaller particles upon 
redispersion of the powder than would be expected in spray drying, where the particle 
sizes are usually above one micron.  
6.2 RECOMMENDATIONS 
It is recommended that other means such as NMR to be applied to test the 
ketoprofen-Pluronic F127 interaction in water.  It is also recommended that hydrophobic 
silica with similar particle size of ketoprofen, ~50 nm to be dispersed into 5% w/v 
Pluronic F127 aqueous solution and the viscosity of the suspension to be measured and 
compared with ketoprofen-Pluronic F127 gel.  
It is recommended that the concept of high potency by centrifugation or filtration 
to get rid of free surfactant to be generalized to antisolvent precipitation.  The surfactant 
adsorption in antisolvent precipitation, the dissolution rate and long term stability of high 
potency drug particles from antisolvent precipitation to be investigated. 
It is recommended that the adsorption of various surfactants onto naproxen drug 
particles during antisolvent precipitation and after to be measured and compared with 
other drugs with higher LogP.  It is also recommended that the concentrations of 
remaining surfactants, Pluronic F127 and PVP K-15, after salt flocculation and filtration 
to be quantitatively measured. 
It is recommended that the particle size of drug particle in antisolvent 
precipitation to be controlled by manipulating the mixing time of organic solution and 
aqueous antisolvent, the nucleation and growth rate of drug particles, and the surfactant 
adsorption rate.  
It is also recommended that the crystal growth of drug particles produced by 
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Rapid Dissolution of High Potency Itraconazole Particles Produced by 
Evaporative Precipitation into Aqueous Solution 
A.1 INTRODUCTION  
Itraconazole is a water-insoluble active pharmaceutical ingredient (API) used to 
treat systemic fungal infections.  These fungal infections are a major cause of morbidity 
and mortality in immunocompromised patients.  Itraconazole inhibits the fungal enzymes 
that produce ergosterol, an important component of the fungal cell wall.  For oral 
delivery, high dissolution rates are required to drive sufficient permeation through the 
intestines to achieve the desired bioavailability.  Currently available antifungal products, 
including amphotericin B, liposomal amphotericin B, flucytosine, and the azole 
antifungal agents (e.g. fluconazole, ketoconazole and itraconazole) have poor oral 
bioavailabilities which limit their use.  Itraconazole is a weakly basic API (pKa= 3.7) 
possessing an extremely low water solubility of 0.472 ng/ml, which impedes its 
bioavailability.1  The dissolution rate of an API into an aqueous solution depends upon 
the diffusion coefficient, D, the surface area, S, the local equilibrium concentration of 
API in the diffusion layer surrounding the particle, Cs, and the diffusion layer thickness, 






s −=  
where C is the concentration of the API in dissolution media at time t.  The surface area S 
may be increased by reducing the particle size, by increasing the porosity and by 
enhancing wetting of the particles by the dissolution media.  Wetting may be enhanced 
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with hydrophilic excipients that are surface active at the API-aqueous interface.2  The 
value of Cs may also be enhanced by trapping the API in metastable crystalline or 
amorphous states with higher free energies than the lowest energy equilibrium crystalline 
state.  The metastable states may produce a higher local value of Cs. 
Various techniques have been used to improve the bioavailability of poorly 
soluble APIs including the use of surfactants to enhance wetting,3, 4 mechanical milling to 
reduce particle size5 and the formation of solid dispersions.6  Widely used mechanical 
techniques based on high shear or impaction, including microfluidization and milling can 
be limited by unfavorable yields due to solid losses, high polydispersity in particle size, 
shear-induced particle denaturation, long processing time, high energy requirements and 
the need for separating the product and processing agent.7-10  To overcome many of these 
limitations, various approaches are being developed to form particles from solution in 
semi-continuous spray processes, for example spray drying, precipitation with a 
compressed fluid antisolvent and.11, 12  
Evaporative precipitation into aqueous solution (EPAS) is a new process that 
produces submicron to micron-sized hydrophobic API particles stabilized by surfactants 
and dispersed in an aqueous medium.13-15  As shown in Figure A.1, API dissolved with or 
without surfactant (s) in organic solvent, for example, dichloromethane or diethyl ether, 
is sprayed through an atomizer into a hydrophilic surfactant aqueous phase.  The organic 
phase is heated prior to atomization while the temperature of the aqueous solution is 
controlled at a temperature above the boiling point of the organic solvent but below the 
thermal decomposition temperature of the API.  The rapid evaporation of the organic 
solvent produces high supersaturation and rapid precipitation of the API in the form of 
suspended particles that are stabilized by a variety of surfactants present in either or both 
the organic and aqueous phases.  The surfactants adsorb onto the API surface and prevent 
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particle growth during the spray process.  EPAS produces systems with a high API-to-
surfactant ratio or payload relative to formulations in which the API is dissolved in 
micelles or liposomes.5, 13-15   
Chen et al.13 developed a concept to produce high potency APIs with API-to-
surfactant ratios greater than 13, corresponding to potencies (wt API/wt API + wt 
surfactant) as high as 93%.  Typical potencies for APIs dissolved in micelles or vesicles 
are lower by an order of magnitude or more.  Aqueous dispersions formed by EPAS were 
centrifuged to remove the non-adsorbed or free surfactant.   The desirable orientation of 
the small amount of adsorbed surfactant on the surface of the particles, which were 
produced by EPAS, led to stable particles with high wettability and dissolution rates.  
Because the hydrophilic segment of the surfactant stabilizes the aqueous dispersions, it is 
also oriented properly to produce high dissolution rates with very large API-to-surfactant 
ratios with a minimal amount of surfactant.  For danazol stabilized by polyvinyl 
pyrrolidone (PVP) alone or with sodium lauryl sulfate (SLS), high surface areas on the 
order of 5 m2/g produced high dissolution rates.  
The objective of this study was to demonstrate that high potency itraconazole 
particles with rapid dissolution rates may be produced by the EPAS process followed by 
centrifugation and vacuum drying.  We chose to look at a considerably more challenging 
API, itraconazole, versus the previous study with danazol.13  The extreme hydrophobicity 
for itraconazole is reflected in the octanol/water partition coefficient (LogP) of 5.66 
versus 4.21 for danazol.  Consequently, dissolution rates are extremely slow for bulk 
itraconazole without surfactant stabilization.  The experimental variables included the 
type of nozzle, surfactant concentration in the organic phase and the stabilization 
mechanism of various surfactants (API concentration was fixed). A micrometering valve 
nozzle and a conical nozzle were investigated to determine the effects of the intensity of 
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atomization.  The dissolution rate was analyzed as a function of the particle size in the 
original EPAS dispersion, surface area, and crystallinity to provide an understanding of 
the mechanism of enhanced dissolution rates. 
A.2 EXPERIMENTAL 
A.2.1 Materials  
Itraconazole was purchased from Spectrum Chemicals& Laboratory Products 
Corporation (Gardena, CA).  Pluronic F127 (BASF, Mount Olive, NJ), 
Polyvinylpyrrolidone (PVP K-15, Mw =10, 000 and PVP 40T, Mw = 40, 000) (Sigma, St. 
Louis, MO), Myrj 52 (Sigma, MO), sodium lauryl sulfate (Sigma, MO) and deoxycholic 
acid (Sigma, St. Louis, MO) were used as received.  HPLC grade acetonitrile was from 
EM Science (Gibbstown, NJ) and spectro grade dichloromethane was from Fisher 
Scientific Co. (Houston, TX). 
A.2.2 Evaporative precipitation into aqueous solution (EPAS) 
The EPAS apparatus resembled an earlier version13-15 and is shown in Figure A.1.  
The organic itraconazole solution in dichloromethane was fed by an HPLC pump through 
a 3 m long 1/16 in. o.d. × 0.030 in. i.d. stainless steel coiled tube contained within a 1-
1/2″ OD × 24″ long plastic water jacket (Alltech, Deerfield, IL).  Water was circulated 
through the jacket with a Julabo MP temperature controller (Julabo USA Inc., Allentown, 
PA).  The aqueous solution was contained in a 125 ml separatory funnel submerged in a 
temperature-controlled water bath.  The nozzle was submerged approximately 4 cm 
below the surface of the aqueous solution the water.  The nozzle was insulated to the 
point where it entered the aqueous solution.  To suppress and drain the foam produced by 
the organic vapor, air was blown downwards on top of the foam into the separatory 
funnel through three 1/16 in. o.d. × 0.030 in. i.d. stainless steel tubes.  The surfactant in 
the organic phase in all cases was Pluronic F127 while the surfactant in the aqueous 
phase was present with a concentration of 1% w/v in each case.  After spraying for a 
required time to produce the desired API-to-surfactant ratio, the dispersion was recovered 

























Figure A.1. Apparatus for evaporative precipitation into aqueous solution (EPAS) 
Two nozzles were used in EPAS.  The micrometering valve nozzle was an 
assembly that is part of a supercritical fluid extraction apparatus (5 mm o.d. × 136 mm 
long, ISCO, Lincoln, NE).  The tip of the valve stem was located at the bottom of the 
nozzle well below the level of the aqueous solution.  Atomization was achieved by 
adjusting the valve manually to maintain a pressure drop of ~ 3500-4500 psi for a flow 
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rate of 1 to 3 ml/min.  The conical nozzle was made from a 10 in. long, 1/16 in. o.d. × 
0.030 in. i.d. stainless steel tube.  The tube was cut with a wire cutter to produce an 
elliptical conical thin slit orifice.  The tapered section of the tube was only 0.5 mm long.  
The tip was filed until the desired pressure drop was achieved for a given flow rate of 
organic solvent into air.14, 16  When the solution was later sprayed into aqueous solution, 
the spray looked similar to the photograph reported earlier.14  
A.2.3 High potency itraconazole powder by centrifugation 
Solutions comprising 2% w/v itraconazole with 3% w/v Pluronic F127 and 2% 
w/v itraconazole with 2% w/v Pluronic F127 were prepared in dichloromethane for the 
experiments with the conical nozzle and micrometering valve nozzle, respectively.  The 
solution was sprayed at a flow rate of 1 ml/min unless otherwise specified into 50 ml 
aqueous solution containing 1% w/v surfactant or a surfactant mixture at 1:1 w/w ratio 
with a total concentration of 1% w/v, if two surfactants were used.  The temperatures of 
both the heating jacket and water bath were 75oC and the pressure drop was 3500-4500 
psi.  After 25 min of spraying, dispersion with an API-to-surfactant ratio of 0.4 (conical 
nozzle) or 0.5 (micrometering valve nozzle), and an API concentration of 10 mg/ml water 
was recovered.  The dispersions were centrifuged (BECKMAN, Model TJ-6) at 3500 rpm 
for 30 min.  The supernatants were decanted and the precipitates were placed into a 
vacuum oven and dried at 40oC, and -30 in Hg overnight.  The potency was determined 
by dissolving a known amount, about 10 mg, dry powder into 50 ml acetonitrile/water 
mixture (v:v = 70:30) and measuring itraconazole concentration by HPLC (Shimadzu, 
LC-600, Japan). 
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A.2.4 Crystallinity and surface area measurement 
Wide angle X-ray scattering was employed to detect the crystallinity of 
itraconazole.  CuKα1 radiation with a wavelength of 1.54054 Å at 40 kV and 20 mA 
from a Philips PW 1720 X-ray generator (Philips Analytical Inc., Natick, MA) was used.  
The samples were well-mixed to minimize the effects of preferred orientation.  A Philips 
goniometer was used to measure the reflected intensity at a 2θ angle between 3 and 45° 
with a step size of 0.05° and a dwell time of 1 s.  Specific surface area was measured 
using a NOVA-2000 instrument (Quantachrome Corporation, Boynton Beach, FL).  A 
known amount of powder (~0.1 g) was loaded into a Quantachrome sample cell and 
degassed for at least 3 h prior to analysis.  Nitrogen was used as the absorbate.  The 
degassed sample weight was used for surface area determination. 
A.2.5 Dissolution test 
After centrifugation and vacuum drying, ~10 mg of dry powder was placed into a 
USP II dissolution assembly at a stir rate of 75 rpm for 1 h in pH 1.6 aqueous solution 
that contained 0.5% w/v sodium lauryl sulfate and 0.1 M hydrochloric acid.  Aliquots of 
the dissolution medium (5 ml) were sampled at 2, 5, 10, 20, 30 and 60 min.  The aliquots 
were filtered through 0.45 µm syringe filters and 2 ml aliquots of each sample were 
diluted with 0.1 ml acetonitrile before analysis.  Itraconazole concentrations were 
measured by HPLC (SHIMADZU, LC-600, Japan).   
A.2.6 Particle size  
Particle size distributions, based on volume fraction, of the original EPAS 
dispersion were measured by static light scattering with a Malvern Mastersizer-S 
(Malvern Instruments Inc., Southborough, MA).  A 5 ml aliquot of dispersion containing 
10 mg API/ml concentration in water, was diluted with 500 ml distilled water to produce 
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a light obscuration in the range of 10-30%.  The solution was sonicated until the mean 
particle size of the dispersion reached a constant value.  In a control experiment, 0.2 g 
bulk itraconazole was dispersed in 100 ml 3% w/v non micelle-forming PVP K-15 
aqueous solution overnight under vigorous stirring, since it is very hydrophobic and 
difficult to disperse in pure water.  20 ml bulk itraconazole suspension was diluted with 
500 ml pure water to measure the particle size of bulk itraconazole by Malvern.  
Ultrasound was used in the measurement to break up the agglomerated particles. 
A.3 RESULTS AND DISCUSSION  
The results are presented below for the micrometering valve nozzle and the 
conical nozzle.  The smaller particles for the conical nozzle were shown to be consistent 
with a finer spray and greater degree of atomization.   
A.3.1 Micrometering valve nozzle: particle size and dissolution rate 
The effect of several surfactants as stabilizers in the aqueous phase was 
investigated with the micrometering valve nozzle.  Without Pluronic F127 in the organic 
phase, surfactant in the aqueous phase alone could not stabilize the itraconazole particles.  
The API particles floated on top of the aqueous phase due to poor surfactant adsorption.  
With the addition of 2% w/v Pluronic F127 in the organic phase, stable itraconazole 
suspensions were formed by EPAS.  The organic solutions containing 2% w/v Pluronic 
F127 and 2% w/v itraconazole were sprayed into 50 ml of 1 % w/v surfactant aqueous 
solution at a flow rate of 1 ml/min unless specified otherwise.  The spray time was 25 
min.  For each EPAS sample, the pressure drop across the nozzle was maintained at ~ 
3600 psi for each spray.  Visual observation of the EPAS spray indicated that the angle of 
the jet was narrower and the droplets appeared to be larger in comparison with those 
 154
produced with the conical nozzle.  Samples were analyzed to determine the particle size 
and dissolution rate of the surfactant stabilized itraconazole particles.   
The particle sizes produced with the surfactants are shown in Table A.1.  After 
sonication, the mean diameters of the particles in dispersion were dependent on the 
structure of the aqueous surfactant and the flow rate of organic phase.  When the flow 
rate of organic phase was increased from 2 ml/min to 3 ml/min, itraconazole particle size 
increased from 9.4 µm to 13.8 µm.  Despite the large particle size, Figure A.2 shows that 
the release rate after 5 min with PVP K-15 and Pluronic F127 was 36.1% compared to 
7.5% from the bulk itraconazole, a slight improvement in API dissolution.  The 
dissolution rate enhancement for the itraconazole particles after EPAS illustrates the 
importance of wetting of the API particle surface due to the hydrophilic surfactants. 
Experiments were performed with anionic surfactants, sodium lauryl sulfate and 
deoxycholic acid, but the dissolution rates were poor due to incompatibility of the 
surfactants and the acid dissolution media.  For all of the surfactants, the poor 
atomization with this nozzle produced particles that were too large with too little surface 
area.  In order to produce powder with a faster dissolution rate, all the experiments below 
were performed with a conical nozzle that produced more intense atomization.  
Table A.1. Mean particle size D (v, 0.5) of itraconazole particles in the EPAS suspension 
for various organic phase flow rates with the micrometering valve nozzle.  
Experimental conditions were the same as in Figure A.2.   
Aqueous surfactant D (v,0.5)  
(µm) 
 
PVP K-15 (Q= 2 ml/min) 18.6 
PVP 40T (Q= 2 ml/min) 9.4 
PVP40T (Q= 3 ml/min) 13.8 
DCA (Q=1 ml/min) 11.5 
SLS (Q=1 ml/min) 19.2 



































PVP 40T (Q=2 ml/min)
PVP 40T (Q=3 ml/min)
PVP K-15 (Q=2 ml/min)
Bulk itraconazole
Figure A.2. Dissolution rates for dried EPAS itraconazole particles produced with the 
micrometering valve at various organic flow rates and aqueous surfactant 
concentration of 1% w/v.  
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A.3.2 Conical nozzle 
Experiments with the micrometering valve nozzle showed that adding Pluronic 
F127 in the organic phase and decreasing the flow rate of organic phase led to 
itraconazole suspensions with smaller particle size.  Therefore, for the experiments with 
the conical nozzle, more Pluronic F127 was added into the organic phase and the flow 
rate was decreased to 1 ml/min.  Additional nonionic surfactants were studied with the 
conical nozzle due to the unsuccessful results with the micrometering valve nozzle for 
ionic surfactants.  A concentration of 3% w/v Pluronic F127 was used in the organic 
phase with the conical nozzle to stabilize the particles for an aqueous solution 
concentration of 1% w/v of various surfactants.  The solution containing 3% w/v Pluronic 
F127 and 2% w/v itraconazole was sprayed into 50 ml aqueous solution at a flow rate of 
1 ml/min for 25 min. The appearance and angle of the atomized jet were comparable to 
those reported earlier.14  Visually, the spray appeared to be composed of finer droplets 
than for the micrometering valve nozzle above, consistent with the finer orifice.  
A.3.2.1 Dissolution rate  
As shown in Figure A.3, the dissolution rate of the high potency powder after 
centrifugation was strongly dependent on the type of surfactant.  It was much higher for 
PVP K-15 than the other surfactants.  In 10 min, 35, 60, 70 and 90% itraconazole was 
dissolved with PVP 40T, Myrj 52, Pluronic F127 and PVP K-15 as the surfactants, 
respectively.  For each surfactant, the dissolution rate was substantially higher than for 
the bulk itraconazole.  The properties of the EPAS dispersions and powders after 






























Figure A.3. Dissolution rates for dried EPAS itraconazole particles produced with conical 
nozzle for various aqueous surfactants at a concentration of 1 % w/v and 
organic flow rate of 1 ml/min.  
A.3.2.2 Particle size and surface area 
For the EPAS dispersions without centrifugation, Table A.2 shows the mean 
particle diameters based on volume, the particle size distributions of EPAS suspensions 
and surface areas, itraconazole potencies of dried EPAS particles.  Itraconazole coated 
with PVP K-15 yielded the smallest mean diameter, 8.7 µm, with small particle in 
nanometer range, D (v, 0.1)= 0.9 µm and high surface area, as high as 9.38 m2/g.  The 
calculated surface area for monodisperse spheres with a similar particle diameter would 
be 1.04 m2/g.  The much larger surface area for the powders in Table A.2 suggests that 
the particles were not uniform spheres but were aggregates composed of smaller primary 
particles.  Therefore, the increase of surface area must be due to factors other than the 
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average particle size of the aggregates measured by light scattering.  In addition, particles 
with smallest particles in the distribution contribute high surface area.  In the dissolution 
rate experiments, not only was the surface area, 9.38 m2/g, higher for these particles, but 
this much larger surface area was accessible for wetting by the dissolution media given 
the hydrophilic surfactant coating on the particle surface. 
 
Table A.2. Mean particle size D (v, 0.5), and particle size distribution of itraconazole in 
EPAS suspension formed with the conical nozzle; and surface area and 
potency of itraconazole in dried EPAS powder. Experimental conditions were 




D (v, 0.5) 
(µm) 









Bulk itraconazole 3.10 1.5, 6.6  5.13 
PVP K-15 8.7 0.9, 55.4 78.9 9.38 
PVP 40T 15.2 3.2, 39.5 72.5 3.28 
Myrj 52 18.7 3.4, 48.0 68.8 3.17 
Pluronic F127 10.6 4.2, 26.6 47.3 3.87 
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The average particle diameters were 10.6, 18.6 and 15.2 µm for Pluronic F127, 
Myrj 52 and PVP 40T systems respectively.  The dissolution rates for these systems, with 
larger particle sizes and surface areas, on the order of 3 m2/g, were significantly lower 
than for the PVP K-15 system.  Even though these systems had larger particle size and 
lower surface areas compared to the bulk itraconazole, D (v, 0.9)= 3.1 µm and S= 5.13 
m2/g, they still exhibited better dissolution profiles compared to the bulk API.  Thus the 
increase in accessible surface area to the dissolution medium resulting from the 
hydrophilic surfactant coating on the particle surfaces was a key property that enhanced 
the dissolution rate.  This correlation between the dissolution rate and the surface area 
was also observed for the earlier study with danazol.13 
A significant fraction of the surfactant was free and not adsorbed; thus the 
potency increased markedly after removing the free surfactant for all systems 
investigated.  The API-to-surfactant ratio for PVP K-15 was 9.3 times higher after 
centrifugation versus the fed amount with itraconazole potency increased from 28.6% to 
78.9% after centrifugation.  The observation of the highest dissolution rate for 
itraconazole coated with PVP K-15 is consistent with the higher surface area, smaller 
particle size.  The higher surface area suggests that the surfactant adsorbed more quickly 
onto the growing itraconazole particles than for the other surfactants to retard particle 
growth.  Relative to PVP 40 T, the diffusion rate of lower molecular weight PVP K-15 is 
faster, leading to faster adsorption kinetics.  A higher level of adsorption for PVP K-15 
versus PVP 40 T was confirmed explicitly in the EPAS study of danazol.13 
Slower API dissolution for Pluronic F 127 was also observed for danazol and was 
attributed to a lower degree of adsorption reflecting slower adsorption dynamics.  
Fundamental studies indicate that slow adsorption dynamics for this type of block 
copolymer on solid surfaces results from rearrangements of the blocks on the surface.17  
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For PVP homopolymers, these rearrangements between two types of blocks are not 
needed leading to faster adsorption and thus faster release.  Myrj 52 
(CH3(CH2)~16(OCH2CH2)~40OH) has a shorter PEO (40) chain than Pluronic F127 
(HO(CH2CH2O)~98(CH2C(CH3)HO)~67(CH2CH2O)~98H).  It is possible that this shorter 
PEO chain provided less satisfactory steric stabilization, leading to larger particle size.  
The quality of each EPAS spray depends on the size (diameter) and geometry of 
the nozzle, and the physical properties of the dispersed and the continuous phases.18  To 
investigate the effect of the geometry of the conical nozzle on the particle size, three 
conical nozzles were produced.  After cutting the tubing, the tips were filed to produce 
different size cones.  The pressure drops for the three nozzles to produce a flow rate of 1 
ml/min were 4500, 3600 and 3000 psi.  The mean particle size was similar in each case, 
in the range of 7.6-8.7 µm.  The variations in dissolution rate were within experimental 
error.  Therefore, the slight difference in atomization for the three nozzles was not 
enough to influence the particle size and dissolution rate.  In these experiments both the 
organic dispersed phase (2% w/v itraconazole, 3% w/v F127 in dichloromethane solvent) 
and the continuous phase (1% w/v PVP K-15 aqueous solution) were kept identical.    
A.3.2.3 Crystallinity  
Figure A.4, illustrates the X-ray diffraction profiles of itraconazole contained in 
the dry powders.  The crystalline peak positions were the same as for the bulk 
itraconazole.  The α-peak heights of itraconazole in different surfactant systems at 2θ 
=20.5o are also listed in Figure A.4.  The crystallinity was found to be similar to that of 
the bulk itraconazole after correction for the presence of the surfactants in the dry 
powder.  It was assumed that the itraconazole peak height was linear in concentration for 






























Figure A.4. X-ray diffraction pattern and α peak height, h, at 2θ = 20.5o of dried EAPS 




EPAS followed by removal of free surfactant produced high surface area particles 
with high potencies up to 79% and rapid dissolution rates.  A significant fraction of the 
surfactant was free and not adsorbed; thus the potency increased markedly after removing 
the free surfactant.  The hydrophilic segment of the surfactant stabilizes the aqueous 
dispersions formed in the EPAS sprays.  This segment extends outwards from the particle 
surface and facilitates wetting and thus high dissolution rates.  In essence, the EPAS 
process orients the surfactant in an optimal architecture for subsequent high dissolution 
rates in aqueous media.  The dissolution rate was highest for PVP K-15 as the surfactant 
in the aqueous phase, 90% dissolved in 10 minutes, consistent with the highest surface 
area for this system.  The surface areas reached 9.38 m2/g despite the high potencies and 
thus the relatively small amounts of adsorbed surfactant.  The high dissolution rates and 
high potencies are desirable for the goal of achieving high bioavailabilities of poorly 
water soluble drugs. 
 164
A.5 REFERENCES 
(1) Peeters, J.; Neeskens, P.; Tollenaere, J. P.; Van Remoortere, P.; Brewster, M. E. 
Journal of Pharmaceutical Sciences 2002, 91, 1414-1422. 
(2) Reddy, R. K.; Khalil, S. A.; Gonda, M. W. J Pharm Sci 1976, 65, 115-118. 
(3) Brown, S.; Rowley, G.; Pearson, J. T. Int J Pharm 1998, 165, 227-237. 
(4) Rowley, G.; Pearson, J. T.; Hussian, M. S.; Hartup, D. E.; Jones, B. E. J Pharm 
Pharmcol 1985b, 37, 112P. 
(5) Pace, S. N.; Pace, G. W.; Parikh, I.; Mishra, A. K. Pharm Technol 1999, 23, 116-
134. 
(6) Jung, J. Y.; Yoo, S. D.; Lee, S. H.; Kim, D. S. Y.; Lee, K. H. Int J Pharm 1999, 
187, 209-218. 
(7) Rubinstein, M. H.; Gould, P. Drug Dev. Ind. Pharm. 1987, 13, 81-92. 
(8) Byers, J. E.; Peck, G. E. Drug Dev. Ind. Pharm. 1990, 16, 1761-1779. 
(9) Illig, K. J.; Mueller, R. L.; Ostrander, K. D.; Swanson, J. R. Pharm Technol 1996, 
20, 78-88. 
(10) Aiache, J. M.; Beyssac, E. Powder as dosage forms; Marcel Dekker: New York, 
1994. 
(11) Dixon, D. J.; Johnston, K. P.; Bodmeier, R. A. AIChE Journal 1993, 39, 127-139. 
(12) Rogers, T. L.; Johnston, K. P.; Williams, R. O. Drug Development and Industrial 
Pharmacy 2001 Nov, 27, 1003-1015. 
(13) Chen, X.; Williams, R. O.; Johnston, K. P. J. Pharm. Sci. 2004, 93, 1867-1878. 
(14) Chen, X.; Young, T. J.; Sarkari, M.; Williams, R. O.; Johnston, K. P. Int J Pharm 
2002, 242, 3-14. 
(15) Sarkari, M.; Brown, J.; Chen, X.; Swinnea, S.; Williams, R. O.; Johnston, K. P. 
Int J Pharm 2002, 243, 17-31. 
(16) Young, T. J.; Mawson, S. M.; Johnston, K. P. Biotechnol Prog 2000, 16, 402-407. 
(17) Tripp, C. P.; Hair, M. L. Langmuir 1996, 12, 3952-3956. 
(18) Lefebvre, A. H. Atomization and Sprays; Taylor&Francis, 1989. 
 165
Bibliography1-127 
(1) Federal Register: International Committee on Harmonization, Quality Guidance 
Q3C, 1997. 
(2) The Merck Index: an encyclopedia of chemicals, drugs, and biologicals; Merck & 
CO., Inc.: Rahway, 1996. 
(3) Pharmaceutical practice; Churchill Livingstone: New York, 1990. 
(4) Electronic orange book: approved drug products with therapeutic equivalence 
evaluations.; U.S. Dept. of Health and Human Services, Public Health Service, 
Food and Drug Administration, Center for Drug Evaluation and Research, Office 
of Information Technology, Division of Data Management and Services.: 
Rockville, Md. 
(5) Aiache, J. M.; Beyssac, E. Powder as dosage forms; Marcel Dekker: New York, 
1994. 
(6) Alessi, P.; Cortesi, A.; Kikic, I.; Foster, N. R.; Macnaughton, S. J.; Colombo, I. 
Ind. Eng. Chem. Res. 1996, 35, 4718-4726. 
(7) Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. Pharm. Res 1995, 12, 
413-420. 
(8) Ansel, H. C.; Allen, L. V.; Popovich, N. G. Pharmaceutical dosage forms and 
drug delivery systems, 7th ed. ed.; Lippincott-Williams & Wilkins: Philadelphia, 
PA, 1999. 
(9) Arias, M. J.; Gines, J. M.; Moyano, J. R.; Perez-Martinez, J. I.; Rabasco, A. M. 
Int J Pharm 1995, 123, 25-31. 
(10) Bahadur, P.; Li, P.; Almgren, M.; Brown, W. Langmuir 1992, 8, 1903-1907. 
(11) Bahadur, P.; Pandya, K.; Almgren, M.; Li, P.; Stilbs, P. Colloid and Polymer 
Science 1993, 271, 657-667. 
(12) Bakatselou, V.; Oppenheim, R. C.; Dressman, J. B. Pharm Res 1991, 8, 1461-
1469. 
(13) Blankschtein, D.; Thurston, G. M.; Benedek, G. B. J. Chem. Phys. 1986, 85, 
7268-7288. 
(14) Bodmeier, R.; Chen, H. Journal of Controlled Release 1990, 12, 223-233. 
 166
(15) Broadhead, J.; Rouan, S. K. E.; Rhodes, C. T. Drug Dev. Ind. Pharm. 1992, 18, 
1169-1206. 
(16) Brown, S.; Rowley, G.; Pearson, J. T. Int J Pharm 1998, 165, 227-237. 
(17) Brown, W.; Schillen, K.; Almgren, M. Journal of physical chemistry 1991, 95, 
1850-1858. 
(18) Byers, J. E.; Peck, G. E. Drug Dev. Ind. Pharm. 1990, 16, 1761-1779. 
(19) Cathrein, E.; Stein, H.; Stoller, H. J.; Viardot, K.: EP, 1991. 
(20) Cevc, G. Advanced Drug Delivery Reviews 2004, 56, 675-711. 
(21) Chattopadhyay, P.; Gupta, R. B. Ind. Eng. Chem. Res. 2001, 40, 3530-3539. 
(22) Chen, X. Drug. Del. Sci. Techn. to appear. 
(23) Chen, X.; Lo, C. Y.; Sarkari, M.; Williams, R. O.; Johnston, K. P. In 
preparation. 
(24) Chen, X.; Vaughn, J. M.; Yacaman, M. J.; Williams, R. O.; Johnston, K. P. J. 
Pharm. Sci. 2004, 93, 1867-1878. 
(25) Chen, X.; Young, T. J.; Sarkari, M.; Williams, R. O.; Johnston, K. P. Int J Pharm 
2002, 242, 3-14. 
(26) Choudhury, S.; Nelson, K. F. Int J Pharm 1992, 85, 175-180. 
(27) Chowhan, Z. T. Journal of Pharmaceutical Science 1978, 67, 1257-1260. 
(28) Cohn, D.; Sosnik, A.; Levy, A. Biomaterials 2003, 24, 3707-3714. 
(29) Couvreur, P.; Puisieux, F. Advanced Drug Delivery Reviews 1993, 10, 141-162. 
(30) Cussler, E. L. Diffusion, Mass transfer in fluid systems; Cambridge University 
Press: NY, 1986. 
(31) de Bruijn, V. G.; van den Broeke, J. P.; Leermakers, F. A. M.; Keurentjes, J. T. F. 
Langmuir 2002, 18, 10467-10474. 
(32) De Gennes, P. G. Adv Colloid Interface Sci 1987, 27, 189-209. 
(33) Dijt, J. C.; Cohen, S. M. A.; Hofman, J. E.; Fleer, G. J. Colloids and Surfaces 
1990, 51, 141-158. 
(34) Dixon, D. J.; Johnston, K. P.; Bodmeier, R. A. AIChE Journal 1993, 39, 127-139. 
 167
(35) Elder, E. J.; Hitt, J. E.; Rogers, T. L.; Tucker, C. J.; Saghir, S.; Svenson, S.; 
Evans, J. C. Polymeric Materials Science and Engineering 2003, 89, 741. 
(36) Esumi, K.; Iitaka, M.; Torigoe, K. Journal of Colloid and Interface Science 2002, 
232, 71-75. 
(37) Fagerholm, U.; Borgstrom, L.; Ahrenstedt, O.; Lennernas, H. J. Drug Targeting 
1995, 3, 191-200. 
(38) Fuller, M. A.; Sajatovic, M. Drug information handbook for psychiatry 1999-
2000; Lexi-Comp: Hudson, OH, 1999. 
(39) Ghaderi, R.; Artursson, P.; Carlfors, J. Pharm. Res. 1999, 16, 676-681. 
(40) Gilbert, J. C.; Hadgraft, J.; Bye, A.; Brookes, L. G. International Journal of 
Pharmaceutics 1986, 32, 223-228. 
(41) Grant, D. J.; Higuchi, T. Solubility behavior of organic compounds; New York: 
Wiley, 1990. 
(42) Gref, R.; Quellec, P.; Sanchez, A.; Calvo, P.; Dellacherie, E.; Alonso, M. J. 
European Journal of Pharmaceutical and Biopharmaceutics 2001, 51, 111-118. 
(43) Güner, A.; Ataman, M. Colloid & Polymer Science 1994, 272, 175-180. 
(44) Guven, O.; Eltan, E. Makromolekulare Chemie 1981, 11, 3129-3134. 
(45) Hocking, M. B.; Klimchuk, K. A.; Lowen, S. Journal of Macromolecular 
Science: Polymer Reviews 1999, 39, 177-203. 
(46) Horn, D.; Rieger, J. Angew. Chem. Int. Ed. 2001, 40, 4330-4361. 
(47) Hu, J.; Johnston, K. P.; Williams, R. O. European Journal of Pharmaceutical 
Sciences 2003, 20, 295-303. 
(48) Hu, J.; Johnston, K. P.; Williams, R. O. Polymeric Materials: Science & 
Engineering 2003, 89, 743. 
(49) Hu, J.; Johnston, K. P.; Williams, R. O. International journal of pharmaceutics 
2004, 271, 145-154. 
(50) Hu, J.; Roger, T. L.; Brown, J.; Young, T. J.; Johnston, K. P.; Williams, R. O. 
Pharmaceutical Research 2002, 19, 1278-1284. 
(51) Illig, K. J.; Mueller, R. L.; Ostrander, K. D.; Swanson, J. R. Pharm Technol 1996, 
20, 78-88. 
 168
(52) Johnson, B. K., Princeton, 2003. 
(53) Johnson, B. K.; Prud'homme, R. K. Polymeric Materials: Science & Engineering 
2003, 89, 744-745. 
(54) Jung, J. Y.; Yoo, S. D.; Lee, S. H.; Kim, D. S. Y.; Lee, K. H. Int J Pharm 1999, 
187, 209-218. 
(55) Khoultchaev, K. K. H.; Kerekes, R. J.; Englezos, P. The Canadian Journal of 
Chemical Engineering 1997, 75, 161-166. 
(56) Khoultchaev, K. K. H.; Kerekes, R. J.; Englezos, P. AICHE Journal 1997, 43, 
2353-2358. 
(57) Kushida, I.; Ichikawa, M.; Asakawa, N. J Pharm Sci 2002, 91, 258-266. 
(58) Labhasetwar, V.; Song, C.; Humphrey, W.; Shebuski, R.; Levy, R. J. Journal of 
Pharmaceutical Science 1998, 97, 1229-1234. 
(59) Laibinis, P. E.; Whitesides, G. M. J Am Chem Soc 1992, 114, 1900-1905. 
(60) Lee, E. J.; Lee, S. W.; Choi, H. G.; Kim, C. K. Int J Pharm 2001, 218, 125-131. 
(61) Lefebvre, A. H. Atomization and Sprays; Taylor&Francis, 1989. 
(62) Lengsfeld, C. S.; Delphanque, J. P.; Barocas, V. H.; Randolph, T. W. B. J. Phys. 
Chem. 2000, 104, 2725-2735. 
(63) Lennernäs, H.; Ahrenstedt, O.; Hallgren, R.; Knutson, L.; Ryde, M.; Paalzow, L. 
K. Pharm. Res 1992, 9, 1243-1255. 
(64) Lennernas, H.; Ahrenstedt, O.; Ungell, A. L. Br. J.Clin. Pharmacol. 1994, 37, 
589-596. 
(65) Lennernas, H.; Nilsson, D.; Aquilonius, S. M.; Ahrenstedt, O.; Knutson, L.; 
Paalzow, L. K. Br. J.Clin. Pharmacol. 1993, 35, 243-250. 
(66) Lipinski, C. Am.Pharm. Rev. 2002, 5, 82-85. 
(67) Liversidge, G., G,; Cundy, K. C. Int J Pharm 1995, 125, 91-97. 
(68) Liversidge, G. G.; Cundy, K. C.; Bishop, J. F.; Czekai, D. A.: U. S., 1991. 
(69) Lyklema, J. Fundamentals of interface and colloid science, Vol II: solid-liquid 
interfaces.; New York: Academic Press, 1991. 
(70) Malmsten, M.; Lindman, B. Macromolecules 1993, 26, 1282-1286. 
 169
(71) Malmsten, M.; Lindman, B. Macromolecules 1992, 25, 5440-5446. 
(72) Margarit, M. V.; Rodriguez, I. C.; Cerezo, A. Int J Pharm 1994, 108, 101-107. 
(73) Martin, A. N. Physical pharmacy: physical chemical principles in the 
pharmaceutical sciences, 4th ed.; Lea & Febiger: Philadelphia, 1993. 
(74) Masters, K. Spray Drying Handbook, 3rd ed.; New York: John Wiley and Sons, 
1979. 
(75) Mawson, S.; Yates, M. Z.; O'Neill, M. L.; Johnston, K. P. Langmuir 1997, 13, 
1519-1528. 
(76) Miyazaki, S.; Tobiyama, T.; Takada, M.; Attwood, D. Journal of pharmacy and 
pharmacology 1995, 47, 455-457. 
(77) Mortensen, K.; Brown, W.; Norden, B. Physical Review Letters 1992, 68, 2340-
2343. 
(78) Müller, R. H.; Benita, S.; Böhm, B. Emulsion and nanosuspensions for the 
formulation of poorly soluble drugs; Medpharm: Stuttgart, 1998. 
(79) Na, G. C.; Yuan, B. O.; Stevens, H. J.; Weekley, B. S.; Rajagopalan, N. Pharm 
Res 1999, 16, 562-568. 
(80) Napper, D. H. Polymeric stabilization of colloidal dispersions; Academic Press: 
New York, 1983. 
(81) Oh, D.; Curl, R. L.; Amidon, G. L. Pharm Res 1993, 10, 264-270. 
(82) Paavola, A.; Yliruusi, J.; Rosenberg, P. Journal of Controlled Release 1998, 52, 
169-178. 
(83) Pace, S. N.; Pace, G. W.; Parikh, I.; Mishra, A. K. Pharm Technol 1999, 23, 116-
134. 
(84) Palakodaty, S.; York, P. Pharm. Res. 1999, 16, 976-985. 
(85) Pandit, N.; Trygstad, T.; Croy, S.; Bohorquez, M.; Koch, C. Journal of Colloid 
and Interface Science 2000, 222, 213-220. 
(86) Pang, P.; Englezos, P. Fluid Phase Equilibria 2002, 194-197, 1059-1066. 
(87) Pang, P.; Englezos, P. Colloids and Surfaces A: Physicochemical and 
Engineering Aspects 2002, 204, 23-30. 
 170
(88) Peeters, J.; Neeskens, P.; Tollenaere, J. P.; Van Remoortere, P.; Brewster, M. E. 
Journal of Pharmaceutical Sciences 2002, 91, 1414-1422. 
(89) Pelton, R. H. Journal of Polymer Science, Part A:  Polymer Chemistry 1988, 26, 
9-18. 
(90) Peracchia, M. T.; Vauthier, C.; Desmaele, D.; Gulik, A.; Dedieu, J. C.; Demoy, 
M.; d'Angelo, J.; Couvreur, P. Pharm. Res 1998, 15, 550-556. 
(91) Peters, D. Journal of Materials Chemistry 1996, 6, 1605-1618. 
(92) Pleštil, J.; al., e. Macromol. Chem. Phys. 2001, 202, 553-563. 
(93) Pozarnsky, G. A.; Matjevic, E. Colloids Surf. A Physico. Chem. Eng. Asp. 1997, 
125, 47-52. 
(94) Radtke, M. New drugs 2001, 3, 62-68. 
(95) Randolph, T. W.; Randolph, A. D.; Mebes, M.; Yeung, S. Biotechnology 
Progress 1993, 9, 429-435. 
(96) Rasenack, N.; Muller, B. W. Pharm Res 2002, 19, 1894-1900. 
(97) Rasenack, N.; Müller, B. W. Pharmaceutical Developent and Technology 2004, 
9, 1-13. 
(98) Reddy, R. K.; Khalil, S. A.; Gonda, M. W. J Pharm Sci 1976, 65, 115-118. 
(99) Reverchon, E. J. Supercritical Fluids 1999, 15, 1-21. 
(100) Rogers, T., L.; Nelsen, A. C.; Sarkari, M.; Young, T. J.; Johnston, K. P.; 
Williams, R. O. Pharmaceutical Research 2003, 20, 485-493. 
(101) Rogers, T. L.; Hu, J.; Yu, Z.; Johnston, K. P.; Williams, R. O. International 
Journal of Pharmaceutics 2002, 242, 93-100. 
(102) Rogers, T. L.; Johnston, K. P.; Williams, R. O. Pharmaceutical Development and 
Technology 2003, 8, 187-197. 
(103) Rogers, T. L.; Johnston, K. P.; Williams, R. O. Drug Development and Industrial 
Pharmacy 2001 Nov, 27, 1003-1015. 
(104) Rogers, T. L.; Nelsen, A. C.; Hu, J.; Brown, J. N.; Sarkari, M.; Young, T. J.; 
Johnston, K. P.; Williams, R. O. European Journal of Pharmaceutics and 
Biopharmaceutics 2002, 54, 271-280. 
 171
(105) Rogers, T. L.; Overhoff, K. A.; Shah, P.; Santiago, P.; Yacaman, M. J.; Johnston, 
K. P.; Williams, R. O. European Journal of Pharmaceutics and Biopharmaceutics 
2003, 55, 161-172. 
(106) Rowley, G.; Pearson, J. T.; Hussian, M. S.; Hartup, D. E.; Jones, B. E. J Pharm 
Pharmcol 1985b, 37, 112P. 
(107) Rubinstein, M. H.; Gould, P. Drug Dev. Ind. Pharm. 1987, 13, 81-92. 
(108) Ruch, F.; E., M. Journal of Colloid and Interface Science 2000, 229, 207-211. 
(109) Salamova, U. U.; Rzaev, Z. M. O. Polymer 1996, 37, 2415-2421. 
(110) Sarkari, M.; Brown, J.; Chen, X.; Swinnea, S.; Williams, R. O.; Johnston, K. P. 
Int J Pharm 2002, 243, 17-31. 
(111) Sekikawa, H.; Hori, R.; Arita, T.; Ito, K.; Nakano, M. Chem. Pharm. Bull. 1978, 
26, 2489-2496. 
(112) Shama, J. O.; Zhang, Y.; Finlay, W. H.; Roaa, W. H.; Lobenberg, R. International 
Journal of Pharmaceutics 2004, 269, 457-467. 
(113) Sjöström, B.; Bergenstöhl, B.; Lindberg, M.; Rasmuson, A. C. J. Dispersion 
Science and Technology 1994, 15, 89-117. 
(114) Subramaniam, B.; Rajewski, R. A.; Snavely, K. J. Pharm. Sci. 1997, 86, 885-890. 
(115) Thiering, R.; Dehghani, F.; Dillow, A.; Foster, N. R. J. Chem. Technol. 
Biotechnol. 2000, 75, 42-53. 
(116) Torchilin, V. P. J Controlled Release 2001, 73, 137-172. 
(117) Tripp, C. P.; Hair, M. L. Langmuir 1996, 12, 3952-3956. 
(118) Turker, L.; Guner, A.; Yigit, F.; Guven, O. Colloid and Polymer Science 1990, 
268, 337-344. 
(119) Uekama, K.; Ikegami, K.; Wang, Z.; Horiuchi, Y.; Hirayama, F. J Pharm 
Pharmacol 1992, 44, 73-78. 
(120) Wanka, G.; Hoffmann, H.; Ulbricht, W. Colloid polymer science 1990, 268, 101-
117. 
(121) Wei, G.; Xu, H.; Ding, P. T.; Li, S. M.; Zheng, J. M. Journal of controlled release 
2002, 83, 65-74. 
 172
(122) Wingrave, J. A. Oxide Surfaces; Marcel Dekker: New York, 2001. 
(123) Yaws, C. L. Chemical properties handbook: physical, thermodynamic, 
environmental, transport, safety, and health related properties for organic and 
inorganic chemicals; New York : McGraw-Hill, 1999. 
(124) Yeo, S. D.; Lim, G. B.; Debenedetti, P. G.; Bernstein, H. Biotechnology and 
Bioengineering 1993, 41, 341-346. 
(125) Young, T. J.; Johnston, K. P.; Pace, G. W.; Mishra, A. K. AAPS PharmSciTech 
2004, 5. 
(126) Young, T. J.; Mawson, S. M.; Johnston, K. P. Biotechnol Prog 2000, 16, 402-407. 
(127) Zhang, X.; Burt, H. M.; Mangold, G.; Dexter, D.; VonHoff, D.; Mayer, L.; 






Xiaoxia Chen was born on November 20, 1974 in Dingbian County, Shaanxi 
Province, China to Zhiyi Chen and Jinfang Gao.  She graduated from Dingbian High 
School, Shaanxi Province in 1991 and entered Tsinghua University in Beijing, China.  
She graduated in Chemical Engineering in June 1996.  She then enrolled in the graduate 
program at Tsinghua University, and received her M.S. in Biochemical Engineering in 
June 1999.  She then entered the University of Texas at Austin in August 1999, and 




Permanent address: 1634 West 6th Street, Apt. A, TX 78703 
This dissertation was typed by the author. 
 
 
